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SUMMARY 
Nucleosides and their phosphate esters, known as 
nucleotides ^re vital components of nucleic acids in 
living cells. The main function of nucleic acids is 
storage, transmission and usage of genetic inforamtion 
upon which the continuation of the cell structure and 
function depends. 
Living cells also contain a variety of low mole-
cular weight nucleotides which play an important roles 
in the complex integrated chemical reactions of the 
cell. Some of these nucleotides are close chemical 
relatives of the nucleotides of nucleic acids. 
The biosynthetic pathways of common nucleosides 
and nucleotides in animals and plants are well mapped 
out. Most of the living cells elaborated these mole-
cules from amino acids. The living cells are also 
capable of recycling purine and pyrimidine nucleosides 
that are available to them as by products of metabolism 
of nucleic acids, and this route of synthesis of nucleo-
sides and nucleotides is called "salvage pathway'. The 
qualitative and quantitative differences at enzymatic 
level in nucleotide matabolism of host and parasitic 
cells, normal and cancerous cells, offer specific tar— 
gets for inhibiting vital enzymatic reactions essential 
for the growth of parasites and proliferation of cance-
rous cells. 
Modification of heterocyclic and/or sugar moie-
ties of purine and pyrimidine nucleosides affords modi-
fied nucleosides which may either inhibit or act as a 
competitive substrate of some important enzymes and thus 
exhibit a variety of biological activities. 
In recent years, several non classical nucleo-
sides having moieties such as : tetrahydrofurany1, hyd-
roxyethoxymethyl, tetrahydropyranyl, and xylofuranosy1, 
in place of D-ribofuranosyl have been found to exhibit 
diverse biological activities. Several 2',3'—dideoxy 
adenosine and guanosine derivatives have been synthe-
sized and found effective inhibitors of retroviral reve-
rse-transcriptase, as well as DNA-polymerase. 
The work presented in the thesis is based on the 
above theme and is divifijefi) into the four chapters. 
A review, dealing with "Biologically active 
nucleosides with abnormal sugars" is given in chapter 1. 
Chapter 2, deals with the synthesis of 3,4,6-tri 
methyl thio-lH-pyrazolo[3,4-d.]pyrimidine (16), 4-amino-l-
3-D-ribof uranosyl-lH-pyrazolo[3, 4-d^]pyrimidine (21), 4-
amino-l-(5'-deoxy-5'-alkylthio-p-D-ribofuranosy1)-lH-
pyrazolo[3,4-d_]pyrimidine (23-27), 5 '-deoxy-5 '-a 1 ky 1 thio 
adenosine (29-32), 9-[ 5 '-deoxy-5 '-methyl thio-(3-D-xy lofu-
ranosy1]adenine (38) and their antiviral and antileis-
hmanial activities. 
Synthesis of 4—amino-1-B-D-^ribofuranosyl-lH-pyrazolo-
[3.4-d]pyrimicline (21) 
Condensation of 3, 4 ,6-trifnethy 1 thio-lH-pyrazolo 
[3,4-d.]pyrimidine with J.-0-acety 1-2,3, 5-tri-O-
benzoylribofuranose in the presence of BF3.0Et2 in CH3CN 
gave 3 , 4 ,6-trimethy 1 thio-l-|3-D-( 2 ' ,3' ,5 -tri-0-benzoy 1 
ribofuranosyl )-lH-pyrazoloC3,4-d_]pyrimidine (IS) in 55'/. 
yield. 
SMe 
18 R=COPh 20 R3=SMe=R^ 
19 R=H 2i R3=R6=H 
Deblocking of the blocked nucleoside 1^ with 
methanolic ammonia yielded 3 , 4 , 6-trimethy 1 thio-l-(3-D-
ribof uranosy 1-lH-pyrazoloC3 , 4-d^]pyrimidine (19). Amina-
tion of 1_9 with methanolic ammonia in a steel bomb at 
120 furnished 4-amino-3 , 6)-dimethy 1 thio-l-fi-D-ri bof ura-
nosyl-lH-pyrazoloC3,4-d^]pyrimidine (20). Compound 20^  on 
treatment with Raney Nickel in aq ethanol gave 4-amino-
l-fi-D-ribofuranosyl-lH-pyrazoloC3,4-dL]pyrimidine (21 ) . 
Synthesis of 4—amino-l~(5'-deoxy-5'—alkylthio-l-p-D-
ribofuranosyl )—IH—pyrazolor3,4—d]pyri<nidine (23-27) 
Treatment of 4-amino-l-(3-D-ribafuranosy 1-lH-pyra-
ZQloC3,4-d^3pyrimidine (21) with thionyl chloride in the 
presence of hexamethyl phosphoramide afforded 4-amino-l-
(5'-deoxy-5'-chloro-B-D-ribofuranosy1)-lH-pyrazolaC3,4-
d.]pyrimidine (22). Condensation of 22^ with isobutyl, 
allyl, n-heptyl, p-chlorobenzy1 and L-cysteny1)mercap-
tans in the presence of aq NaOH gave 4-aminD-l-(5 -
deoxy-5'-alkylthio-B-D-ribofuranosy1)-lH-pyrazolo[3,4-
d_]pyrimidine (23-27) respectively. 
, ^ 
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OH6H 
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NH' 
Synthesis of 5'-deoxy-5'-alkylthio adenosine (29-32) 
Treatment of adenosine with thionyIchioride in the 
presence of hexamethy1phosphoramide gave 5'-deoxy-5'-
chloroadenosine (28). The condensation of 28 with p-
chlorobenzy1, hydroxyethy1, n-heptyl, isobutyl 
mercaptans, in the presence of aq NaOH gave 5'-deoxy-5'-
alkylthio adenosine '29-32) respectively. 
29 R=-CH2-CoJ>-Cl 
31. =-(CH2)6CH3 
29-32 
30 R= -CH2CH2OH 
32 -CH2CHCH3 
CH3 
Synthesis of 9-fe"-deoxy-S"-methylthio-B-P-xylofuranosyl] 
adenine (38) 
Condensation of adenine with 1,2,3,5-tetra-O-
acetyl-D-xylofuranose in the presence of stannic chlo-
ride gave 9-C2',3',5'-tri-0-acetyl-R-D-xylofuranosy13a-
denine (35) in 707. yield. Deblocking of 35^ with metha-
nolic ammonia gave 9-|3-D-xylofuranosy 1 adenine (36). 
Tosylation of 36 in the presence of p-toluene 
sulphonyl chloride and pyridine gave 9-[5'-deoxy-5'-
tosy1-0-D-xylofuranosyl)adenine (37) in good yield. 
Acetylation of 37^ in the presence of acetic 
anhydride and pyridine gave 40^ which on treatment with 
methyl mercaptan and DMF furnished 9-L5'-deoxy—5'-
methyl thio-2 ' , 3 ' -di-0-acetyl-(3-D-xy lof uranosy 1 ] adenine 
(41) . 
Deblocking of the' nucleoside 41_ with methanolic 
ammonia yielded 9-[5'-deoxy-5'-methylthio-R-D-xylofura-
nosy 1 ]adenine (38). 
^2 
bJ 
RO-iX)x 35. R = -COCH3 
36 = H 
N 
m. 
•,N 3Z Ri =^  OTs; R=H 
40 Ri = OTs; R=C0CH3 
41_ Rj^  = SMe; R=C0CH3 
38 Rj^  = SMe; R=H 
The compounds 16-38 were evaluated for antiviral 
activity ij2. vitro against Ranikhet disease virus and 
the compounds 1^, 22., 2^, 30^, 3^, 32. and 36^  exhibited 
high order of activity. 
The compounds 16—38 were also tested iji vitro 
against amastigotes of Leishmania donovani. However, 
they showed moderate activity. 
Chapter 3, deals with the synthesis of 1-C2-
hydroxy-1-(hydroxymethyl)ethoxy3methyl-4—(amino/hydro-
xy )-lH-pyfa2olo[3,4-d.]pyrimidine (26, 23), l-C2-hydroxy-
1-(aminomethy1)ethoxy3methyl-4(5H)-oxo-lH-pyra2olo[3,4-
d_]pyrimidine (30), l-[2-hydroxy-l-( amino-methy 1 )ethoxy ]-
methyl-4-amino-lH-pyrazoloC3,4-d.]pyrimidine (34), 1-C2-
(hydroxyethoxy)methyl]-4-(hydroxy/amino)-lH-pyrazolo-
[3 , 4-d_] pyrimidine (38,40) and their antileishmanial 
activity. 
8 
S y n t h e s i s o f l - [ 2 - h y d r o x v - X - ( h y d r o x y m e t h y l j e t h o x y ] 
n i e t h y l - 4 - ( a m i n o / h y d r o x y ) - l H - p y r a z o l o C 3 . 4 - d ] p y r i m i d i n e 
( 2 6 & 2 3 ) 
Condensation of 4-methylthio-lH-pyrazolo[3,4-
d^Jpyrimidine with 1 , 3-diben2y loxy-2-chloromethy loxypro-
pane in the presence of Et3N and DMF gave l-[2-benzy1o-
xy-l-(benzyloxymethy1)ethoxy]methyl-4-methylthio-lH-
pyrazolo[3,4-d_]pyrimidine (21) in 707. yield. 
Compound Zl^ on reaction with NaOH yielded 22. 
Hydrogenolysis of 22^ with PdCl2 in H2 atmosphere 
furnished l-[2-hydr-oxy-l-( hydroxymethy 1 )ethoxy ]methy 1-
4 (5H)-oxa-lH-pyrazoloC3,4-d.]pyrimidine (23) in good 
yield. 
Compound 21_ on reaction with methanol ic ammonia 
under pressure afforded 25.. Hydrogenolysis of 25. with 
PdCl2 in H2 atmosphere gave the l-C2-hydroxy-l-(hydroxy-
methy 1 ) ethoxy 3methy l-4-amino-lH-pyrazoloC3 ,4-d^]pyrimi-
dine (26). 
N 
SMe 
N' 
:N 
OBn 
2 1 
%. 
bJ 
^N-^ ^r^' 
^ 
^R 
n 
22. R4 = OH; R = CH2Ph 
23. R4 = OH; R = H 
25. R4 = NH2; R = CH2Ph 
26 R4 = NH2; R = H 
Synthesis of l-i;2-hydroxy-l-(aminomethyl )ethoxy]methyl-
4(5H)-oxQ-lH-pyrazolo[3.4—dlpyrimidine (30) 
Condensation of bis(trismethyi silyl)derivative 
of 4-hydroxy-lH-pyrazo 1 o[3 , 4-d^ ] pyr imidine with 2-chloro~ 
methoxy-l-benzyloxy-3-phthaIoy1imidopropane in refluxing 
benzene gave l-[2-benzyloxy-1-(phthaloy1imidomethyi)et-
hoxy ]methy 1-4 ( 5H)-oxo-lH-pyrazolo[3,4-d^]pyrimidine (28) . 
Deblocking of phthaloyl group in 28. with 
hydrazine hydrate at O yielded 29^ . Hydrogenolysis of 
29 with PdCl2-H2 gave 30. in 30"/. yield. 
28 
29 
30 
R = -CH2Ph; Ri = " ^ ^ J S 
5 
R = - C H 2 P h ; Rj^ = NH2 
R = H; R l = NH2 
10 
Synthesis of 1—[2-hydrQxy-l-(aminQmethy1)ethoxy]methy1-
4-aniino-lH-pyra2olQ[3.4-d]pyrimidine (34 ) 
Condensation of 4-amino-lH-pyrazolaC3 , 4-d^ ] pyrimi-
dine with 2-chloromethoxy-i-benzyloxy-3-phthalQy1imidop-
ropane in dry DMF gave l-C2-benzyloxy-1-(phthaloy1imido-
methy 1 ) ethoxy ]methy l-4-amino-lH-pyra2olo[3 ,4-d_]pyrimi-
dine (32). 
Deblocking of phthaloyl group in 32^ with hydra-
zine hydrate at 0 gaye 33^. Hydrogenolysis of 33^ with 
PdCl2 in H2 atmosphere afforded 34. 
NH2 
C N^ N 
R O ^ ^ 
32. R = CH2Ph; R^ 
33 R = CH2Ph; R^ NH2 
34 R = H; Rl = NH2 
Synthesis of 1—C2—(hydroxyethoxy)methyl]—4—(hydroxy/ami-
no )-lH-pvrazolo[ 3.4—dlpyrimidine (38,40) 
Condensation of 4-methy1thio-iH-pyra2olo[3,4-
d.]pyrimidine with benzoyloxyethoxy methylene chloride in 
the presence of Et3N and DMF gave 1-(benzoyloxyethoxy)-
methy 1-4-methy 1 thio-lH-pyrazolo[3,4-d_]pyrimidine (36) in 
60'/. yield. 
11 
Deblocking of compound 36^  with methanolic ammonia 
afforded 37^. Treatment of 37. with KOH gave l-(hydroxy 
ethoxy)methyl-4(5H)-oxo-lH-pyrazoloC3,4-d^]pyrimidine 
(38) . 
Compound 38^ was also prepared by condensing of 2_± 
and 35^ in refluxing benzene yielded l-[benzoyloxyetho-
xy )-ethy 1-4 ( 5H)-oxo-lH-pyra2oloC3,4-d^]pyrimidine (39) in 
587. yield. Deblocking of 39^ with methanolic ammonia 
afforded 3£ in 60'/. yield. 
Treatment of 37_ with methanolic ammonia in steel 
bomb furnished 1-(hydroxyethoxy)methy1-4-amino-lH-pyra-
2oloC3,4-d.]pyrimidine (40) in good yield. 
SMe 
36. R = COPh 
37 R = H 
MH-; 
Ho-voJ 
J 
^ 
38 R = H 
39 R = COPh 
12 
The compounds 21-40 were evaluated iji vivo 
against amastigotes of Leishmania donovani and the com-
pounds 23., 30^ and 40. exhibited high order of antileis-
hmanial activity. The compound 39^  exhibited very promi-
sing activity were studied in detail. 
Chapter 4, deals with the synthesis of 6-amino-l-
( tetrahydrofuran-2-yl )-4 ( 5H )-oxo-lH-pyrazoloC3,4-d.3pyri-
midine-3-carboxyl ic acid (20), 4-amino-l-(tetrahydrofu-
ran-2-yl )-6-methy 1 thio-lH-pyrazoloC3 , 4-d_] pyrimidine-S-
carboxamide (21), 4-amino-l-(tetra hydropyran-2-y1)-6-
methy 1 thio-lH-pyrazoloL3 , 4-d.3pyrimidine-3-carboxamide 
(26), 6-amino-l-C(2-hydroxyethoxy)methyl]-4(5H)-axo-lH-
pyra:zoio[3,4-d_jpyrimidine-3-carboxy lie acid (31), 4-
amino-l-[(2-hydraxyethoxy)methy1]-6-methy1thio—IH-pyra-
zoloC3,4-d[]pyrimidine-3-carboxamide (33), 4-methoxy-6-
methy 1 thio-l-R-D-ribof uranosy l-lH-pyrazolo[3, 4-d_j pyrimi-
dine-3-imidocarboxylate(37) and their antiviral activity. 
Synthesis of 6—amino—l—(tetrahydrofuran—2—yl)—4(5H)—oxo— 
IH—pyrazolo[3.4—dlpyrimidine—3—carboxvlic acid (20) 
Condensation of 3-cyano-4,6-dimethy1thio-lH-pyra-
zolo[3,4-d^3pyrimidine with 2,3-dihydrofuran in the pre-
sence of p-toluene sulphonic acid afforded 3-cyano-4,6-
dimethylthio-l-(tetrahydrofuran-2-yl)-lH-pyrazoloC3,4-
13 
d^ ] pyr imidine (17) in 11'/. yield. 
Treatment of 1_7 with IN NaOH in diaxane at 80 
gave 4,6-dimethy1thio-1-(tetrahydrofuran-2-y1)-lH-pyra-
zolo[3 , 4-d^ ] pyrimidine-3-carboxamide (18). The compound 
18 was refluxed with 6N NaOH afforded 1^. Treatment of 
compound 1J9^  with ethanolic ammonia in a steel bomb gave 
6-amino-l-(tetrahydrofuran-2-yl)-4(5H)-oxo-lH-pyrazo-
lo[3,4-d_]pyrimidine-3-carboxy 1 ic acid (20). 
Synthesis of 4—amino-1-(tetrahydrof uran-2-yl )-6-tnethy 1-
thio-lH-pyrazolo[3.4-d]pyrifBidine-3-carboxamide ( 21 ) 
Treatment of 18 with methanolic ammonia in a 
steel bomb gave 21^ in excellent yield. Reaction of j ^ 
with methanolic ammonia in steel bomb afforded 4-amino-
1-(tetrahydrofuran-2-yl)-6-methy 1thio-1H-pyrazoloC3,4-
d.]pyrimidine-3-carboxamidine (22) . 
ffc 
N <^^ 
N 
R3 
CN 
CONH2 
COOH 
COOH 
CONH2 
R4 
SMe 
SMe 
OH 
OH 
NH2 
R6 
SMe 
SMe 
SMe 
NH2 
SMe 
17 
18 
19 
20 
21 
22 C(NH)NH2 NH2 SMe 
14 
Synthesis of 4-amino-l-(tetrahydropyran-2-y1)-6-methy1-
thio-lH-pyrazQlo[3.4-d]pyrimidine-3-carboxamide (26) 
Condensation of 1^ with 3,4-dihydro-2H-pyran in 
the presence of p-toluene sulphonic acid gave 3-cyano-
4,6-dimethylthio-i-(tetrahydropyran-2-yl)-IH-
pyrazoloC3,4-d_]pyrifnidine (24) in 6b'/. yield. 
Treatment of 24. with IN NaOH in dioxane at 80 
afforded 25^, which on treatment with methanolic ammonia 
in a steel bomb gave 4-amino-l-(tetrahydropyran-2-y1)-6-
methy 1 thio-lH-pyrazoloC3 , 4-d^]pyrimidine-3-carboxamide 
(26) . 
S -^le 
1 N 
% 
N 
MeS'Sj- '^^'^ 
< - ^ 
:0NH2 
24 25. R4 = SMe 
26. R4 = NH2 
Synthesis of 6-amino-l-C (2-hydroxyethoxy )«nethy 1 ]-4( 5H)-
oxo-lH—pyrazoloC3.4—d ]pyritnidine-3-carboxy 1 ic acid ( 31 ) 
15 
Condensation of 1^ with benzoyloxyethoxymethy1ene 
chloride in the presence of DMF and Et3N gave 3-cyano-l-
[ ( 2-ben zoyloxyetho>!:y) methyl ]-4 ,6-dimethy 1 thio-lH-pyrazo-
lo[3,4-d.]pyrimidine (28). 
Treatment of 28. with IN NaOH in dioxane at 80 
yielded 2£ in 787. yield. The compound 29^  on refluxing 
with 6N NaOH furnished 30^, which on treatment with 
ethanolic ammonia in a steel bomb afforded 6-amino-l-
C(2-hydroxyethoxy)methy1]-4(5H)-oxc-lH-pyrazQloC3,4-
d_3pyrimidine-3-carboxy 1 ic acid (31). 
The compound 28, on reaction with sodium methoxide 
in methanol at 20 gave 4-methoxY-l-[(2-
hydroxyethoxy)methyl]-6-methy1thio-lH-pyazoloC3,4-
d_]pyrimidine-3-imidacarboxylate (32) in excellent yeild. 
Synthesis of 4—amino—1—[(2—hydroxyethoxy)methy1]—6-met-
hylthio—IH—pyrazolo[3.4—d3pyrimidine-3-carboxamide (33) 
Amination of 4,6-dimethylthio-l-[(2-hydroxyetho-
xy ) methyl ]-lH-pyrazolo[3, 4-d^3pyrimidine-3-carboxamide 
(29) with methanolic ammonia in a steel bomb gave 4-
amino-l-[(2-hydroxyethoxy)methy1]-6-methy1thio-lH-pyra-
zoloC3 , 4-d_]pyrimidine-3-carboxamide (33) . 
28 
PKOCO-, ^ O,] 
IG 
% 
N 
R3 R4 R^ 
29 CONH2 Sne SMe 
30 COQH QH SMe 
31 COOH ' OH NH2 
32 C(NH)OMe OMe SMe 
33 CONH2 NH2 SMe 
Synthesis of 4-giethQxy-6—aie±hylthio-l-(3-D—ribofuranosyl-
lH-pyrazolo[3.4—d]pyrimidine-3—imidocarboxylate (37) 
Condensation of 1^ with l-Q-acety1-2,3,5-tri-Q-
benzoylribofuranose in the presence of BF3,0Et2 afforded 
3-c>ano-4,6-dimethylthio-1- -D-2',3',5'-tri-0-
benzoy 1 ribof uranosy l-lH-pyrazoloC3, 4-d.]pyrimidine (36) 
and 3-cyano-4,6-difnethyl thio-l-B-D-2' ,3' ,5'-tri-0-
benzoyl ribof uranosyl-lH-pyrazoloC3,4-d[]pyrimidine (35) . 
Treatment of compound 3^ with sodium methoxide in 
methanol at 10 temperature furnished 4-methoxy-6-methy-
1 thio-1-(3-D-ribofur anosyl-lH-pyr azoloC 3, 4-d_]pyrimid ine-
3-imidocarboxylate (37) in good yield. 
The compounds 15-37 were evaluated for antiviral 
activity i_n^  vitro against Ranikhet disease virus and the 
17 
compounds 1^, 3J^ , Z2_ and 3Z exhibited high order of 
antiviral activity. The remaining compounds eitrier 
showed low order of activity or found inactive. 
Me 
MeS^^Ss 
SMe 
Me' 
OHe NH 
HO 
OH6H 
^^sumPi^i'^'''^'*" 
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PREFACE 
Living cells contain a variety of loi^ molecular 
tr^eight nuc leotides, inihich have important roles as 
reaction intermediates in the complex integrated 
chemical reactions of the cell. They synthesize their 
requirement of purine and pyrimidine nucleotides from 
amino acids. In contrast, the protozoal parasites meet 
their requirement of purine and pyrimidine bases from 
host cells by 'salvage pathr^ays'. This, thus provides 
an opportuni ty to interfere h/ith the groi^th of these 
parasites. 
Many of the pioneers of nucleoside chemistry had 
an intense interest not only in the natural 1y occurring 
nucleosides and their biochemical phenomenon but also in 
the effects of synthetic nucleasides on living systems 
and in the synthesis of modi fied nuclosides as 
chemotherapeutic agents. The synthetic activi ty in this 
field i^as further spurred by discovery of nucleoside 
antibiotics f>ra-A and acyclovir as c 1 inical ly effective 
antiviral drugs. 
Modifications of heterocyc1ic and/or sugar 
moieties affords modified nucleasides Mhich may either 
inhibit or act as a competitive substrate of some 
J 2 
important enzymes and thus exhibit a variety of 
biological activi ties. The work presented in the thesis 
is based on the above theme and is divided into four 
chapters. 
Chapter I is a general review and deals with 
Biological 1y active nucleosides with abnormal sugars. 
Chapter I I deals with the synthesis of 5'-deoxy-
5'-alkylthio-lH-pyrazolo[3,4-dJpyrimidine nucleosides, 
5'-deoxy-5'-alkylthio purine nuc1eosides and 5'-deoxy-
5'-methylthioadenine xyloside and their biological 
acti vi ty. 
Chapter I I I deals with the synthesis of acyclic 
nucleosides of 4-substituted pyrazolo[5,4-dJpyrimidine 
and their biological activity. 
Chapter IV deals with the synthesis of 3,4,6-
trisubstituted-IH-pyrazolo[3,4-dJpyrimidine nucleosides 
and their biological activi ty. 
CHAPTER - 1 
BIOLOGICALLY ACTIVE NUCLEOSIDES WITH 
ABNORMAL SUGARS 
1 
INTRODUCTION 
Nucleosides, the nitrogen glycosides of purines 
and pyrimidines and their phosphate esters called nuc-
leotides are vital components of nucleic acids that 
occur in all living cells and are also essential compo-
nents of all viruses. The main function of nucleic 
acids is the storage, transmission and use of the gene-
tic information. Living cells also contain a variety of 
low molecular weight nucleotides which have important 
roles in the complex integrated reactions of the cell. 
Several microorganisms synthesize nucleosides 
which are structually analogous to the nucleosides of 
nucleic acids and inhibit the growth of the other micro 
organsims. These nucleosides are, therefore, called 
nucleoside antibiotics. Some of the nucleoside anti-
biotics exhibit high order of antiviral and anticancer 
activities. In recent years several abnormal nucleo-
sides showing biological activities have also been iso-
lated from marine organisms. Taking lead from these 
naturally occurring nucleosides, hundreds of nucleosides 
analogs have been synthesized and evaluated for biologi-
cal activities. Some of the nucleosides have been deve-
loped as drugs. 
An interesting feature of the biologically active 
nucleosides is that the heterocyclic and/or the glucone 
moieties in these molecules are not the normal purine or 
D-ribose units. Since we were interested in modulating 
the biological activities of nucleosides by use of modi-
fied glucone moieties, it was thought worth while to 
review the literature available on nucleosides with the 
unusual glucone moieties. 
Excellent reviews dealing with various aspects of 
purine and pyrimidine nucleosides having D-ribose sugar 
are available in literature . Analogs of natural 
purine and pyrimidine nucleosides have proved to be 
quite effective as antibacterial, antiviral, anticancer 
and antitumor agents, due to their role as enzyme inhi-
bitors. Depending on the nature of the glucone moiety 
the biologically active nucleosides could be divided 
into following groups. 
Purine and pyrimidine nucleosides with D-ribose sugar 
Adenosine (1) 
It is widely distributed in nature as one of the 
principal nucleoside of nucleic acids. Recently it has 
been isolated from a marine sponge Dasychaline cyat-
11 12 
hine . Its transport formation and interaction in 
3 
different tissues and involvement in the pathophysio-
logy of the renal change observed in various types of 
14 
renal insufficiency have been discussed recently. The 
bronchodilation efficacy of methyl xanthine is due to 
15 the adenosine antagonism . Recently, the role of its 
uptake inhibitors as probe and neuropharmaceutica1 has 
been established . A number of thioalkyl substituted 
adenosine analogs have been prepared with a view to 
modulating the coronary vasodilator activity of adeno-
17-19 
sine . It has been found that substitution by an 
alkyl thio group at position-2 in adenosine increased 
the duration of action but reduced the potency of coro-
20 
nary vasodilation as compound to the adenosine . More-
over, as the length of the alkyl chain increased, the 
coronary vasoditor activity become more pronounced while 
21 22 branching of the alkyl chain reduced the activity ' 
23 2-Fluoroadenosine (5) and a series of related 2-fluo-
24 25 
ropurines an highly toxic to the cells m culture 
2-Chloroadenosine (6) is only 1/350 and 2-bromQadenosine 
2/, 
(7) only 1/6000 as cytotoxic as 2-fluoroadenosine even 
though these compounds are much more resistant to deami-
25 
nation . 8-Methylaminoadenosine (8), first synthesized 
27 
and reported significant activity against Lewis Lung 
carcinoma in mice. 
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1.2.2 3-riethYl cytidine ( 9) 
The only nucleoside belonging to this class has 
28 been isolated from the marine sponge Geodia baretti 
The characteristic feature of this nucleoside is that it 
has a methyl function at N-3. 3-Methyl cytidine showed 
29 
contractile activity . The presence of 3-methyl cyti-
dine at selected sites in the RNA molecule significantly 
alters the properties of the RNA, perhaps more so than 
some of the other methylated base found in RNA . 3-
Methyleytidine differed in reactivity from the correspo-
nding deoxyribonucIeosides because of the hydrogen bon-
ding between the 2'-OH and C(2) carbonyl group 
1.2.3 Isoquanosine (10) 
Isoguanosine (2-hydroxy-9-^—D-ribofuranosylade-
nine) (10) also known as crotonoside was first isolated 
32 from Croton tig 1ium seeds . Recently, it has been 
isolated from a marine nudrbranch mollusc Diautula 
33 
sandieqensxs and was prepared by selective deamination 
of 2,6-diaminQ-9-^-D-ribofuranosy1 purine (11) with 
34 
nitrous acid . A new synthesis has been reported from 
our lab . Isoguanosine showed significant vasodepres-
sant activity. Similar to adenosine it stimulates accu-
mulation of cylcic AMP in brain tissue . Its ara-
analog is active against Vaccinia virus and HSV-1 in 
6 
37 
vivo but inactive in in vi tro 
1-2.4 Doridosine (12) 
Doridosine (N-methy1isoguanosine) (12) was iso-
38 lated from marine sponge Tedania diqi tata and Anisodo-
39 40 
ris nobi1 is ' A synthesis of doridosine is repor-
41 ted . It produced muscle relexant, hypothermic and 
cardiovascular effects following oral administration in 
42 
mice and rats . It interacts directly with adenosine 
receptor in guinea-pig brain to stimulate adenylate 
43 
cyclase . Unlike adenosine, doridosine (12) was found 
43 
resistant to deamination by adenosine deaminase 
1.3 Purine and pyrimidine nucleosides with 2'-deoxy ribose 
sugar 
1.3.1 2-Deoxy uridine (13) 
2'-Deoxy uridine has recently been isolated from 
44 
starfish Acanthaster planci . As majority of the anti-
viral and anticancer drugs in use are considered as 
analogs of 2'-deoxy uridine and a number of biologically 
45 
active nucleosides had been obtained . The important 
compounds are : 5-Ethy1-2'-deoxy uridine (14) is used in 
the treatment of herpetic keratitis . Within the infe-
cted cells EDU is preferentially incorporated into viral 
DNA and is more inhibitory to viral than cellular DNA 
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47,48 49 
synthesis . 5-Fluoro-2 -deoxy u n d i n e ilt; an 
anticancer drug and its congeners are also efficient 
inhibitors of tumor cell proliferation. (E^)-S-Bromovi-
nyl-2 -deoxy uridine (16, BVDU) is one of the most 
52 
potant anti HSV-1 agent known . It also exhibited 
cytostatic activity against murine mammary carcinoma 
(FM3A) cells transformed witi- the HSV-1 and HSV-2. It 
is effective in topical formulation against HSV-1 in 
animals and as an oral formolation against VZV in chil-
54 55 48 
dren ' . 2'-Deaxy-5-viny1 uridine (17) is a nucleo-
side analog, and active acainst a number of viruses 
including HSV-1 and HSV-2^*^. 
Thymidine (18) 
1-(2 '-Deoxy-^-D-ribof L.--anosyl ) thymine (18) was 
44 isolated from star fish Acan t 'taster pi anc i , alongwith 
2'-deoxy uridine (13) and haz been synthesized^ . It 
binds 4-6 time less tightl\ to uridine phosphory1ase 
42 (Urd Pase) then the corresponding ribonucleosides 
The most important compound c* this group is AZT (azido-
thymidine, 1*?), retrovir or ( 3 '-az ida-3 -deoxy thymi-
d i n e ) . It is a potent inhibitor of human immunodeficie-
58 59 
ncy syndroms (AIDS) ' 
9 
1.3.3 3-Hethy1-2'-deoxycytidine (20) 
3-Methy1-2'-deoxycytidine (20) has been isolated 
very recently from a marine sponge Geodia baretti, for 
the first time as a free natural product . It exhi-
bited high order of contractile activity in the isolated 
, 29 
gumea-pig eleumn assay 
1.3,4 2 -Deoxy adenosine (21) 
2'-Deoxyadenosine (21) a normal component of 
nucleic acids had been isolated from a marine sponge 
Dasychalina cyathina . Its synthesis has also been 
80 
reported . 3'-Azido-2,'3'-dideoxyadenosine (22) had 
81 been prepared acid tested for its Anti-HSV properties 
1.4 Purine and pyrimidine nucleosides with 2".3'-dideoxy 
ribose sugar 
Although several retro viruses were associated 
with malignancies (leukemia, sarcoma) and chronic dege-
nerative diseases of the CNS in animals, there was no 
definitive proof of their implication in these diseases 
until 1980. Robert C.Gallo and his colleagues, unequi-
vocally demonstrated the casual relationship between 
human T-cell leukemia virus (HTV-1) and adult T-cell 
leukaemia (ATL). This was followed by the isolation of 
a second human retrovirus, HTLV-II, from a patient ha-
.10 
ving cell leukemia, and in 1984, by the identification 
of HTLV-III (Human T-cell lymphotropic virus) as the 
causative agent of the acquired immuno deficiency 
syndrome (AIDS) . In 1983, LucMontagnier and his asso-
ciates isolated a new retrovirus from a patient with 
lymphadenopathy which is characteristic of Pre-AIDS and 
turned the virus as lymphadenopathy associated virus 
(LAV). HTLV-III and LAV were subsequently proved to be 
very similar in the make up of their genome. All these 
viruses are now commonly called as human immuno deficie-
ncy virus (HIV). 
Excellent reviews ' on selective antiviral 
agents active against the AIDS virus have appeared rece-
ntly. Certain dideoxy nucleosides exhibit potent anti-
viral activities against human immuno deficiency viruses 
(HIV) in_ vitro. 2 ' , 3 '-Dideoxycy t id ine (020*^*^ (23), 
2',3•-dideoxy adenosine (D2A), (24) and 2',3'-dideoxy 
inosine (D2I) (25) are currently undergoing clinical 
trials in patients with AIDS and AIDS-related complex. 
It is reported that 2',3'-dideoxy nucleosides as their 
triphosphates inhibite the HIV reverse transcriptase and 
can cause chain termination of DNA ' . D2A(24) is a 
potent anti-HIV nucleosides iji vitro, which undergoes 
rapid deamination by adenosine deaminase to D2I ' 
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12 
(25). Interestingly, D2I is partially phosphory1ated to 
D21 monophosphate, which is converted to D2A monophos-
72 phate, and subsequently to D2A triphosphate . Thus it 
has been proposed that the antiviral activity of D2I may 
be attributed to D2A triphosphate. Therefore, D2I can be 
considered to be a prodrug of D2A monophosphate. 
The structure activity relationships of 2,3'-
dideoxy and 2',3'-didehydro-2',3'-dideoxy primidine and 
48 
purine nucleosides as anti HIV agents have been repor-
ted. From these studies N -methyl-2',3'-dideoxy adeno-
73 
sine (D2MeA) (26) was the most potent compound among 
purine nucleosides. The most effective drug for the 
treatment of AIDS today is 3'-azido-2',3'-dideoxy thymi-
74 dine (AZT) (19). The mechanism of action of the drug 
has been will established. AZT is phosphorylated to its 
5'-mono-,5'-di-and 5'-triphosphate by cellular enzymes. 
The 5'-triphosphate of AZT inhibits HIV reverse tran-
scriptase 100 to 300 times more effectively than DNA 
polymerase 
1.5 Purine nucleosides with 3'—deoxy and 3'—substituted 
ribose sugar 
Structural changes at C-3' of purine nucleoside 
result in nucleosides with marked changes in thier bio-
logical properties. Five 3'-deoxy adenine nucleosides 
13 
antibiotics have been isolated from the streptomyces and 
fungi that are extremely toxic to bacteria, animal cells 
in culture, tumors and viruses. These nucleosides are 
excellent biochemical tools for studying several reac-
tions with partially purified enzymes or cellular proce-
sses. Some of the representative nucleosides of the 
class are discussed below: 
1.5.1 Cordycepin (27) 
Cordycepin (3'-deoxyadenosine) (27) as antivi-
ral drug was isolated from the culture filterates of 
78 Cordyceps mi 1i taris and Asperqi1lus nidu1ans . The 
79 go 
synthesis of cordycepin has oeen reported '" . It is 
cytotoxic and inhibits the growth of Baci11 us subti1 is 
avian lubercle bacillus and Ehrlich ascites tumor cells 
81 
and H.Ep # 2 cells . Cordycepin is converted intracel-
lularly into its 5'-mono, di, and triphosphates. The 
r, 
latter product can terminate normal 3'-phosphodiester 
polymer elongation upon incorporation onto a growing 
RNA. It has been found recently that cordycepin inter-
82 feres with the processing of nuclear transcribed RNA 
Recently, cordycepin showed good antiparasitic acti-
83 
vity against Leishmania donovani alongwith other bio-
logical activities. 
14 
1.5.2 Puromycin (28) 
Puromycin, 6-dimethy1amino-9-[3-(p-methoxy-L-B-
phenyla Ianylamino)-3-deaxy-B-D-ribofuranosy1]purine (28) 
is a nucleoside antibiotic, isolated "from the mold Stre-
ptomyces a 1boniqer, has been found to be active against 
84 
certain bacteria and Trypanosomes . The synthesis of 
85 puromycin has already been reported . Puromycin is 
structurally similar to the 3'-terminus of aminoacyl-t 
86 RNA and a valuable biochemical tool in the molecular 
biology for the elucidation of the mechanisms involved 
in reaching the genetic message by which the nascent 
87 polypeptide chain on the peptidyl site is transferred 
to the aminoacyl-t RNA on the amino acyl site on the 
88 89 
ribosomes ' . It is suggested that the hydrophobic 
interaction between the p-methoxy group and the adenine 
ring of puromycin and its analogs may interfere and 
90 inhibit the protein synthesis 
1.5.3 3'—Amino—3'—deoxy adenosine (29) 
3'-Amino-3'-deoxy adenosine (29) was isolated 
from the culture filterates of Helminthosporium. Cordy-
91 
ceps mi 1itaris and Asperqj1lus nidulans . The compound 
92 3•-amino—3'-deoxyadenosine has been synthesized , and 
93 94 
showed antitumor and antimitotic activity . It is 
converted into the 5'-mono,di and triphosphates by Eh-
15 
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16 
rlich ascites tumor cells in culture and is potent 
95 inhibitor of RNA and DNA synthesis . The analogs of 
96 3'-amino-3'-deoxy adenosine inhibit HIV-1 replication 
1.5.4 3 • -Acetaniido-5 ' -deoxyadenosine (30) 
92 97 3 -Acetamido-3'-deoxyadenosine ' (30) had been 
isolated from the culture filtrates of He 1 mintho spo-
98 
rium . This nucleoside is not a substrate for adeno-
sine kinase and does not inhibit Ehrlich ascites tumor 
99 
cells or bacteria 
1.5.5 Homocitrullylamino adenosine (31) 
Homocitrullylamino adenosine (31) had been iso-
lated from mycelia of Cordyceps mi 1i taris . In biolo-
gical evaluation, it exhibited inhibition of poiy(U) 
directed polyphenylalanine synthesis analogous to that 
of puromycin. It also inhibited the incorporation of 
amino acids into proteins in cell-free extracts of E^ 
coll and rat liver 
1.6 Purine and pyrimidine nucleosides with D-arabinose sugar 
1.6.1 Arabinosyl Adenine (Ara-A) (32) 
Ara-A (32) was synthesized before its isola-
tion as a natural product and was first discovered as a 
17 
naturally occurring nucleoside in the culture filtrates 
102 
of Streptomyces antibioticus . Ara-A exhibited signi-
^- - , i. • .u 103,104 . .^,- , . . ficant antiviral activity against DNA containing 
virus making it first antiviral drug for the treatment 
of usually fatal herpes encephalitis . It has been 
found that 9-/8-D-arabinof uranosyl adenine-5 '-phos-
phate , which penetrate the cell without degradation 
has more sustained toxicity against mouse fibroblasts 
(L-cells) that does it nucleosides . It is also effe-
ctive in the therapy of herps keratitis, herpes encepha-
litis and varicel1azoster infections in immino suppres-
sed patients .e<-Anomer of Ara-A is also a good antivi-
ral agent 
Degradation of Ara-A by adenosine deaminase 
109 yields 9-p-D-arabinosy1 hypoxanthine (33, ara-H) , 
which is about one tenth as active as Ara-A, but is of 
comparable activity when assayed iri, vivo . Excellent 
review regarding chemistry, biochemistry and pharmaco-
logy of Ara-A and analogs has been discussed . Rece-
ntly, both Ara-A and its 3'-0-acyl derivatives have been 
112 isolated from gorgonian Eunicella cavolim 
1.6.2 Sponqouridine (34) 
Spongouridine ( l-(3-D-arabinof uranosyl uracil) 
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Ara-U (34) isolated from the sponge Cryptotethia cryp-
ta '^^^, had been synthesized . Its 5-substituted 
116-118 
l-R-D-arabinofuranosy1 uracil (ara-u) analogs 
have attracted cosiderable interest. In addition to 
their high ir^ vitro and iri vivo effect against HSV-1 
119 
, (E)-5-(2-bromovinyl)-ara-U (35) and 5-viny1-ara-U 
120 (36) possess superior antiviral activity against VZV 
and HSV-2 and cause considerably less toxicity to 
human embryonic lung fibroblasts (HELF). 
1.6.3 Sponqothymidine (37) 
Spongothymidine ( l-(3-D-arabinofuranosy 1 thymine) 
Ara-T (37) isolated from the sponge Cryptotethia crypta 
121 
had been synthesized . Pyrimidine nucleosides contai-
ning the l-(3-D-arabinofuranosy 1 moiety exhibited intere-
sting biological properties. Ara-T exhibited antitumor 
122 
activity 
1.6.4 1-B-D-Arabinofuranosy1 cytosine (Ara-C) (3B) 
Pyrimidine nucleosides containing l-(3-D-arabina-
furanosyl moiety have exhibited significant biological 
122 
activities. Ara-C is effective against several expe-
123 
rimental tumors was shown to inhibit several DNA 
124 
viruses in cell cultures and is effective against 
herps simplex keratitis in the rabbit, it also inhibits 
20 
124 the growth of the cell . Analogs of Ara-C, l-(3-D-
arabinofuranosy1-5-iodouraci1 (39) which is active a-
125 gainst herpes and vaccinia virus in cell cultures , 1-
12^ 3-D-arabinofuranosy1-5-fluorouraci1 (FUA) (40) , which 
is active against leukemia B82 and Sarcoma 180 and 
finally l-f3-D-arabinof uranosy 1-5-f 1 uorocytosine ( FCA } 
(41) which is active against Sarcoma 180 and leuke-
mias"^^^ P38e, P815 and Li2i0. 
1.7 Pyrimidine nucleosides with 4—amino hexose sugar 
1.7.1 Gouqerotin (42) 
127 Gougerotin (42) an amino acyl-amino hexosyl 
128 
cytosine antibiotic , was isolated from Streptomyces 
...129 . ..... . . 4.L, 130 . 
qouqerotti inhibits protein synthesis by preven-
ting the transfer of amino acids from aminoacyl t—RNA to 
polypeptid ' . Several synthesis of gougerotin had 
been reported in the literature ' . Gougerotin has 
r, 
been shown to possess versatile antibacterial , AC&ri-
.. ,136 .- , 137 _^  ^. . ,138 ^. . 
cidal , antimycoplasma , and antiviral activi-
ties, of which at least the former Are due to the inter-
139 ference with protein biosynthesis at the peptids 
chain elongation stage. 
1.7.2 Blasticidin S (43) 
Blasticidin S[(1-cytosinyl)-4-L-3'-amino-5'-tetra 
21 
NH 
(CH2)2—N—C—NH2 
CH3 
t 2 if3 
Fig 6 Pyr imidine nucleosides w i th ^-amino hexose sugar 
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140 deoxy-R-D-erythrohex-2-enuronic acid] (43) was isa-
141 lated from Streptomyces qriseochromoqenes . Its che-
m ical structure consists of a pyranosyl cytosine nucleo-
side, cytosinine, and a novel amino acid, E-N-methy 1-f3-
142 
arginine or blastidic acid . Blasticidin S, is known 
143 to inhibit protein synthesis by acting at the riboso-
mal peptidyl transferase site and blocking peptide bond 
formation 
1.8 Pyrimidine nucleosides with p-D—disaccharide glucose 
sugar 
1.8.1 Anticetin (44) 
Amicetin (44), a new antitubercular antibiotic, 
is produced in deep culture fermentation by Streptomyces 
145 
vinaceus-drappus . The total structure and stereoche-
mistry has been established . Amicetin inhibits Gram-
positive and Gram-negative bacteria and is a potent 
- ,^ ,^ • 4- * i- - 4.K • • -4. 1 4 7 , 1 4 8 
inhibitor of protein synthesis xn_ vitro . Ame-
cetin showed anti herpes activity and also found active 
149 
against viruses other than herpes simplex 
1.8.2 Bamicetin (45) 
Bamicetin (45) was isolated from the fermentation 
cultures of S_^  pi icatus and had been synthesized 
Bamicetin is active against experimental mouse tubercu-
CH3 
0. 
OH 
0-J 
R - N OH 
CH3 
NHR, 
23 
i^it 
0 
-C-C—(CH3)—CH2OH 
NH2 
R2 R3 
H CH-, 
0 
^ -C—C—(CH3)—CH2OH H 
NH2 
H 
46 H H CH3 
Fig 7 Pyr imidine nucleosides w i th B-D-disaccharide glucose 
24 
losis. Bamicetin was found less potent then amicetin in 
inhibiting the growth of ri_^  f or tui turn 
1.8.3 Plicacetin (46) 
Amicetin, bamicetin and plicacetin the three 
structurally similar amino sugar containing nucleoside 
antibiotics were isolated from the filterates of an 
_. 4. -1 c^  , • i. 145,146 -r. 
actinomycete designated S_^ pi icatus . The syn-
thesis of this disaccharide pyrimidine nucleoside anti-
152 biotic, had been reported . Plicacetin is a potent 
inhibitor of iji vitro protein synthesis 
1 .9 Purine arrd pyrimidine nucleosides with carbocyclic sugar 
The term carbocyclic nucleoside is used to des-
cribe a group of compounds structurally analogous to 
natural and synthetic nucleosides in which the furanose 
oxygen has been replaced by a methylene group. It will 
be more correct to refer these compounds as "carbocyclic 
nucleoside isosteres" because, they are not nucleosides 
in true sense. The majority of carbocyclic nucleosides 
known to date are of synthetic origin but nature has 
provided two of the most active compounds, aristeromycin 
(47) and neplanocin-A(48). 
25 
1.9.1 Aristeromycin (47) 
The first compound of this class that was synthe-
sized as a carbocyclic analog of adenosine (C-Ado,47) 
154 
obtained as a racemate . Subsequently an optically 
active compound from the culture filterate of Strepto-
myces ci tricolor and was characterised as (i'R, 2 R, 
3' R, 4 'R)-9-[f3-D-2'o< ,Z'e< -dihydroxy-4 ' -P—( hydroxymethy 1 )-
eyelopentyl]adenine (47) ' . Several other synthe-
sis of C-Ado have been reported including a recent 
enantioselective synthesis ' . C-Ado displayed a 
^ ^ 1 • 1 ^ - -4- - 159,160 _ Wide range of biological activities . It was 
found highly cytotoxic to both H. Ep.-2 and L1210 
cells in culture. A recent reinvestigation of the meta-
bolism of C-Ado in H.Ep.-2 and Li210 cells revealed that 
in addition to C-ATP, the corresponding carbocyclic 
guanosine triphosphate (C-6TP) was also formed. This 
metabolite was found to be the most effective known 
r, 
162 inhibitor of HGPRT . C-Ado showed no significant 
antiviral activity against HSV, vaccinia, rhino, or 
influenza viruses . Several analogs of aristeromycin 
containing xylose, arabinose sugar moieties showed very 
. . . . . 4. • -4. 165,166 good antiviral activity 
1.9.2 Carbocyclic uridine nucleoside (C-Urd) (48) 
The carbocyclic uridine analog (C-Urd) (48) was 
2G 
NH2 
OH OH 
HN 
O ' ^ N 
OH OH 
kl 
0 
^8 
OH OH 
NH2 
XI 
OH OH 
49 50 
Fig 8 Purine and pyr imidine nucleosides w i th carbocycl ic sugar 
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167 first reported by Holy , but since the structure of 
his starting C-rib-NH2 was later confirmed to be erro-
168 
neous , the isolated compound was rather an isomer of 
16*9 
C-Urd of yet unknown structure . All carbocyclic ura-
cil nucleosides with isosteric ring moieties of ribose, 
2-deoxy, and 3'-deoxy ribose were found active in 
culture against KB as well as Li210 cells''"'^ .^ C-Thy 
(49) was only the member of the pyrimidine series with 
modest and reproducible activity iji vivo against L1210 
leukemia and was found inactive against KB and H.Ep.-2 
14- ^71 in cells culture 
1.9.3 Carbocyclic cytidine (C-Cyt; Carbodine) (50) 
C-Cyt (50) had been prepared from the 2',3',5-
tri-0-benzoy1 carbocyclic uridine via the intermediate 
4-chloro derivative by treatment with methanolic ammonia 
172 
under pressure . A number of carbocyclic analogs were 
synthesized by the same procedure from the corresponding 
uracil derivatives . The C-Cyt analogs showed better 
anticancer activity then their uridine counter parts. 
Both C-Cyt and C-ara-Cyt demonstrated good and reprodu-
174 
cible activity against L1210 leukemia in mice . C-Cyt 
exhibited marginal antiviral activity against HSV-1, 
however, it showed good activity ijx vi tro against in-
fluenza virus in mammalian cell culture 
28 
i • 10 Mycalisme A (51) and Mycalisine B (52) 
A search for bioactive marine metabolites resul-
ted in the isolation of two unusual compounds named 
mycalisine A (51) and mycalisine B (52) from a lipophi-
lic extract of a marine sponge Mycela spp . These are 
the pyrrolo[2,3-c[]pyrimidine nucleosides with unsatura-
tion between the 4' and 5'-position of the ribose moie-
ty . A number of structurally related pyrrolo[2,3-
d^ ] pyrimidine nucleosides have been isolated from natura-
lly occurring sources , as weil as preparea by synthe-
178 tic procedures . Very recently, the structure of 
179 
mycalisine A (51) has been confirmed . These com-
pounds were found to inhibit the cell division of ferti-
lized star fish eggs and also exhibited some very inte-
resting biological and chemotherapeutic activi-
180,181 ties 
1.11 9—[5'-Deoxy—5'-methylthio-p-D—xyloturanosy1]adenine (53) 
9-[ 5 ' -Deoxy-5 ' -methyl thio-(3-D-xy lof uranosy 1 lade-
nine (53) had been isolated from the digestive glands 
182 
and mantles of marine nudibranch Doris verrucosa 
This is the first example where a marine nucleoside had 
been found to have a substituted xylose moiety. The 
biosynthesis of the unusual nucleoside had been stu-
?9 
' N ^ ^N 
OH OH 
51 
XN 
- ^ 
OH 
53 
30 
died . A synthesis of nucleoside is reported 
This nucleoside showed anticancer activity against leu-
kemia L1210''"^^. 
1.12 Polyoxins (54) 
The polyoxins represent a group of pyrimidine 
1 8^ 
nucleoside peptide antibiotics ,which are elaborated 
1S7 by Streptomyces cacaoi \/ar. asoensis . Synthesis of 
188 
some polyoxins is reported • Polyoxins are unique in 
that they are extremely toxic towards phytopathogenic 
189 fungi . The structural similarity with UDP-N-acety1-
glucosamine is perhaps responsible for its selective 
inhibitory properties in chitin synthetase of fungi and 
. 187 
yeasts 
1.13 Nucleocidin (55) 
Nucleocidin (55) an antibiotic substance related 
to adenosine was isolated from micro organism Strepto-
190 
myces calvus from an Indian soil sample . Several 
191 192 
synthesis of this nucleoside had been reported ' 
Nucleocidin exhibited a rather broad antibacterial spec-
193 trum and is particularly active against trypanosomes 
Nucleocidin has been shown to be a highly potent inhibi-
194 195 tor of protein biosynthesis ' 
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CHAPTER - 2 
SYNTHESIS OF 5'-DEOXY-6'-ALKYLTHIO-1H-
PYRAZOLOl3,4-d]PYRIMIDINE NUCLEOSIDES, 
6'-DEOXY-6'-ALKYLTHIO PURINE NUCLEOSIDES 
5'-DEOXY- 5'-METHYLTHIOADENINE XYLOSIDE 
AND THEIR BIOLOGICAL ACTIVITY 
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2.1 INTRODUCririN 
-.nee S-adenosy Imethianine (Adafiet) (1) was 
discovered in 1952 by Cantoni, it has been shown to be 
one of r-,ture's most versatile molecule. AdoMet serves 
directl/ as the methyl-donor for numerous methyl tran-
sferases and as a precursor to decarboxy1 a ted AdoMet ' . 
Decarbo//1ated AdoMet is the aminopropy1-donor for the 
aminopr(oyl-transferases, which are involved in the 
biosyntf<3sis of the polyamines, spermidine and sper-
4,5 (^ ine , AdoMet has also been shown to be a 3-amino-3-
carboxy;.'opyl-donor in tRNA modification and as an 
adenosy. donor in the modification of the enzyme pyru-
vate fo'Tiate-lyase (Fig. 1). 
'.f these group transfer reactions, the one that 
has re-eived the greatest attention is that of methyl 
transfe- ' , In the intervening 28 years since Cantoni s 
origina discovery , many AdoMet-dependent methyltran-
sferases have been identified. In this capacity, methy-
lation would appear to be analogous to phosphoryla-
tion , except much broader in scope (Fig. 2 ) . These 
methyla^ions are well characterized and have been shown 
to have dramatic effects on important biological proces-
ses sue- as viral replication (mRNA methylation), bacte-
rial a* d leucocyte chemotaxis ' (phospholipid and 
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protein carboxymethylations), 1igand-receptor or recep-
2,3 12 tor-adeny1 ate cyclase interactions ' ' and neurosecre 
13 14 tory processes ' (protein carboxymethy1ations). All 
of these physiological processes are of obvious interest 
to medicinal chemists. 
Several recent observations, however, have sugge-
sted that a re—examination of AdoMet analogs as methy-
lase inhibitors might be warranted. One particularly 
significant observation is the potent inhibitory activi-
ty of Sinefungin (2) and A9145C (3) (Fig. 3) towards 
various methyl transferases . Sinefungin (2) and 
A9145C are antifungal antibiotics which are isolated 
21 
from Streptomyces qriseolus and are structurally simi-
lar to Adohet. 
The structure-activity relationships for the 
22 binding of AdoHcy analogs to purified tRNA methylase , 
viral mRNA (guanine-7-), (nucleoside-2')-methy1transfe-
23 1B 
rases and protein carboxymethy1trasferases have been 
examined and significant differences in their reguire-
ments for binding of AdoHcy have been detected. The 
AdoHcy analogs exhibiting the most interesting activity 
19 20 in vivo include sinefungin (2) ' , 5'-deoxy-5'-isobu-
24-28 tylthioadenosine (SIBA) (4) and S-tubercidiny1-L-
18 homocysteine (5) (Fig. 3 ) . 
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Compound Base 
i AdoMet adenine 
2^  Sinefungine adenine 
3 A9145C 
4 SIBA 
5 TubHcy 
6_ AdoHcy 
7. MTA 
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CH2CHCH2CH2CHNH;; 
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CH3 
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COOH 
CH2SMe 
CH2OH 
Fig—3 Inhibitors of AdoMet—dependent methylations 
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B—Adenosy 1-L-methionine (SAM) (1), synthesized ij2 
VIVO from adenosine triphosphate and L-methionine by 
28 
ATP: L-methionine adenosy1 transferase , an enzyme that 
appears to be ubiquitous in both normal and malignant 
tissues functions as a methyl group donor for transmet-
29 hylations and as a propylamine donor for polyamine 
synthesis ' (Fig. 1 ) . In carrying out these transfo-
rmations, SAM is converted to S-adenosy1-L-homocysteine 
(SAH) (6) and 5'-deoxy-5'-methylthioadenosine (MTA) (7), 
both of which are known to inhibit the transmethylation 
32 33 
reactions of SAM iri vi tro ' . Analogs of these com-
pounds could interfere with the biosynthesis of SAM, 
with methylation by SAM, with the decarboxylation of SAM 
or with the propyl amino transfer from "decarboxy1ated 
SAM' to putrescine to form spermidine. Either one^ of 
the latter two events would interfere with polyamine 
synthesis. In addition, metabolism of analogs by 
SAt^-metabol izing enzymes could release cytotoxic purines 
or purine nucleosides. 
Until now, most of the analogs of MTA or SAH that 
have been synthesized are derivatives of adenosine 
(8), however, analogs of SAH containing guanine , hypo-
14 34 
xanthine and a derivative of 2,8-dichloropurine have 
also been prepared. In the present work we undertook to 
54 
study the effect of changes in all three parts of the 
molecule: the purine, the sugar and the S-substituent, 
on biological activity. 
2.2 PRESENT WORK 
The above reports prompted us to undertake the 
synthesis of 5 '-deoxy-5 '-a 1 ky 1 thio-lH-pyrazo 1Q[ 3 , 4-d^ 3 py-
rimidine nucleosides and the 5'-deoxy-5'-methylthioade-
nine xyloside. 
The present chapter deals with the synthesis, 
antiviral and antileishmania1 activities of 3,4,6-trime-
thy 1 thia-lH-pyra2aloC3 ,4-d_]pyrimidine (il), 4-amino-l-B-
D-r ibof uranosy 1-lH-pyrazolo[3 , 4-d^ ] pyr imidine (16), 5 -
deoxy-5 ' -al ky 1 thio-lH-pyrazoloC 3,4-d^]pyrimidine ribo-
sides (18-22), 5 -deaxy-5'-a 1ky1thioadenosine (24-27), 
9-[5•-deoxy-5'-methylthio-R-D-xylofuranosy1]adenine 
(33) . 
2.3 SYNTHESIS 
2.3.1 Synthesis of 3.4.6—trimethylthio-lH-pyrazolo[3.4-d]pyri-
midine (11) 
Title compound 1A_, which is unknown, was synthe-
39 
sized following the general procedure of Gompper 
Thus condensation of 5-amino-3-methy1thio-lH-pyrazole-4-
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NC-s^^ ^SMe 
I— NH 
^ H 
SMG 
N 
r 
H 
IJ 
SMe 
SMe 
N 
SMe 
10 
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(iii) MeI,NaOH 
Scheme - 1 
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carbonitrile (9) with CS2 m pyridine yielded the inter-
mediate 3-methylthio-4(5H)-imino-6(7H)-pyra2ola[3,4-
d]thiazinethione. Treatment of above intermediate with 
NaOH afforded pyrazoloC 3 , 4-d[] pyr imidine~-3-methy 1 thio-
4,6-dithione (10) in quantitative yield. Methylation of 
10 iMith methyliodide and sodium hydroxide gave 3,4,6-
tr imethy 1 thio-lH-pyrazolo[3 , 4-d^3pyrimidine (11) in 657. 
yield (Scheme 1 ) . In the PMR spectrum of 1_1_, three 
singlets at 2.5, 2.6 and 2.4, were due to the methyl-
thio functions. In the mass spectrum of JJ^ , the molecu-
lar ion peak was at m/z 258 (M ). 
2.3.2 Synthesis of 4-amino-l-p-D-rlbQfuranosy1-lH-pyrazo-
lo[3.4-d3pyrimidine (16) 
Condensation of 3,4,6-trimethy1thio-lH-pyrazo-
lo[3,4-d^]pyr imidine (11) (Scheme 2) with 1-0-acetyl-
2,3,5-tri-O-benzoy1ribofuranose (12) in the presence of 
•r 
BF3.0Et2 gave a mixture of a- and p-isomers of 3,4,6-
trimethy 1 thio-l-a/(3-D-( 2 ' ,3' , 5 '-tri-0-benzoyl ribof urano-
sy 1 )-lH-pyrazolo[ 3 , 4-d^] pyrimidine . The f3-isomer was 
separated by column chromatography over Si02 column. 
The a-isomer, less polar of the two, could not be sepa-
rated in pure form. Elution of the column with 
CHCl3:MeOH (99:1, v/v) gave the |3-isomer 13.. 
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Deblocking of the compound 1^ with methanolic 
ammonia afforded 3 , 4 , 6-t r imethy 1 t hio-l-f3-D-r i bof ura-
noBy i-lH-pyrazQlo[3,4-d^]pyr imidine (14) (yield 627.). 
Compound 1^ analysed for C j^ 3H •[^QN404S3 and had the mole-
+ 
cular ion peak at m/z 390 (N ) in the mass spectrum. 
The other significant ions peaks in the spectrum were at 
the m/z 258, m/z 242 and m/z 288. 
Although the sugar moiety could be attached to 
any one of the four nitrogen atoms, however, as the 
reaction had been carried out at a high temperature, 
only the thermodynamica11y stable products were expected 
to be formed. 
In the case of trisubsti tuted pyrazo lo[ 3 , 4-d^]py-
40 
rimidine nucleosides as showed by Robins , there was 
shift at longer wavelength i.e. 303 nm. The compound 1^ 
had the UV absorption maxima 303 nm and 260 nm (MeOH) 
indicating that the ribofuranosy1 moiety in the compound 
is attached to the N-1 position 
The PMR spectrum of the compound 14 had a doublet 
at 6.15, J^-2'~^-0 Hz for the anomeric proton. General-
ly, the signal for anomeric proton for (3-isomer appears 
41 
relatively at higher field then that of a-isomer and 
further the coupling constant of the anomeric proton in 
42 43 P-isomer is smaller as compared to that in a-isomer ' 
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Since the anomeric proton of the compound lj5 had a 
coupling constant of 4.0 Hz, therefore, it was assigned 
the p-configuration. 
3,4,6-Trimethylthio-i-(3-D-ribofuranosyl-iH-pyra-
zolo[3,4-d1pyrimidine (14), when treated with ammonia at 
120 afforded 4-amino-3,6-dimethy1thio-1-B-D-ribofurano-
sy l-lH-pyrazolo[3,4-d[]pyrimidine (15) in 697. yield. The 
PMR spectrum of compound 1^ had characteristic peaks of 
both, heterocycle as well as sugar moieties. A broad 
singlet at 7.0 was for the amino function and at 2.5 
and 2.4 each singlet for the two methylthio functions. 
The mass spectrum of compound 1_5^  had the base peak at 
m/z 359 ( M"^ ) . The other significant ion peaks in the 
spectrum were at m/z 327 (Cj^ j^ H2^ 4N 50382) and m/z 180 
(C5N4S2)-
4-Amino-3,6-dimethylthio-l-f3-D-ribofuranosyl-lH-
pyrazoloC 3, 4-d^] pyrimidine (15) was treated with Raney 
nickel in aq ethanol to afford the compound 16^ in 60"/. 
yield. The compound 1^ was in full agreement with the 
44 
1iterature 
3.3 Synthesis of 4—amino—l-(5"—deoxy-5'-chloro-p-D-ribofura-
45 
nosyl)-lH-pyrazoloC3.4-d]pyrimidine (17) 
Treatment of 4-amino-l-p-D-ribofuranosy1-IH-pyra-
61 
zal aC3 ,4-d J pyr imidine (16) (Scheme 3) with thiunvi chifD-
ride and hexamethy I phosphoramide , afforded the i_7 in 
good yield. The pmr spectrum of compound 17 has charac 
teristic peaks of base moiety as well as sugar moK.^ty. 
The two singlets at 8.6 and 8.45 for H- 6 and H-3 respec-
tively, while at 7.5 for amino function. The compound 
17 analysed for CJ^QHJ^2^5^301 and had the molecular ion 
peak at m/z 285 (M ) in its mass spectrum. The other 
characteristic ion peaks were at m/z 250 ( C •^ o^^ l^2'^ 5'-'3 ^  > 
m/z 134 (C5H4N5). 
2.3.4 Synthesis of 4—amino—1—( 5 ' —deoxy--5 ' —al ky 1 thio-(3—D-
ribofuraosyl)-IH-pyrazoloC3,4-d]pyrimidine (18-22) 
4-Amina-l-C 5'-deoxy-5'-(isobutyl, allyl,n-heptyl, 
p-chlorobenzy 1 , L-cysteiny 1 ) thio-f3-D-ribofuranosyl ]-lH-
pyrazolo[3,4-d^]pyrimidine (18-22) (Scheme 3) were syn-
thesized by condensing 4-amino-l-(5'-deoxy-5 -chloro-B-
D-ri bofuranosyl )-lH-pyrazoloC3 , 4-d^] pyr imidine (17) with 
(isobuty1,a 11y1 , n-heptyl, p-chlorobenzy1)mercaptanes 
respectively, in the presence of aq NaOH. The crude 
products were purified on SiQ2 column to give the pure 
compounds 18-22 in fairly good yield. The compound 1^ 
analysed for Cj^/jH2iN503S and had molecular ion peak at 
m/z 339 (M ) in mass spectrum. The characteristic peaks 
were at m/z 281 (Cio'^2l'^503S) , m/z 249 {C ^Q\-\^2.^^'^Z'^ ^^'^ 
6^ 
( i ) 
18 R = -CH2CH< 
,CH 
:H. 
i 9 ^ -CH2-CH = CH^ 
20 = - < C H J , C H , 
OH OH 
21 =-CH2-<. / - C I 
22 = -CH2-CH<r 
CO2H 
NH. 
Reagents: 
(i) SOCl^-HMPA, R.T. 
(ii) N a O H , A 
Scheme - 3 
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m/z 135 (Cc,Hz)Nc|) confirmed the compound (Fig. 4 ) . The 
pmr spectrum of the compound had three singlets at 8.15, 
8.0 and 6.55 for H-6, H-3 and NH2 protons respectively. 
The peak for anomeric proton at 5.9 and for alkyl chain, 
two singlets at 0.9 and 0.8 for two methyl groups confi-
rmed the structure of compound 18. 
The compound 1^ analysed for Cj^3Hj^7N503S and had 
+ 
molecular ion peak at m/z 323 (M ) in the mass spectrum. 
The pmr spectrum of the compound 19^ had three singlets 
at 8.25, 8.05 and 6.3 for H-6, H-3 and NH2 respectively 
which confirmed the presence of base moiety. The peak 
for anomeric proton was at 6.0 and multiplet at 5.8-5.5 
for methylene protons, which confirmed the structure of 
compound 19. 
The compound 20 analysed for Cj^7H27N503S and had 
molecular ion peak at m/z 381 (M ) in the mass spectrum. 
The characteristic ion peaks in the spectrum at m/z 282 
(C10H12N5O3S), m/z 250 (0^0^12^503), m/z 136 (C5H4N5) 
and m/z 162 (C^H4N50) (Fig. 5 ) . The pmr spectrum of the 
compound had three singlets at 8.3, 8.05 and 6.45 for 
H-6, H-3 and -NH2 respectively which confirmed the pre-
sence of base moiety and a multiplet at 1.1-1.6 for n-
heptyl group. For anomeric proton, a doublet at 6.0 
confirmed the structure of compound 20. 
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NH-
N-
H 6H 9*^ 
m/z28i C H C H 2 S - , ^ 0 
hi 
Jhh 
iM^^N > ^ 
^N^ ^N , ^ ^ 
m/z 135 
OH OH 
m/z 339 
'2 \^ (Cj^H2^N303S) 
m/z 249 
(C joH,2N503) 
Fig—4 Mass spectral fraqmentatlon pattern of 4—amino—1-
(5'—deoxy—5'—isobuty1thio—fi—D—ribofuranosyl)—IH—pyrazolo 
[3.4-d]pYrimidine 
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f2 
N ^ 
m/z 136 
J^ 
N 
H 2 
CH3<i:H2)gS-i/Ox 
N j< 
•N-^ ^N ,>J 
U 
m/z 162 I ^ mi z ibz 
m/z 282 
( ^ 1 0 ^ 1 2 ^ 5 ^ 
)H 
m/z 381 
m/z 250 
(Cl0"l2^S^ 
Fig—5 Mass spectral fragmentation pattern of 4-amino-l-
[5'-deoxv-5"-(n—heptylthio)—P—D—ribofuranosyl]—IH-
pyrazQlQ(^3.4—djpyrimldine 
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The compound 21 analysed for C | 7H ^ Q N t^O xSC 1 and 
had molecular ion peak at m/z 407 (M ) m the mass 
spectrum. The characteristic ion peaks in the spectrum 
at m/2 282 ( CJ^QH-I^ 2^^5035) , m/z 162 (C^H4N50), 136 
(C5H4N5) (Fig. 6 ) . The pmr spectrum of the compound 21^ 
had two singlets at 8.3 and 8.1 for H-6 and H-3 pro-
tons respectively. There was a singlet at 7.2 for 
phenyl protons, a doublet at 6.0 for anomeric proton, 
and a singlet at 3.75 for 2 protons of benzyl group 
which confirmed the structure of compound 21. 
The compound 4-amino-1-(5 -deaxy-5 -(L-cystei-
nyl )-R-D-ribcf uranosy 1 )-IH-pyrazo 1 o[ 3 , 4-d^j pyrimidine 
(22) was synthesized from 4-amino-l-(5'-deoxy-5 -chloro-
(B-D-ribof uranosy 1 )-lH-pyra2oloC3 , 4-d^3pyrimidine (17), L-
cysteine and liquid ammonia at -70 temperature. The 
ammonia was allowed to evaporate and the compound was 
passed through IRC-i20 (H fc^ rf^  ) ion exchange resin. 
The elution of the column with NH4OH gave the compound 
22 in 707. yield. The compound 22^ analysed for 
+ 
Cj^3HJ^QN^OSS and had molecular ion peak at m/z 370 (M ) 
in the mass spectrum. The infrared spectrum showed the 
peak at 3400 cm for N-H and at 1680 cm for carboxy-
lic acid which confirmed the presence of cysteine group 
in the compound 22. The structure of compound 22. was 
NH^  
N 
m/z 162 
(C H^N30) 
^ 
Cl/o\cHoS 
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NH2 
N 
m/z 136 
m/z 'fO? 
(C j^Hj^N^O^SCI) 
m/z 282 
Fig—6 Mass spectral fragmentation pattern of 4—amino—1-
C5'—deoxy—5'—(p—chlorobenzylthio)—P—D—ribofuranosy1]-lH-
pyrazolo[5.4-d]pyrimidine 
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again confirmed by the elemental analysis. 
2.3.5 Synthesis of 5'-deoxy-5 -chloro adenosine (23) 
Treatment of adenosine (8) (Scheme 4) with thio-
nylchloride and hexamethy1phosphoramide with exclusion 
of moisture and protection from light followed by treat-
ment with resin (IRC-50) (H form) gave 5-deoxy-5 -
chloroadenosine (23) in good yield. The PMR spectrum of 
compound had two singlets at 8.1 and 8.0 for H-B and H-
2 respectively and at 6.7 for amino function. Mass 
spectrum of the compound 2_3^  showed the molecular ion 
+ 
peak at m/z 285 (M ). 
2.3.6 Synthesis of 5'-deoxy-5'-alkyIthioadenosine (24-27) 
5'-Deoxy-5'-(p-chlorobenzy1, hydroxyethy1, n-hep-
tyl, isobutyl )thioadenosine (24-27) (Scheme 4) were 
synthesized by condensing (p-chlorobenzy1, hydroxyethy1, 
n-heptyl, 'isobutyl) mercaptanes with 5 '-deoxy-5 '-chlo-
roadenosine (23) in the presence of aq NaOH (Scheme 4 ) . 
The compounds were purified on Si02 column to 
give compounds 24-27 in good yield. The compound 24_ 
analysed for Cj^7Hj^gN503SCl and had molecular ion peak at 
+ 
m/z 407 (M ) in its mass spectrum. The PMR spectrum of 
compound 24 had a doublet at 5.85 for einomeric proton 
and had singlet at 7.2 for four protons of phenyl ring 
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(0 
OH OH 
IZ 
11 
11 
26 
Reaj 
CH3 
R = -CH^CH^ 
- -CH.^QKI 
- -CH^CH^-OH 
= -(CH2),CH3 
?ents: ,; 
(i) SOCI^, HMPA, R.T. 
(ii) N a O H , A 
NH2 
Cu 
OH OH 
Scheme - ^ 
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which showed the attachment of p-ch1orobenzy1 mercaptan. 
The compound 2^ analysed for C2iHj^7N5a4S and had molecu-
lar ion peak at m/z 327 (M ) in its mass spectrum. The 
PMR spectrum of compound 25^  had three singlets at 8.45, 
8.3 and 7.35 for H-8, H-3 and NH2 respectively and 
multiplet at 4-4,5 and 2.6-2.9 for HaCH2 and CH2S 
showed the attachment of mercaptoethano 1 . 
The compound 26. analysed for Cj^7H27N503S and had 
+ 
molecular ion peak at m/z 381 (M ) in mass spectrum. 
The PMR spectrum of compound 26^  had three singlets at 
8.2, 8.1 and 6.3 for H-B, H-2 and -NH2 respectively, 
while a multiplet at i-i.5 for heptyl group showed the 
presence of n-heptyl mercaptan in the compound 26. 
37 The compound 27^ analysed ior Cj^4H2iN503S and 
+ 
had molecular ion peak at m/z 339 (M ) in mass spectrum. 
The PMR spectrum of the compound had three singlets at 
8,2, 8.1 and 6.5 for H-8, H-2 and NH2 respectively while 
at 0.95 and 0.89 each singlet for two methyl protons 
showed the presence of isobutyl mercaptan in the com-
pound 27. 
Synthesis of 9-C5'-deoxy-5'-methylthlo-p-D-xylofuranosyl] 
^ . .-,^.45,47,48 
adenine (33) 
Condensation of adenine (28) (Scheme 5) with 
7.1 
AcO 
nr6AcV^0Ac; ( i i ) 
OAc 
28 29 
kJJ^ 
McS 
Reagents; 
(i) 
OAc 
30 
NH2 
, Y y 
(ii) 
(iii) N^^Nr'N, 
31 
'TS= I ^ ^ 
'AC= COCH3 
CH3NO2, SnCJ^, R.T. 
(ii) MeOH-NH^, R.T. 
(iii) TSCl-Py, O'c 
(iv) MeSNa, D M F , A 
H3 
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i,2,3,5-tetra-O-acety1-D-xy1 ofuranose (29) in the prese-
nce of stannic chloride afforded 9-[2',3',b-tri-0-
acety1-B-D-xylofuranosy1)adenine (30) in good yield. 
The compound was purified by Si02 column chromatography. 
In the pmr spectrum of the compound 3(), the two 
singlets at 8.35 and 8.15 for H-8 and H-2 respectively 
and there is a broad singlet at 6.45 for NH2 protons 
which confirmed the presence of adenine in the compound. 
There was a doublet at 6.25 for anomeric proton confir-
ming the attachment of sugar moiety. 
Deblocking of 9-[2',3',5'-tri-0-acetyi-B-D-xylo-
furanosy 1 jadenine (30) with methanolic ammonia afforded 
49 known 9-(3-D-xylofuranosyladenine (31) in good yield. 
Tosylation of the compound 9-(3-D-xylofuranosy 1 
adenine (31) in the presence of pyridine and p-toluene 
sulfonyl chloride (freshly crystallized) at 0-5 tempe-
rature gave the 9-[ 5 '-deoxy-5 '-tosy 1-(3~D-xy 1 of uranosy 1 ] 
adenine (32) in good yield. In the PMR spectrum of the 
compound 32^ having a doublet at 5.9 for anomeric pro-
ton, and a singlet at 2.35 ior three methyl protons. 
Purity of the compound was again confirmed with the help 
of •'•^C-NMR. 
Compound 9-C5'-deoxy-5'-tosyl-R-D-xylofuranosy1] 
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adenine (32), DMF and methyl mercaptan were heated to 
give a mixture of two compounds 9-C5'-deoxy-5 -methy1-
thio-B-D-xylofuranosy1)adenine (33) in minor amount and 
9-C3 ' , 5 '-epoxy-[3-D-xylaf uranosy 1 ]adenine (34) in major 
amount. The two compounds could not be separated by 
column chromatography. The compounds 33^  & 34^ analysed 
for mass spectrum gave the molecular ion peak m/z 297 
(M ) and other peak at m/z 249, which showed the presen-
ce of two compounds 3^ & 34. 
The PMR spectrum of the reaction product gave two 
anomeric peaks at 6.5 for major compound 34^  and at 
5-86 for minor compound 33. 
The desired compound 33^ was synthesized by acety-
lation of 9-[ 5 '-deoxy-5 ' - tosy l-(3-D-xy lof uransoy 1 ]adenine 
(32) (Scheme 6 ) . The PMR spectrum of the compound 35^  
gave two singlets at 8.8 and 8.3 for H-8 and H-2 pro-
tons and a doublet at 6.3 for anomeric proton and two 
singlet at 2.38 and 2.51 for acetyl protons. Treatment 
of 9-C5'-deoxy-5'-tosyl-2' ,3 '-di-0-acety 1-(3-D-xy lof ura-
nosy1^adenine (35) with methyl mercaptan in DMF afforded 
the compound 36^  as an oil. Infra-red spectrum showed 
the presence of acetyl group. The PMR spectrum of the 
compound 36. showed the absence of tosyl group and the 
presence of SMe group at 2.5. 
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NH2 
' IT kj 
'Y 
32 
-•N 
1 
1 
OH 
McS 
33 
(iii) 
TSO 
MeS 
OAc 
36 
Reagents 
(i) Ac^O-Py 
(ii) MeSNa, DMF 
(iii) MeOH-NH^, R.T. 
Scheme - 6 
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NH2 
0;>t 
28 
( i ) 
NH2 
k^X—OAc 
OAc 
(ii) 
OAc 
36 
MeS 
33 
Reagents; 
(i) CH^NO^, SnCl^, R.T. 
(ii) MeOH-NH^, R.T. 
Scheme - 7 
7G 
Deblocking of the compound 36 with methanolic 
ammonia afforded the 9-[ 5 '-deoxy-5 '-methyl thio-(3-D-xy lo-
45 furanosy1]adenine (33) , The compound 33 was analysed 
for C j^  j^H •i^ 5N503S and had molecular ion peak at m/z 297 
(M ) which confirmed the compound. The PMR spectrum of 
the compound 33^  showed two singlets at 8.2 and 8.1 for 
H-8 and H-2 protons, a broad singlet at 7.32 for NH2 
protons, a doublet at 5.82 for anomeric proton and a 
singlet at 2.15 for Slie protons. 
The PMR, mass & UV spectrum of the compound were 
identical with the com.pound isolated from marine source 
47 
Nudibranch mollusc Doris-Verucosa . The PMR spectrum 
of the compound was again identical with the compound 
prepared in our laboratory . In the synthesis, the 
i,2,3-tri-0-acetyI-5'-deoxy-5'-methylthio-D-xylofura-
45 
nose (37) (Scheme 7) was condensed with adenine (28) 
in the presence of stannic chloride afforded 9-[5'-
deoxy-5-methylthio-2',3'-di-a-acetyl-(B-D-xy lof uranosy 1 ] 
adenine (36) in good yield. Removal of the protecting 
groups of 36 by treatment of methanolic ammonia at 
ambient temperature gave the desired nucleoside 33^  in 
fairly good yield. 
2.4 BIOLOGICAL ACTIVITY 
2.4.1 Antiviral activity 
The compounds synthesized were screened for their 
77 
antiviral activity by Dr. M.N.Joshi in the Virology 
Division of Central Drug Research Institute, Lucknow. 
The compounds were evaluated for their antiviral 
activity ijri vi tro [ Chor io-al 1 antoic membrane ( CAN )-
cultures] against Ranikhet disease virus (RDV), an In-
dian strain of Newcastle disease virus (NDV). The 
strain of RDV, the haemagglutination (HA) test, the 
method of preparation of CAM cultures and optimal condi-
tions of the infection by the virus are described ear— 
52-54 1 ler 
Ranikhet disease virus (RDV) was maintained by 
serial passages in the allantoic cavity of 11-12 days 
old chick embryos by inoculating 0.064 NA units/embryo 
and the allantoic fluid was harvested after 48 hr. The 
concentration of virus in the allantoic fluid was tit-
rated by HA test against fowl red blood carpuscles 
(RBC). For ijT^  vi tr^ testing against RDV, each compound 
was given at a non-toxic dose (0.1 mg/ml/cu1ture), using 
6 cultures tubes/compound. The compounds were given 
along with virus challenge. The percent inhibition of 
virus replication was calculated by the reduction in HA 
titre of the compound treated culture (T) as compared to 
that of virus control (c) usi^§^fS^^ig: ZAX 
(- Asc No. 
.( 
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(C-T ) 
-X 100 
C 
The compounds referred above were tested against 
RDV and the compounds 14., iZ J 20^ 24^ » 2 5_, 26. and 3_i exhibited 
high order of activity. The remaining compounds either 
showed low order of activity or were found inactive 
(Table 1 ) . 
ftntileishmanial Activity 
Anti1eishmania 1 screening of the compounds was 
carried out in collaboration with Mr. P.Y. Guru and his 
coworkers at Parasitology Division of Central Drug 
Research Institute, Lucknow (India). 
Materials and Method 
The macrophages isolated from the peritoneal 
cavity of cotton rats (siq modern hispidus) infected 
with amastigotes were used for the it± vi tro antileishma-
nial screening. Cotton rats weighing 60 g and above 
were injected with 2 ml each of IX soluble starch intra-
peritoneal 1 y . Three days later, the animals were sacri-
ficed and macrophages were isolated from peritoneal 
cavity using RPM-1640 medium containing heparin. These 
macrophages were washed and finally suspended in a me-
7B 
Ta^ble 1 fViJ^i^M^^xal A c t i y i t y cornpuuiuJ' . i n (^ AM 
c u l t u r e a g a i n s t RDV y i ru^j 
S . N o , S t r u c t u r e L o d e 
Ma . b 1, t- 1 on 
t-M< 
'If' 
.Sf^\«-
6 H O H 
1 4 ( 9 0 - 2 6 3 1 ^1 
N ^ < . 
ti 
Ci- i , 0 -
,»^  
/ 
tTTin 
1 / ( Q a - 5 f J 0 ) bo 
N M , 
N i ^ -kXj 
ft 
^H 6( 
2 0 ( 8 8 - 5 7 8 ) A.j 
4 . 
•^Jri, 
H 6H 
MH^ 
*^ J 
H O C H C H ^ S - , ^ . 0 ^ 
OH iw 
2'^! ( Q 8 - 2 : ^ A : 
2 5 ( 8 8 - 5 1 6 
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MH, 
M > ' .11 N 
>W fiH 
KJH 
2 6 ( 8 8 - 3 2 9 ) bO 
3 1 ( 8 9 - 1 6 6 ) 3 5 
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dium containing 107. featal c a 1 t syrum to cjive t fie final 
count of 10 macrophages per ml. 1 hese were ther ^.eeded 
in Leighten tubes. After 24 hrs the medium was changed 
with the fresh complete medium containing 2x10 promas-
tigotes per ml. The promastigotes were obtained irom 
the stock cultures of som.e strain of parasite maintained 
on biphasic medium. the promastigotes enter into the 
attached macrophages. 
The reguired amount of drug was dissolved and the 
final suspension was prepared in the complete medium. 
the earlier medium was repaired with the medium 
containing the drug. After 48 hr the medium was again 
changed and replaced with the fresh medium containing 
the same concentration of the drug has the ear Iler 
medium. Finally 48 hr later the amount of amastigotes 
in treated as well as untreated control was calculated 
using the formula: 
PTXIOO 
PC 
Percentage inhibition = 100 -
The an ti leishmania 1 screening data of 4 ai d 5 -
substituted pyrazoloC 3 , 4-d^] py r imid ine nucleosides are 
reported (Table 2 ) . The compounds tested die; not 
exhibit any significant activity at 25 mg/kq nose in 
hamsters . 
8:^  
i a b l e 2 : An i i 1 r - i ' i h m a n i a^] a i . t . i v j l y o j ' ^U I J ' J t i < l i t e d 
p y r a z o l ^ t 3 J A : d . I p y r i m i d i n t » t u i c I »?a"j J d p s 
(1) o '5 e : 2 5 mg / k q ) 
V-i.O \ 
0\\ '^^ 
S.No. R/ R^ ^3 V. Inhibition 
on 7th day 
14 SMe SMe SMe OH 
NH2 SMe SMe OH il 
19 NH- H H SCHnCH-CH 2 16 
22 
CC'C.H 
NHo H H SCHnCHCf 2i 
CM 
18 NH2 H H SCH2CH<^ O 
2 1 NH2 H H S C H 2 - \ 0 > - c l O 
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Table 5 Antileishmanial activity of substituted purine 
nucleosides (Dose : 25 mq/kq) 
N i / ^ ^ T :H 
X = xylose 
R = ribose 
S.No. R^ R9 •/. Inhibition 
on 7th day 
24 NHo CWoVcH-7-S-R. 12 
25 NH2 HOCH2CH2-S-R 22 
26 NH2 CH3(CH2)5-S-P> 
31 NH2 O H — X 25 
32 NHo Tso—X 22 
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EXPERIMENTAL PROCEDURE 
Melting points were taken in an electrically 
heated instrument IEC-45 and are uncorrected. Compounds 
were routinely checked for their spots were visualized 
under UV lamp, or by iodine vapours by spraying with 
Dragendrof f ' s reagent. UV spectra (y^mBx in nm) were 
recorded on Shimadzu PR-1 model. IR spectra (cm ) were 
13 
recorded on Perkin-Elmer 157 model. C NMR spectra 
were recorded on varian VXR 200 MHz instrument and PMR 
spectra were recorded on Perkin-Elmer R-32 or Efi-360 L 
instrument, using TMS as internal references. Chemical 
shifts are in ^units. Mass spectra were run on Jeol JMS 
D 300 instrument using direct inlet system. 
3.4,6-Tritnethy 1 thlo-lH—pyrazolo[3,4-d Jpyrimidine (11 ) 
A mixture of 5-amino-3-methy1thio-lH-pyrazole-4-
carbonitrile (9, 4g, 26 mmol) , pyridine (50 ml) and 
carbon disulphide (50 ml) was refluxed for 4 hr, cooled, 
acidified with acetic acid and neutralized with IN NaOH 
solution. This resultant solid was filtered off and 
dried to give 1^ (4.3 g, 727. yield); m.p.: >250° ; MS 
(m/z): 230 ( M"^ ) . This product 10. (4g, 17 mmol) was 
dissolved in IN NaOH solution (50 ml) and excess of 
methyliodide (15 ml) added to it at 0 ° . The reaction 
85 
mixture was stirred for 1 hr at ambient tempjera tur e. 
The solid thus obtained was filtered, washed with water 
and crystallized with hot water to give pure LL (2.9 g, 
657. yield); m.p. : 128°; MS (m/z) : 258 (h^); PMR 
(CDCl3-DMS0-d^): 2.4, 2.5, 2.6 (each s, 9H, 3 SCH3); 
Analy. Calcd. for C Q N J ^ Q N 4 S 3 : C , 37.2; H, 3.87; N, 21.7; 
Found: C, 37.3; H, 4; N, 21.57.. 
3.4,6-Trimethylthio-l-B-D-[:2' ,3' , 5 '-tri-Q-benzoyl 
ribofuranosy1]—IH—pyrazolQL3,4—djpyrimidine (13) 
A mixture of 3,4,6-trimethy1thio-lH-pyrazo1o[3,4-
d^ ] pyr imid ine (11, 4g , 15.5 mmol) and 1-0-ace ty 1-2 , 3 , 5-
tri-0-benzoy1ribofuranose (12, 12 qm, 23.8 mmol) in 
nitromethane (200 ml) was refluxed for 1 hr till a clear 
solution was obtained. It was then cooled to 70 , to it 
was added BF3.0Et2 (Freshly distilled) (8.0 ml) and the 
mixture was removed iji vacuo. The product, thus ob-
tained, was extracted with ethyl acetate, washed with 
aqueous NaHC03 dried (Na2S04) and the solvent removed. 
The crude product (12g), thus obtained, was chromatogra-
phed over Si02 column. Elution of the column with 
CHCl3:MeOH (99:1,v/v) gave (3-isomer 1_3 as foams (3.6 
g, 557. yield); UV (MeOH) : 303, 260; PMR (CDCI3) : 8.1-
7.7 (m, 6H, P h - H ) , 7.1-7.6 (m,9H, P h - H ) , 6.6 (d, IH, 
^l',2'=2.5 Hz, H - 1 • ) , 6.1-6.4 (m, IH, H - 2 ' ) , 4.4-4.9 (m, 
8B 
4H, H-3- , 4'and b'), 2.5, 2.54 and 2.55 (s, 9H , :'. SCH3 ) . 
3,4 ,6-Tri(nethy 1 thio-l-p-D-ribof uranosy 1-lH-pyrazolp 
r.3,4-d]pyri(nidine ( 14 ) 
A mixture of 1^, (2 g, 2.8 mmal) and methanolic 
ammonia (MeOH at 0 saturated with NH3) was kept at 
ambient temperature for 24 hr. Removal of the solvent 
from the resulting mixture iji vacuo afforded the crude 
product which was chromatographed over SiQ2 column. 
Elution of the column with CHCI3 : MeOH (97:3, v/v) gave 
i4_ (0.8g , 62'/. yield); m.p. : 184°; UV (fleOH) : 303.2, 
260 (pH-7); IR (KBr) : 3400 (OH), 1200 (SCH3); MS (m/z): 
390 (M"*"); P M R (CDCI3 - DMSQ-d^.,) : 6,15 (d, IH, Ji'2 = 
4.0 Hz, H - 1 ' ) , 4.9-4.2 (m, 2H, H-2- and H - 3 ) , 4.1-3.5 
(m, 3H,H-4', H - 5 ' ) , 2.6, 2.65 and 2.7 (each s, 9H, 3 
S C H 3 ) ; Analy. Caled. for C I 3 H J ^ Q N 4 0 4 S 3 : C, 40; H, 4.6; 
Found: C, 39.6.; H , 4 . 57.. 
4—Amino-3.6-di(nethyl thio-1-p-D-ribof uranosy l-lH-
pyrazolo[3,4-d]pyrimidine ( 15 ) 
A mixture of 3 , 4 , 6-trimethy 1 thio-l-(3-D-r 1 bof ura-
nosyl-lH-pyrazolo[3,4-d^) pyrimidine (14, 0.35g, 0.9 mmal), 
and methanolic ammonia (MeOH at O saturated with NH3) 
was hated at 120 in a steel bomb for 10 Hr. The sol-
vent and excess of reagent from the resulting mixture 
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were removed iji vacuo. The crude product, thus obtained 
was chromatographed over S1O2 column. Elution of the 
column with CHC 1 3 : MeOH (95:5,v/v) afforded 1_5 ( 0 . 22g , 
697. yield); m.p. : 192°; UV (MeOH): 244 (pH-7), 244.8 
(pH-11), 245.2 (pH-1); IR (KBr) : 3300 (NH2); MS (m/z): 
359 (M"*"); P MR ( DMSO-d^ ) : 7 ( bs , 2H , NH2 ) , 5,95 (d, IH, 
Jj^'2'='^.5 Hz, H-1'), 4.6-4.45 (m, IH, H-2'), 4.1-4.3 (m, 
IH, H-3'), 3.3-4 (m, 3H, H-4', 5'), 2.5, 2.4 (each 
s,6H,2 SCH3); Analy. Calcd. for C^ iH]^4N503S2: C, 36.7; 
H, 3.89; Found: C, 36.7; H, 3.97. 
4-Amino-l-p-D-ribofuranosyl-lH-pyrazolo[5,4-d]pyrimldine 
( 16) 
A mixture of 4-amino-3 , 6-dimethy 1 thio-1-(3-D-
r i bof uranosy l-lH-pyrazolo [3 , 4-cL3 pyrimidine (15, Iq , 2.7 
mmol ) in 507. aqueous EtOH (100 ml) was added Raney-Ni 
(10 g, wet) and the mixture was refluxed for 45 minute 
and filtered. The solid was wahsed with boiling H2O (2 
X 75 ml). The solvent was evaporated iji vacuo. The 
product was crystallized from MeOH to give compound 1_6^  
(0.4 g, 607 yield); m.p. : 256°; IR (KBr): 3240 (NH2), 
3400 (OH); UV (MeOH) : 272.4 (pH-7), 274.8 (pH-11), 
258.8 (pH-2); MS (m/z): 267 (M"*"); P MR (DMSO-d^): 8.55 
(s, IH, H-3), 8.45 (s, IH, H-6), 7.7 (bs, 2H, NH2, 
exchanged with D2O), 6.18 (d,lH, JJL-2-=4.5 Hz H-1 ' ) , 
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5.4-5.8 (m, 2H, H-2' H~3'), 4.7-5.1 (m, 3H, H-4' , 5 ) ; 
Analy. Calcd. for C10H13N5O4: C, 44.9; H, 4.8; N, 26.2; 
Found : C, 45.5; H, 5.04; N, 26.47.. 
4-A(nino-l-( 5' -deoxy-5' -chloro-p-P-ribof uranosy 1 ) IH-
pyrazoloC5,4—d]pyrimidine (17) 
A mixture of 4-amino-l-(3-D-ribofuranosy 1-IH-pyra-
zolo[3,4-d^]pyrimidine (16, 4 g, 15 mmol), SOC12 (8 f"! ) 
and hexamethy1phosphoramide (40 ml) in a R.B. flask 
(covered by black paper) was stirred at ambient tempera-
ture for 20 hr. The resulting mixture was poured into 
ice cold H2O (250 ml), it was then passed through resin 
(IRC-50) H"^  form. Elution of the column with 2L of IN 
NH4OH gave product, which was lyophilized to give a 
white solid, crystallized from MeDH to give the desired 
compound 1^ (2. 9g , 70V. yield); m.p. : 185 ; MS (m/z) : 
285 (M"*"); IR (KBr):3400 (OH); UV (MeOH) :258.2 (pH-1), 
259.2 (pH-7), 272.4 (pH-11); PMR (DMSO-d<^) : 8.6 (s, IH, 
H-6), 8.45 (s, IH, H-3), 7.5 (bs, 2H, NH2), 6.15 (d, IH, 
Jl'2-=5 Hz, H-1-), 5.6-5.9 (m, 2H, 2 OH), 4.9 (m, IH, H-
2'), 4.5 (m, 2H, H - 3 ' , 4 ) , 4-4.2 (m, 2H, H-5'); Analy. 
Calcd. for Cio'^12'^503C 1 : C,42,l; H, 4.2; N, 24.5; Found: 
C, 41.8; H, 4.2; N, 24.57.. 
4-Amino-l-(5'-deoxy-5'-isobuty1thio-p-P-ribofuranosyl)-
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IH^pyrazolo[3,4-d]pyrimidine (18) 
To a solution of 4-amino-1 - ( 5 '-deoxy-5 ' -c h 1 oro-f?-
D-ribofuraosyl )-lH-pyra2olo[3,4-d^]pyrimidine (17,Q.25g, 
0.84 mmol), 2N aq NaOH (10 ml) was added 2-methyl-l-
propane thiol (3.5 ml). The mixture was heated at 80 
for 2 hr, cooled at ambient temperature, acidified with 
dil acetic acid to pH 4-5 and evaporated to dryness in 
vacuo. The crude product thus obtained was chromatogra-
phed on Si02 column. Elution of the column with 
CHCl3:MeOH (94:6, v/v) afforded the compound 18. (0.19 g, 
657, yield); m.p. : 65°; MS (m/z) : 339 (h"^  ) ; IR ( KBr) : 
3100, 3300; PMR (CDCl3-DMS0-d^) : 8.15 (s, IH, H-6}, 8.0 
(s, IH, H-3), 6.5 (bs, 2H, NH2), 5.9 (d, IH, Ji'2= ^-^ 
Hz, H-1'), 4.5-4.7 (m, IH, H-2'), 4.1-4.3 (m, 2H, H-3 , 
4'), 2.85 (m, IH, H-5'), 2,4 (d, 2H, J=7.2 Hz, CH2S), 
1.5-1.9 (m, IH, CH), 0.9-0.B (each s, 6H, 2 CH3); Analy. 
Calcd. for C j^4H2i.N503S: C, 49.5; H, 6.2; Found: C, 49.5; 
H, 6.27.. 
4-Affiino-l-(5'—deoxy—5'-ally1thio-p-D-ribofuranosyl)-
IH—pyrazolor3.4—d]pyrimidine (19) 
To a warm solution of 4-amino-l-(5'-deoxy-5 -
chloro-f3-D-r ibof uranosy 1 ) -lH-pyrazoloC3 ,4-d^]pyrimidine 
(17, 0.2 g, 0.7 mmol) in 2N aq NaOH (8 ml) was added 
allyl mercaptan (4 g ) . The mixture was heated at 80 
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for 90 min, coaled to ambient temperature, acidified 
with dil acetic acid to pH-5 and evaporated to dryness. 
The crude product thus obtained was chromatographed o 
S1O2 column. Elution of the column with CHCl3:MeOH 
(94:6, v/v) afforded compound 1_9 (0.15 g, 667. yield); 
m.p.: 55-60°; MS (m/z): 323 (M"^); IR ( KBr) ; 3200 (NH2), 
340Q (OH); UV (MeOH): 258.2, 217; PMR (CDCl3-DMSQ-d^): 
8.25 (s, IH, H-6), 8.05 (s, IH, H-3), 6.3 (bs, 2H,NH2), 
6.0 (d, IH, J;i^ -2-=4 Hz, H-1'), 5.8-5.5 (m, iH,=CHR), 
5,2-4.7 (m, 3H, H-2'and =CH2), 4.3-4.7 (m, 2H, H-3', 
4 ) , 3.3-3.1 (m, 2H, CH2S), 2.0-3 (m, 2H, H - 5 ) ; Analy. 
Calcd. for Ci3Hi7N503S:C, 48.28; H, 5.3; N, 21; Found : 
C, 48.2; H, 5.28; N, 21.2*/.. 
4-Amino-l-(5'-deoxy-S'-n-hepty1thio-g-D-ribofuranosy1)-
lH-pyrazolor3.4-d]pyrimidine (20) 
To a warm solution of 4-amino-l-(5'-deoxy-5 '-
chl oro-(3-D-r ibof uranosy 1 ) -IH-pyrazo lo[ 3 , 4-d^ ] pyrimidine 
(17, 0.15 g, 0.5 mmol) in 2N aq NaOH (8 ml) was added n-
heptyl mercaptan (2 ml). The mixture was heated at 80 
for 2 hr, cooled to ambient temperature and acidified 
with dil acetic acid to pH 4-5. The solid that sepa-
rated was filtered off, washed with dry ether to give 
compound 20. (0.14 g, 727. yield); m.p.: 118° ; MS (m/z): 
381 (M"^); IR (KBr): 3400, 3200; PMR (CDCl3-DMS0-d5) : 8.3 
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(s, IH, H - 6 ) , 8.05 (s,lH, H - 3 ) , 6.45 (bs, 2H, N H 2 ) , 6.1 
(d, IH Ji-2- = '^•^ ^^2, H-1 • ) , 4.6-4.85 (m, IH, H-2 ), 
4.1-4.6 (m, 2H, H-3', 4 ' ) , 2.9-3.0 (m, 2H, H - 5 ) , 1.1-
1.6 (m, 15H, C7H;i^5) . 
4-Amino-l-(5'-deoxy-5'-p-chlorobenzy1thio-p-P-
ribofuranosy1)-lH-pyrazolo[3.4-d]pyrimidine (21) 
To a warm solution of 4-amino-l-(5'-deoxy-5'-
chloro-R-D-ribof uranosy 1 )-lH-pyrazoloC3, 4-d^] pyrimidine 
(17, 0.15 g, 0.5 mmol) in 2N aq NaOH (8 ml) was added p-
chlorobenzyl mercaptan (2 m l ) . The mixture was heated at 
80 for 2 hr, cooled to ambient temperature and acidi-
fied with dil acetic acid to pH 4-5. The solid, that 
separated was filtered off, washed with dry ether to 
afford the compound 2J^ (0.14 g, 65"/. yield); m.p.: 130 ; 
MS (m/z): 407 ( M " ^ ) ; I R ( KBr ) : 3200 (NH.2 ) , 3400 (OH); 
PMR (CDCl3-DMS0-d^): 8.3 (s, IH, H - 6 ) , 8.1 (s, IH, H - 3 ) , 
7.2 (5, 4H, p H - H ) , 6.6 (b5, 2H, N H 2 ) , 6.0 (d, IH, J i - 2 = 
4 Hz, H - 1 ' ) , 4,5-4.8 (m, IH, H - 2 ) , 4.1-4.4 (m, 2H, H-
3 ' , 4 ' ) , 3.75 (s, 2H, CH2Ph), 2.9-2.7 (m, 2H, H - 5 ) ; 
Analy. Caled. for Cj^oHi2N503S : C, 29.4; H, 2.9; Found : 
C, 29.5 ; H, 37.. 
4-Amino-l-( 5' -deoxy-5' -( L-cysteine )-|3-D-ribof uranosy 1-lH-
32 
pyrazolo[3.4-dJpyrimidine (22) 
To a mixture of L-cysteine (0.13 g, 1.1 mmo1) ana 
freshly distilled liquid NH3 (25 ml) was added Na m 
small pieces until a blue colour persisted. To it was 
added 4-amino-l-(5'-deoxy-S'-chloro-B-D-riboTuranosyl) 
pyrazoloC 3 , 4-d^] pyr imidine (17, 0.15 g, 5 mmo 1 ) and the 
mixture was stirred vigorously at -70 for 5 hr. Ammo-
nia from the resulting mixture was allowed to evaporate. 
The solid residue, thus obtained was dissolved in H2O 
(10 m l ) , neutralized with IN H2SG4 to pH-7. The product 
thus obtained was passed through on exchange resin IRC-
+ 
120 (H form). The column was eluted with H2O followed 
by IN NH4OH. The fractions containing the product were 
concentrated ij2 vacuo and lyophilized. The lyophilized 
product on standing gave the desired compound 22^ (0.14 
g, 707. yield); m.p. : 250°; MS (m/z): 370 ( M " ^ ) ; IR 
(KBr): 3200 (NH), 3400 (OH), 1680 (C=Q); Analy. Calcd. 
for CJ^3HJ^QN^0 5 S : C , 42.1; H, 4.8; N, 22.7; Found: C, 
42.1 ; H, 4.5; N, 22. SV.. 
5'—Deoxy-5'—chloroadenosine (23) 
A mixture of adenosine (8, Ig, 3.7 mmol), SOCI2 
(1.5 ml) and hexamethy 1phosphoramide (10 ml) in a R.B. 
flask (covered with black paper) was stirred at ambient 
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temperature for 20 hr. The resulting mixture was poured 
into ice cold H2O (90 m l ) . The product that separated 
out was taken in H2O and passed through resin (IRC-50) 
(H -form). Elution of the column with IN NH4OH gave the 
product, crystallized from hot H2O to give 23 {0.7 g, 
667. yield); m.p.: 190° (H2O); MS (m/z) : 285 ( M"^ ) ; IR 
(KBr) : 3400; PMR (CDC 13-DMSO-d^) : 8.1 (s, IH, H-8) , 8.0 
(s, IH, H - 2 ) , 6.7 (s, 2H, NH2) , 5.9 (d,lH, J^2'=^-^ ^^ •> 
H - 1 ) , 4,5-4.7 (m, IH, H - 2 ' ) , 4.1-4.4 (m, 2H, H-3', 4 ) , 
3.7-3.9 (m, 2H, H - 5 ' ) ; Analy. Calcd. for C10H12N5O3CI : 
C, 42.1; H, 4.2; N, 24.5; Found: C, 42.1; H, 4.2; N, 
24.3/;. 
5'-Deoxy-5'-p—chlorobenzy1thioadenosine (24) 
To a warm solution of 5'-deoxy-5'-chloroadenosine 
(23, 0.3 g, 1 mmol ) in 2N aq N'aOH (20 ml) was added p-
chlorobenzyl mercaptan (4 m l ) . The mixture was heated 
at 80 for 2 hr. The resulting mixture was cooled at 
ambient temperature and acidified with dil acetic acid 
to pH 4-5. The solid that separated was filtered off 
and crystallized from dry MeOH to give the compound 2£ 
(0.29 g, 707. yield); m.p. : 110°; MS (m/z): 407 ( M " ^ ) ; IR 
(KBr): 3400 (OH), 3200 (NH) ; PMR (CDC 13-DMSO-d^) : 8.1 
(s, IH, H - 8 ) , 8.0 (s, IH, H - 2 ) , 7.2 (s, 4H, P h - H ) , 6.74 
(bs, 2H, N H 2 ) , 5.85 (d, IH, Ji-2'=5.4 Hz, H - 1 ' ) , 4.5-4,7 
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(m, IH, H - 2 ) , 3.9-4.3 (m, 2H, H-3 , 4 ), 3.6 ( 5, , 2H, 
CH2Ph), 2.6-2.8 (m, 2H, H - 5 ' ) ; Analy. Calcd. tor 
Cl0'^12^503S: C, 29.4; H, 2.9; Found : C, 29.1; H, 2.9V.. 
5'-Deoxy-5'-hydroxyethy1thioadenosxne (25) 
To a warm solution of 5'-deoxy-5 -chioroadenosine 
(23, O.lg, 0.35 mmoI) in 2N aq NaDH ( 6 ml) was added 
mercaptoethanol (3 m l ) . The mixture was heated with 
stirring at 100 for 4 hr. The resulting mixture was 
cooled to ambient temperature, acidified with dil ace-
tic acid to pH 5, and evaporated in_ vacuo. The crude 
product, thus obtained was chromatograpned over S1Q2 
column. Elution of the column with CHC13:MeQH (95:5, 
v/v) gave the compound 25^ (57 mg , 507. yield); m.p. : 
188°; !iS (m/z): 327 ( M"^ ) ; IR ( KBr ) : 3600, 3250 (NH) ; PMR 
(DMSO-d^): 8.45 (5,1H, H - 8 ) , 8.3 (s, IH, H - 2 ) , 7.35 (bs, 
2H, NH2 ) , 6.1 (d, IH, Jj^^'^**-"^ ^^ - H - l ) , 5.2-5.8 (m, 
IH, H - 2 ' ) , 4.6-5.1 (m, 2H, H - 3 ' , 4 ) , 4.0-4.5 (m, 2H, HO-
C H 2 ) , 2.9-3.1 (m, 2H, H - 5 ) , 2.6-2.9 (m, 2H, CH2S). 
5'-Deoxy—5'-n—hepty1thioadenosine (26) 
To a warm solution of 5'-deoxy-5'-chloroadenosine 
(23, 0.3 g, 1 mmol) in 2N aq NaOH (16 ml) was added n-
heptyImercaptan (5 m l ) . The mixture was heated at 80 
for 2 hr. The resulting mixture was cooled to ambient 
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temperature and acidified with di! acetic acid to pH 4. 
The solid that separated was filtered off and washed 
with dry ether. The crude product was chromatagraphed 
over SiD2 column. Elution of the column with CHCl;7:NeOH 
(96:4, v/v) gave compound 26^ (0.38 g, 11'/. yield); m.p. : 
85-90°; MS (m/z): 381 ( M"^ ) ; IR ( KBr ) : 3400 (OH); PMR 
(CDCl3-DMS0-d^) : 8.2 (s, IH, H - 8 ) , 8.1 (s, IH, H-2), 
6.3 (b5, 2H, NH2), 6.0 (d, IH, Ji'2'=5 Hz, H - 1 ' ) , 4.6-
4.9 (m, IH, H - 2 ' ) , 4.1-4.4 (m, 2H, H - 3 ' , 4 ' ) , 2.3-2.9 (m, 
2H, H - 5 ' ) , 1-1.5 (m, 15 H, CyH-js). 
5'—Deoxy—5'—isobutyIthioadenosine (27) 
To a warm solution of 5'-deoxy-5'-chloroadenosine 
(23, 0,15 g, 0.5 mmol) in 2N aq NaOH (8 ml) was added 2-
methy1-1-propane thiol (2 m l ) . The resulting mixture 
was heated at 80 for 4 hr, cooled at ambient tempera-
ture and acidified with dil acetic acid to pH 4-5. The 
product, thus obtained was chromatographed over S1O2 
column. Elution of the column with CHCl3:MeOH (94:6 
v/v) afforded the compound 27^ (0.1 g, 55"/. yield); m.p. : 
71° (MeOH); MS (m/z): 339 ( M " ^ ) ; IR (KBr) : 3150 3400 
(OH); PMR (CDCl3-DMS0-d^): 8.2 (s, IH, H - 8 ) , 8.1 (s, IH, 
H - 2 ) , 6,5 (bs, 2H, NH2), 5.95 (d, J i 2 ' = 5 . 4 Hz, H - 1 ) , 
4.6-4.8 (m, IH, H - 2 ' ) , 4.1-4.4 (m, 2H, H-3',4'), 2.9 
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(„i,iH, H - 5 ' ) , 2.4 (d, 2H, J = 8.1 Hz, C H 2 S ) , 1,6-1.9 (m, 
IH, CH-CH2), 0.95, 0,89 (each s, 6H, 2 C H 3 ) ; Analv. 
G.ilcd. for Cj^4H2iNc,G3S : C, 49,5; H, 6.2; Found: C, 
4 9.3; H, 6.2'/.. 
? P-(2'.3".5"-tri-0-acetyl-D-xylofuranosyl)adenine (30) 
To a mixture of adenine (28, 135.1 mg, 1 mmol), 
1,2,3,5-tetra-O-acetyl-D-xylofuranose (29, 0,505g, 1 
mniol ) and anhydrous nitromethane (50 ml) was added stan-
nic chloride (2 mmol) and the mixture was stirred at 
ambient temperature for 20 hr, TLC showed the disappea-
m n c e of starting sugar and base. The resulting mixture 
wcis concentrated to (5 m l ) , NaHC03 (600 mg ) and H2O ( 2 
ml) were added. When vigorous evolution of CO2 ceased, 
it was extracted with hot CHCI3 filtered and evaporated, 
Tfie crude product thus obtained was chromatographed over 
S1O2 column, Elution of the column with CHCl3:MeOH 
(7753 v/v) gave colorless foam of compound 30. (0.38 g, 
!<)'/. yield) ;IR ( KBr) : 3200 (NH) , 1750 (C = 0 ) ; MS (m/z) : 
3V3 (M^); PMR (CDCI3) • 8-35 (s, IH, H - B ) , 8,15 (5, IH, 
H 2 ) , 6,45 (bs, 2H, NH2) , 6.25 (d, IH, Jj^.2-=3,0 Hz, H-
1 ) , 5,59 (m, IH, H - 2 ' ) , 5.45 (m, IH, H - 3 " ) , 4.5-4.4 (m, 
IH, H - 4 ' ) , 4.2-4.4 (m, 2H, H - 5 ' ) , 2.2, 2.15, 2.1 (each 
s, 9H, 3XCH3CO). 
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9-p-D-XylQfuranosyladenine (31) 
A miKture of (30, 5g, 12.7 mmo1) and methanolic 
ammonia (MeOH at 0 saturated with NH3) was kept at 
ambient temperature for 24 hr. The solvent and excess 
of reagent from the resulting mixture were removed in 
vacuo. The crude product, thus obtained was chromatog-
raphed over SiD2 column. Elution of the column with 
CHCl3:MeOH (90:10, v/v) gave Zl_ (2.5 g, 747. yield); 
m.p.: 135-40°; UV (MeOH): 258.4 (pH-7), 258.4 (pH-11), 
258.0 (pH-2); IR ( KBr ) : 3400, 3200; MS (m/z): 267 ( M " ^ ) ; 
PhR (CDCl3-DMS0-d^): 8.34 (s, IH, H - 8 ) , 8.28 (s, IH, H-
2 ) , 7.15 (bs, 2H, N H 2 ) , 5.99 (d, IH, Jj^-2'=3 Hz, H - l ) , 
4.5 (m, IN, H - 2 ' ) , 4.20 (m, 2H, C-3', 4 ) , 3.85 (d, 2H, 
J= 4.8 H 2 , H - 5 ' ) ; Analy. Calcd. for C J^QH •^3N505: C, 44.9; 
H, 4.9; N, 26.2; Found: C, 44.8; H, 4.9; M, 26.47.. 
9-C5'—Deoxy-5'-tosy1—0—D-xylofuranosy1 ladenine (32) 
A solution of anhydrous 9-R-D-xy2 ofuranosyI ade-
nine (31, 1.2 g, 4.8 mmol) in pyridine (94 ml) was 
cooled to 0-5 . To it was added dropwise over 1 hr, a 
solution of p-toluene sulfonyl chloride (1.44 g, 7.5 
mmol) in CHCl3:pyridine (1:1, 36 ml) and the mixture was 
stirred at O for 8 hr. The resulting mixture was 
poured into a solution of saturated aq NaHC03 at 0-4 . 
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The chloroform layer was separated and the aq phase was 
extracted with CHCI3 (2x20 ml). The combined CHC13 
extracts was washed with H2O and dried (Na2SQ4) and the 
solvent removed under reduced pressure. The crude pro-
duct, thus obtained was chromatographed over SiQo co-
lumn. Elution of the column with CHCl3:MeOH (94:6, v/v) 
gave compound 32. (1,04 g, 517. yield); m.p. : 160 ; UV 
(MeOH) : 259.2 (pH-7), 260 (pH-11), 258.4 (pH-2); IR 
(KBr): 3200 (NH) , 1695, 1610; MS (m/z): 421 (M"^); PMR 
(CDCl3-DMS0-d£,) : 8.1, 8.3 (each s, 2H, H-8,2), 7.2-7.8 
(m, 4H, Ph-H), 7.1 (bs, 2H, NH2), 5.9 (d, IH, H-1 ) , 4.2 
(m, 2H, H-5'), 4.35 (m, 2H, H-3',4'), 4.4 5 (m, IH, H-
2'), 2.35 (s, 3H, CH3); CMR (DMSQ-d^): 156 (C-6), 152.4 
(C-2), 148.7 (C-4), 139.7(0-8), 118.9 (C-5), 145.0, 
132.1, 129.9, 128.1, 127.6, 125.5 (pH), 89.6 ( C - 1 ) , 
80.0 (C-4'), 79.6 (0-3'), 75.3 (0-2'), 69.9 ( 0 - 5 ) , 21.0 
(OH3); Analy. Oalcd. for 0i7Hi9N50^S: 0, 48.4; H, 4.5; 
Found: 0, 48-1; H, 4.8V.. 
9-(5'-Deoxy-5'-methylthio-p-D-xylofuranosy1)adenine (33) 
and 9—(3".5'—epoxy-p-D-xylofuranosy1)adenine (34) 
A mixture of 9-C 5 '-deoxy —5 ' —tosy l-(3-D-xy 1 of urano-
syl]adenine (32, 2 g, 0.47 mmol), DMF (20 ml) and MeSNa 
were stirred at 80 for 16 hr. The resulting mixture 
was cooled and neutralized with dil acetic acid and 
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evaporated ir\ vacuo. The crude product, thus obtained, 
was chromatoqraphed on 5102 column. Elution of the 
column with CHCl3:MeDH (94:6, v/v) afforded the mixture 
of compounds 33^  (minor) and 34^ (major) (0.5 g, 40'/. 
yield); m.p. : 202-5°; MS (m/z) : 249 and 297 ( M"*" ) ; PMR 
CDCl3-DMSQ-d^) for 33. and 34^: 8.45 (s, IH, H-8) , 8.25 
(s, IH, H-2), 7(bs, 2H, NH2), 6.5 (5, IH, H - 1 ) , 8.2 
(s, IH, H-8), 0.05 (5, IH, H-2), 7(bs, 2H, NH2), 5.86 
(m, IH, H-1'), 2.14 (s, 3H, SCH3). 
9-[5 -Deoxy-5 -tosyl-2'.3'-di-Q-acetyl-p-D-xylofurano-
sy1jadenine (35) 
A mixture of 9-[ 5 '-deoxy-5 ' - tosy 1-(3-D-xy 1 of urano-
sylTadenine (32, 0.2 g, 0.47 mm.ol), pyridine (10 ml), 
acetic anhydride (3 ml) and a catalytic amount ofDMAP 
were stirred at ambient temperature for 20 hr. Excess 
of reagent and solvent were removed iji vacuo. The 
residue was taken in CHCI3, washed with H2O, aqueous 
f\JaHC03 and H2O, dried (Na2S04) and the solvent removed 
in vacuo. The crude product, thus obtained, was chroma-
tographed over Si02. Elution of the column with 
CHCl3:Me0H (90:2, v/v) afforded the compound 35 as a 
colourless foam (0.15 g, 617. yield); IR (neat): 1750 
(acetyl); PMR (CDCI3): 8.8 (s,lH, H-8), 8.3 (s,lH, H-2), 
7,55-7.8 (m, 2H, ph-H), 7.1-7.38 (m, 2H, pH-H), 6.3 (d, 
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IH, J^-2'=3 ^2' H - 1 ) , 5.4-5.7 (ni , 2H , H^  2 ' , 3 j, 2.38 
(s, 3H, COCH3), 2.15 (s, 3H,CaCH3). 
9-(5•-Deoxy-5'-methylthio-2',3'-di-Q-acety1-PP-
xylofuranosyI)adenine (36) 
A mixture of compound 3^ (0.4 q, 0.79 mmol), DMF 
(14 ml) and MeSNa (1 g) were stirred at 80° for 24 hr. 
The resulting mixture was cooled and neutralized with 
dil acetic acid and evaporated in vacuo. The crude 
product, thus obtained was passed through sephadex co-
lumn. Elution of the column with MeOH afforded as an 
oil 36^  (0,15 g, 50/: yield); IR (neat) : 1750 (acetyl); 
PMR (CDCI3): 8.52 (s, lH,H-8), 8.2 (s, IH, H-2), 6.2 (d, 
IH, Jj^-2-=3 H2, H - 1 ) , 5.4-5.7 (m, 2H, H-2' , 3 ' ) , 4.25-
4.45 (m, 2H, H-5'), 4.5-4.7 (m, IH, H-4'), 2.5 (s, 3H, 
SCH3), 2.11 (s, 3H, COCH3), 2.05 (s, 3H, C0rH3). 
9—(5'-Deoxy-5'—methylthio-p-D-xylofuranosy1)adenine 
(33) 
A mixture of 36^  (0. 2g, 0.52 mmol) and methanolic 
ammonia (MeOH at 0 saturated with ammonia) was kept at 
ambient temperature for 24 hr. The solvent and excess 
of reagent from the resulting mixture were removed in 
vacuo. The curde product, thus obtained, was passed 
through sephadex column. Elution of the column with 
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MeOH afforded compound 33 (90 mq , 60'/. yield) hygrosco-
pic; UV (MeOH) : 258 (pH-7), 258 (pH-2), 257 (pH-11); IR 
(KBr): 3400; MS (m/z): 297 (fi"^  ) ; PMR (DMSO-d^): 8.2 (s, 
IH, H-8), 8.1 (s, IH, H-2), 7.32 (bs, 2H, NH2), 6.15 (d, 
IH, J=8Hz, OH), 5.95 (d, IH, J=6.A Hz, OH), 5,82 (d, IH, 
Jj^-2-= 1-6 Hz, H-1'), 4.2-4.3 (m, 2H, H-2-, 4'), 3.96 
(m, IH, C - 3 ) , 2.6-2.85 (dd, 2H, J=8,12, H - 5 ) 2.15 (5, 
3H, SCH3); Analy. Calcd. for CiiHi5N503S: C,44.4; H, 
5,05; N, 23,5; Found: C, 44.5; H, 4,9; N, 23.4V.. 
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CHAPTER - 3 
SYNTHESIS OF ACYCLIC NUCLEOSIDES OF 4 
SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE 
AND THEIR BIOLOGICAL ACTIVITY 
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3.1 INTRODUCTION 
Adenosine (1) a well known naturally occurring 
1 2 
nucleoside is an effective coronary vasodialator ' , and 
inhibitor of platelets thrombi . It is believed that, 
when cells a.rB injured, some of their adenosine triphos-
phate (ATP) breaks down to adenosine diphosphate (ADP), 
4 
which initiates the aggregation of blood platelets , ADP 
on further dephosphory1ation by plasma enzymes ' pro-
duces abenosine monophosphate (AMP) or adenosine which 
g 
exerts its inhibitory action on platelets aggregation . 
The analogs of adenosine are reported to have longer 
_, ^ ^ • _ , ^ _ , . 9 , 1 0 
duration of action as compared to adenosine 
The replacement of ring carbon or nitrogen of 
purine (2) by a nitrogen or carbon atom gives aza.dea^a-
purines (3,4) ring system respectively, whereas inter— 
change of nitrogen at position-7 with carbon at posi-
tion-8 of purine system (2) affords pyra2olo[3,4-d^]pyri-
midine (5). A number of deaza and aza purine nucleo-
sides have been synthesized as potential antitumor and 
^. . , ^ 11,12 
antiviral agents 
Pyrazol oC3,4-d^]pyrimidine nucleosides have re-
ceived considerable attention due to their wide spectrum 
of biological activities. Allopurinol [pyrazola[3,4-
108 
d^ ] pyrimid ine-4-one ] (7) an analog of hypoxanthine (6) is 
an inhibitor of purine catabolic enzyme, xanthine oxi-
14 15 
dase and is used for the treatment of hyperurecemia 
responsible for gout . 4-Amino-lH-pyra2ola[ 3 , 4-d^ 3 pyr i-
midine ribosides (8) an analog of adenosine (1) is 
17-22 
active against a number of species of Leishmanla 
Allopurinol ribonucleoside (9) has been shown to be 300 
times more active than allopurinol against Leishmanla 
21 
donovani in vitro Recently, both the 4-amino-lH-
pyrazoloC3,4-d^] pyrimidine (4-APP) and its ribonucleo-
sides (8)were found to be several times more active than 
9 against promastigotes of Leishmania brazi1lensis and 
23 L.mexicana 
The antiparasitic properties of allopurinol, 4-
APP and their corresponding nucleosides, and the 
observation that certain analogs of the normal 
nucleosides, in which the ribose unit was replaced by a 
truncated acyclic residue, all displayed the potent 
biological activities as antiviral agents"^ . 
Several varieties of nucleosides have been syn-
thesized in recent years. Some of these nucleosides 
have shown significant anticancer, antiparasitic and 
antiviral activities. A few of them are being used as 
25 drugs. Ftoraphur C5-fluoro-l-tetrahydrofury1]uraci1 
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NH: 
I I> 
OH OH 
1 
HN 
W 
OH OH 
9 
H 
H 
7 
0 
HN 
H 
0 NHn 
X HN^^N 
0 
OH OH 
0 
C3H7O 
H2N' 
11 
12 
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(10), 9-[hydroxyethoxymethy1Iguanine (11), 9-[cyclQhe-
27 
xy1-2-propoxy]adenine (12) are very active compounds, 
which are specific to the infected cells. These com-
pounds 10—12 are not true nucleosides. Although the 
heterocyclic moiety in these compounds is the same as 
present in the nucleosides of nucleic acid. However the 
glucone moiety is not the usual D-ribose or D-deoxy 
ribose. The tetrahydrofurany1, cyclohexyl, hydroxyetho-
xymethyl moieties attached at position N-9 in these 
compounds, due to their hydrophobic nature may be faci-
litating the transport of these molecules across the 
cell membrane. Inside the cell these compounds might be 
converted into riboside by the action of ribofuranosyi 
transferase and to nucleosides. 
A number of acyclic pyrazaloC3,4-d^]pyrimidine 
28 
nucleosides have been synthesized - Some of the com-
pounds showed highest degree of antileishmanial 
28 
activity , which'' yielded a 87'/. and 96"/. parasite 
inhibi tion. 
3.2 PRESENT WORK 
The above report prompted us to undertake the 
synthesis of acyclic nucleosides of 4-hydroxy and 4-
amino-lH-pyra2olo[3,4-d,]pyrimidine5. 
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23 
30 
38 
NH2 
C. 1 N 
26 
KXJ 
HO 
NH2 
3^ 
W 
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In the present chapter the synthesis of l-[2-
hydroxy-l-(hydroxymethy1)ethoxy]methyl-4(5H)-oxo-lH-
pyrazoloC3, 4-d^]pyrimidine (23), 1-[2-hydraxy-l-( hydroxy-
methy l)et ho xy] methyl-4-amino-lH-pyrazolo[ 3,4-d^]pyrimi-
dine (26), l-[2-hydroxy-l-(aminomethy1)ethoxy]methy1-
4 ( 5H )-oxo-lH-pyrazoloi;3 , 4-d_]pyr imidine (30), l-C2-hydra-
xy-l-(aminomethy1)ethoxy]methyl-4-amino-lH-pyrazola[3,4-
d_3pyrimidine ( 34 ) m !-[ hydroxyethoxy ]methy 1-4 ( 5H )-oxo-lH-
pyrazalo[3 , 4-c[3 pyrimidine (38) , 4-amino-l-C hydroxyetho-
xy 3methyl-IH-pyrazoloC 3 , 4-d_] pyrimidine (40) and their 
anti leishmanial activity in. vivo are reported. 
3.3 SYNTHESIS 
3.3.1 Synthesis of 4—methylthiQ-lH-pYrazoloC3,4-d3pyrimidine 
(19) 
4-Methy 1 thio-lH-pyrazoloC3 ,4-d_] pyrimidine (19) 
(Scheme 1) the key intermediate with synthesis of 4-
substituted pyrazolo[3,4-d^] pyrimidine nucleosides had 
been synthesized by following the method of Robins 
.r, ,. 
Condensation of malononitrile with triethyl orthoformate 
(13) gave ethoxymethylene malononitrile (14) in quanti-
tative yield. Treatment of J^ with hydrazine hydrate 
yielded 5-amino-4-cyano-lH-pyrazole (15) in 307. yield. 
Hydrolysis of 15_ with sulphuric acid afforded 5-amino-
lH-pyrazole-4-carboxamide (16) in excellent yield. Cyc-
lisation of 16^ with formamide gave 4 ( 5H)-oxo-lH-pyrazo-
lis 
E t o ^ 
EtO—CH 
E t O ^ 
13 
( i ) 
EtO—CH=C<^ 
CN 
1^ CN 
0 
N-
H 
16 
Reagents; 
(iii) 
(vi) 
(i) CH2(CN)2,Ac20, Pyridine, 
(ii) H^NNH^, R.T. 
(iii) H^SO^, R.T. 
(iv) HCONH^ 
(v) P_S ^, Pyridine 
(vi) CH3I, NaOH, R.T. 
NC 
H2N 
(ii) 
N' 
H 
15 
Scheme - 1 
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loC3,4-d_]pyrimidine (17) in 58'/. yield. The mass spec-
trum, elemental analysis and the IR spectrum of IZ were 
in accordance with the assigned structure. Treatment of 
17 with P2^5 ^^ refluxing pyridine yielded 4(5H)-mercap-
to-lH-pyra2oloC3,4-d^]pyrimidine (18), which on methyla-
tion with methyl iodide under basic condition yielded 4-
methy 1 thio-lH-pyrazoloC3 , 4-d^]pyr imidine (19) in 52'/. 
yield. The pmr spectrum of 1^ had a singlet at 2.4 for 
the methylthio group and two singlets at 8.2 and 8.0 
for H-6 and H-3 respectively. The mass spectrum of the 
+ 
compound had the base peak at m/z 167 (li ). Other 
significant ions in the spectrum were at m/z 120 
(CqH^N^)and 93 (C4H3N3). 
3.3.2 Synthesis of 1—[2-hydroxy—1—(hydroxyreethyl)ethoxyljmethyl 
-4(5H)-oxo-lH-pyrazolQ[3,4-d]pyrimidine (23) 
Method 1^  
Condensation of 4-methy1thio-iH-pyrazolo[3,4-d] 
pyrimidine (19) (Scheme 2) with 1,3-dibenzyloxy-2-chio-
romethyloxy propane (20) in the presence of .Et3N gave 1-
[2—benzyloxy-l—(benzyloxymethy1)ethoxy]methyl-4-methy 1 -
thio-lH-pyrazoloC3,4-d^]pyrimidine (21) in 70"/. yield as 
an oil. The compound 21_ analysed for C2/\^2h^^^5^ ^'''^ 
had molecular ion peak at 450 (M ) in mass spectrum. PMR 
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Reagents 
l i il + "[^ Osj^ Bn ^^a^ . A 
19 20 
23 
(i) Et^N, DMF 
(ii) KOH, Dioxane, 
(iii) Pda2-H2, R.T. 
(iv) HMDS, (NH^)^ SO^, 
(v) Benzene, A 
Scheme - 2 Bn=CH2Ph 
lib 
spectrum of compound 2J_ had a singlet at Li . BH tor 
OCH2N- protons. Compound 2j_ on reaction with NaOH qave 
4(5H)-oxo derivative (22). Hydrogenolysis of 22 with 
PdCl2 i"^  hydrogen atmosphere furnished the required 
compound 23 in 55"/. yield. Compound 23^  analysed for 
+ 
9^'~*i2'^ 4'-'4 and had molecular ion peak at 240 (M ) in its 
mass spectrum. The ultra violet absorption of compound 
23 gave bands at -Xmax 251, 206 nm. The site of alkyla-
tion in compound 23_ was established by correlating the 
29 
UV absorption pattern (Tabie-1) . Compound 2J)^  shows 
similar UV absorption pattern as a 11opurmol-1-riboside, 
reflecting 2^ to be N-1 isomer PMR spectrum of the 
compound 23 had two singlets at 7.95 and 7.9 for H-6 
and H-3 respectively in the heterocyclic moiety and a 
singlet at 5.75 for -0CH2N-protons suggested the attac-
hment of aglycon moiety. 
Method 2 
The reaction of 4-hydroxy-iH-py razol o[ 3 , 4-d^ ] py-
rimidine (17) with hexamethyIdisi1azane (HMDS) in the 
presence of (NH4)2SO4 gave silylated derivative (24). 
The condensation of 24_ (Scheme 2) with 1 ,3-di benzy loxy-
2-chloromethyloxypropane (20) in refluxing benzene gave 
compound 22^ , which on hydrogenol ysis with PdCl2 furnis-
hed 23^ . The compound 23^  obtained by this procedure was 
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Table - 1 
UV Absorption maxima of substituted pyrazolo[5,4~d] 
pyrimidine derivatives Q 
N—1 isomer HN 
R 
^ 
Compound No. X max 
pH-7 pH-il 
CH2OCHCH2OH 
CHoOH 
251 270 
30 
38 
CH2OCHCH2OH 
CH2NH2 
CH2OCH2CH2OH 
250 
250.6 
270.6 
271 
41 Me 249 270 
42 ribose 252 271 
N—2 isomer 
43 
44 
Me 
ribose 
o 
HN 
^N-^-^-R 
255 
261 
280 
284 
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identical in all respects with the compound made bv 
method-1. 
3.3.3 Synthesis of l-[2-hydroxy-l-(hydroxymethy1)ethoxyJmethyI 
-4-amino-lH-pyrazQlo[3,4-d]pyrimidine ( 2<b ) 
Condensation of 4-methy1thio-lH-pyrazo1o[3,4~ 
d^Dpyrimidine (19) (Scheme 3) with 20 gave 2J^ . Compound 
21 on reaction with ammonia under pressure at elevated 
temperature afforded 25^ in 50"/, yield as an oil. Com-
pound 25^ analysed for C23H25N5D3 had a molecular ion 
peak at 419 (M ) in mass spectrum. FMR spectrum of the 
compound 25^ had a two proton singlet at 5.8 for -QCH2N-
protons. Compound 25. on hydrogenol ysis with PdCIp in 
hydrogen atmosphere furnished the required compound 26 
in 407. yield. The compound 26 analysed for C9H<^3N5QT; 
had molecular ion peak at 239 (M ) in mass spectrum. In 
the infrared spectrum, the N-H stretching was at 3100 
cm . PMR spectrum of the compound 26^  had two singlets 
at Q.l for H-6, and at 7.5 for H-3 of the heterocyclic 
moiety and a singlet at 5.7 for -0CH2N-prQtons. 
3.3.4 Synthesis of l-[2-hydroxy-l-( atninomethyI jethoxy] twgthyl~ 
4(5H)—oxQ-lH—pyrazolo[3.4-d]pyrimidine (30) 
Condensation of bis (trimethyl silyl) derivative 
of 4-hydroxy-lH-pyrazolo[3,4-d^]pyrimidine (24) (Scheme 
4) with 2-chloromethoxy-l-ben2yloxy-3-phthalDy1imidopro-
Reagents; 
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(i) Et^N, DMF 
,r, ,,(ii) NH^-MeOH, 120° 
(iii) PdCl2-H2, R.T. 
OBn 
21 
25 
Scheme - 3 
120 
iMe3 
N- ^ j, ^  t ^ J ^ " k N^^^N-^ 
SiMe3 
24 
(n) 
28 
27 
Reagents; 
30 
(i) Benzene, Z i 
(ii) MeOH-H2NNH2, R.T. 
( i i i ) PdCl2-H2, R.T. 
Scheme -'+ 
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pane (27) in refluxing benzene gave 1-[2-benzy1 oxv^ 1-
( phthaloyl imidomethy 1 ) ethoxy ]methy 1 -'^  ( 5H ) -oxo- IH -py r azo-
loC 3 , 4-d.]pyrimidine (2B). The PMR spectrum of the com-
pound 28 had two singlets at 8.5 for H-6 and 8.2 for 
H-3 in the heterocyclic moiety, while in the 
aglycon moiety, two singlets at 7.6-7.8 and at 7.3 
stood for aromatic protons. Compound 28^ had a singlet 
at 5.7 for -OCH2N- protons. 
The protecting phthaloyl group was removed by the 
reaction of 28^ with hydrazine hydrate at 0 in EtOH to 
yield 29^ in 407. yield as an oil which on debenzy 1 atian 
with PdCl2~H2 to give the required compound 30 m 307. 
yield. Compound 30, analysed for C9HJL3N5Q3 and had moie-
+ 
cular ion peak at 239 (M ) in mass spectrum. The ultra 
violet absorption of the compound 30. (Amax 250, 206 nm) 
shows the similar UV absorption pattern as in the case 
of al lopurinol-1-ribosides, reflecting 30^  to be N-1 
isomer. PMR spectrum of the compound 30 had two sin-
glets at 8.0 for H-6 and 7.8 for H-3 respetively for 
heterocyclic moiety and had a singlet at 5.8 for -OCH2N-
protons. 
3.3.5 Synthesis of i—[2—hydroxy—l — Catninomethyl )ethoxy]methvl -
4—amino—IH—pyrazoloC3,4-d]pyrimidine (34) 
Condensation of 4-amino-lH-pyra2oloC3,4-d^3pyrimi-
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ci 
3^ 
27 
Reagents: 
( i ) 
(ii) 
(iii) 
DMF, NaH, R.T 
EtOH-H^NNH^, 
PdCl^-H^, R.T. 
Scheme - 5 
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dine (31) (Scheme 5) with 2-ch1oramethoxy-1-benzy1oxy-3-
phthaloy1imidopropane (27) in dry DMF gave 1-[2-benzy1o-
xy-1-(phthalay 1imidomethy1 )ethoxy]methy1-4- amino-lH-
pyra2oloC3 , 4-d^]pyrimidine ( 32 ) . The protecting phthaloyl 
group was removed by the treatment of 32^  at 0 with 
hydrazine hydrate to yield 33^  as an oil in 407. yield. 
Debenzylation of 3,3^  with PdCl2~H2 in atmosphere afforded 
the required 34;. in 587. yield. The compound 34_ analysed 
+ 
for C9Hj^4N^02 ^nd had molecular ion peak at 238 (M +1). 
PMR spectrum had two singlets at 8.4 and 8.1 for H-6 
and H-3 respectingly, and also had a singlet at 5.9 for 
-OCH2N- protons of aglycon moiety. 
3.3.6 Synthesis of l-ChydroxyethoxyJmgthy1-4(5H)—oxo-lH-
pyrazolo[3.4—djpyrimidine (38) 
Method 1^  
Condensation of 4-methy1thio-lH-pyrazolo[3,4-
r 
d_3pyrimidine (19) (Scheme 6) with benzoyloxy ethoxymet-
hylene chloride (35) in the presence of Et3N gave 1-
C benzoyloxyethoxy]methyl-4-methy1thio-lH-pyrazolo[3,4-
d.) pyrimidine (36) in 607. yield. Deblocking of the pro-
tected nucleoside 36^ with methanolic ammonia (methanol 
saturated with ammonia at 0 ) at ambient temperature 
afforded 37_ in 557. yield. Treatment of 37_ with aq KOH 
124 
SMe 
SMC 
+ 
CI OCOPh 
19 
38 
35 
( i l l ) 
36 
(H) 
SMc 
(v) 
a 
L/OsT '^ COPh 
39 
35 
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gave l-[hydroxyethoxy]methy 1-4(5H)-oxo-lH-pyrazolo[3,4-
d_]pyrimidine (38) in 307. yield. Compound 3B analysed 
for CgH-[^QN4a3 and had molecular ion peak at m/z 210 
(M ). Ultraviolet absorption of the compound 3£ ( Amax 
250.6, 207.8 nm) suggested position N-1 the site of 
alkylation. PMR spectrum of the compound 38^ had two 
singlets at 7.95 and 7.9 for H-6 and H-3 respectively 
and a singlet at 5.7 for -OCH2N- protons. 
Method 2 
Condensation of 24^ and 35^  in refluxing benzene 
gave i-[benzoyloxyethoxy]methyl-4(5H)-axo-iH-pyrazQlo 
[3,4-d]Dyrimidine (39) in 58"/. yield. Treatment of 39^  
with methanolic ammonia furnished the required compound 
38 The compound 39^  obtained by this procedure was iden-
tical in all respects with the compound made by the 
method-1. 
Synthesis of 1—[hydroxyethoxyjmethyl—4—aroino-lH—pyrazolo 
[3,4-d]pyriniidine (40) 
Treatment of compound 3^ (Scheme 7) with methano-
lic ammonia (methanol saturated with ammonia at 0 ) at 
elevated temperature in a steel bomb gave l-[hydroxyet-
hoxy ]methy l-4-amino-lH-pyrazolo[3 , 4-d^]pyrimidine (40) in 
50"/. yield. Compound 40^ analysed for CgHj^j^N5 O2 and had 
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a molecular ion peak at 209 (M ) m the mass spectrum. 
PMR spectrum of the compound 40^  had two singlets at 8.2 
and 8.1 for H-6 and H-3 proton respectively and a 
singlet at 5.7 for -OCH2N- protons. 
BIOLOGICftL ACTIVITY 
Antileishmanial activity 
Antileishmanial activity has been carried out in 
collaboration with Mr. P.Y. Guru and his coworkers in 
the Parasitology Division of the Central Drug Research 
Institute, Lucknow. 
In vivo tests were carried out against amasti-
gotes of L. donovani in hamsters (fJesocericetus auralus ) 
infected with Ddg strain of L.donovani obtained in 1980 
from a patient in Bihar (India) and maintained in ham-
sters. Male hamsters weighing 35-40 gm were infected 
7 
with 1x10 amastigotes, and four weeks later the inten-
sity of infections was assessed by spleen biopsy, ani-
mals having 2 infection were choosen for screening 
drugs. Usually 2-3 animals were used for each dose 
schedule of the drug, while 2-3 untreated animals were 
kept as controls. The list animals were treated with a 
single daily intraperitoneal injection of the drug sus-
pension for 5 days. The drug suspension employed for 
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the list was prepared by grinding the accurately weighed 
drug with distilled water (2-5 m l ) . In the case of 
unsoluble drugs, 1-2 drops of tween-80 or alcohol was 
mixed with water, thus stock solution being suitably 
diluted for use. The post treatment spleen biopsy was 
conducted one week after the last day of drug adminis-
tration inhibition ofinfection in treated animals was 
compared with that of the control animals and percentage 
inhibition was calculated. Allopurinol (17) used as a 
standard drug. 
The activity of the compounds (Series A) is given 
in (Table 2 ) , 1,5-Dihydroxy pyrazoloL3,4-d]pyrimidine-4-
one (allopurinol) (17) exhibited 88"/. inhibition at 25 
mg/kg dose on the 7th day. Substitution of [2-hydraxye-
thoxy]methyI function which represented (Ci^-C4'-
C5')chain of ribose at N^ of heterocyclic moiety as in 
38 rendered the compound inactive. Introduction of [2-
hydroxy-1-(hydroxymethy1)ethoxy] function which represe-
nted Cj^ •-C3 --C4 •-C5 • of ribose at Nj^ as in 23^ considera-
ble increased the activity 757. inhibition. The activity 
was reduced drastically when the hydroxy function at 2 
of [2-hydroxy-l-(hydroxymethyl)ethoxy] group was rep-
laced by an amino function as in 30^. The data thus 
suggested that not only the nature and chain length of 
glucone moiety at N-1 is critical for antileishmanial 
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Table - 2 
Antileishmanial activity (in vivo) of the nucleoside5 
(series A and B) at 25 mq/kq on 7th day, _aaajLjTs^ t 
amastiqotes of Leishmania donovani in hamster 
Series A 
H 
M 
Compound Ho, R •/. inhibition 
17 H 88 
38 CH2OCH2CH2OH 
39 CH20CH2CH20C0Ph 82 
23 CH2OCHCH2OH 
CH2OH 
75 
30 
Series B 
40 
CH2OCHCH2OH 
CH2NH2 
N 
m 
R 
CH2OCH2CH2OH 
15 
25 
26 CH2OCHCH2OH 
CH2OH 
0 
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activity oi tht alicyclic nucleosides (Series A) but 
also the nature of the functional groups present in it. 
The antileishmanial activity of nucleosides (Se-
ries B) is recorded in (Table 2 ) . The activity of the 
nucleoside 40^  was considerable decreased when [2-hydro-
xyethoxy ]fnethy 1 function was introduced at N-^ of hetero-
cyclic moiety. However, when the hydroxy group m the 
nucleoside 40^ was protected with benzoyloxy function, 
the corresponding nucleoside 39^  exhibited high order of 
activity. The compound 26^  became inactive when the 
hydroxy function at C2 of C2-hydroxy-l-(hydroxymethy])e-
thoxy]moiety was replaced by an amino function. The 
antileishmanial activity in the series B type of alicyc-
lic nucleosides, thus, revealed that the nature and 
chain length and also the nature of the functional 
groups are critical for the activity. Further the high 
r,Qrder of activity of the blocked nucleoside 39^  indirec-
tly suggested that the compound is probably an inhibitor 
of some important enzyme involved in the purine salvage 
process of the parasites. 
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3•5 EXPERIMENTAL PROCEDURE 
l-[2-Benzyloxy-1-(benzyloxymethyl)ethoxy3methy1- 4-methyI 
thio-lH-pyrazolo[3.4-d]pyrimidine (23) 
A mixture of 4-methy 1 thio-lH-pyrazo 1 o[ 3 , 4-d^ ] pyri-
midine (19, 3. Og , 18 mmol), DfiF (30 ml) and Et3N (15 ml) 
was stirred at ambient temperature. To the mixture was 
added a solution of 1,3-dibenzy1oxy-2-ch1oromethoxy 
propane(20, 6g,18 mmol) in DMF (10 ml) and the mixture 
was stirred for 14 hr. The excess of the reagent and 
solvent were removed at reduced pressure. The residue 
was taken in EtOAc, washed with H2O (2x100 mi). dried 
(Na2S04) and the solvent removed. The product thus 
obtained was chromatographed on S1O2 column. Eiutian of 
the column with CHC13 gave 21^  as an oil (3.9 g, 707. 
yield); MS (m/z): 450 (M"^); PMR (CDCI3) : 3.7 (s,iH,H-
6 ) , 7.9 (s,lH,H-3), 7,2 (m, lOH, Ph-H), 5.88 (s, 2H, H-
1'), 4,4 and 4,3 (each s, 4H, 2CH2Ph), 3.9 (m,lH, H-4 ), 
3.6-3.3 (m, 4H, H-3', H - 5 ) , 2.6(s, 3H, SCH3); Faund:C, 
64.1; H, 5.8; N,12.5; C24H2<sN4Q3S requires:C, 64.1; H, 
5.9; N, 12.57.. 
l-[2—Benzyloxy—l—(benzyloxymethyl)ethoxy]methy1-4(5H)-
0x0—IH—pyrazolo C3.4-d]pyriinidine ( 22 ) 
Method—1 
Compound 2_1_ (1.5 g, 3 mmol) in dioxane (30 ml) 
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was refluxed with aquous 207. KOH (30 ml) for 12 hr. The 
resulting mixture was cooled, neutralized with AcOH and 
the solvent removed under reduced pressure. The residue 
was taken in CHCI3, washed with H2O, dried (Na.2S0^) and 
concentrated. The product thus obtained was chromatog-
raphed over Si02 column. Elution of the column with 
CHCl3:MeOH (96:4, v/v) gave 22. as an oi 1 (0.4 g, 307. 
yield); MS (m/z): 420 (M"*"); IR (neat) : 1710 (C=0); PMR 
(CDCI3): 8.4 (s,iH,H-6), 8.1(s,lH,H-3), 7.2 (m, lOH, ph-
H ) , 5.75(s, 2H, H-1'), 4.4 (m, 4H, H-3', 5 ) , 3.7-4.1 
(m, IH, H-4'), 3.3-3.5(each s, 4H, 2OCH2); Found : C, 
65.7; H, 5.7; N, 13.3; C23H24N4O4 requiresiC, 65.8; H, 
5.8; N, 13.57.. 
Method—2 
A mixture of pyrazGlo[3 , 4-d.] pyrimidine-4 ( 5H ) -one 
(17,2.0g, 15 mmol), hexamethyl disilazane (8 ml), dry 
toluene (50 ml) and (NH4)2S04 (150 mg) was refluxed for 
24 hr. The excess of reagent and solvent from the 
resulting mixture were removed at reduced pressure to 
give 24^, which was used as such for further reaction 
without purification. 1,3-Dibenzyloxy-2-chloromethyloxy 
propane (20, 6,Og, 19 mmol) was added to 24 in dry 
benzene and refluxed for 12 hr. It was then coaled and 
filtered. The solvent from the filterate was removed 
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under reduced pressure. The residue was taken in CHCI3, 
washed with aq NaHC03 (2x100 m l ) , saturated aq. NaCl 
solution (2x100 m l ) , H2O, dried (Na2S04) and the solvent 
evaporated. The product thus obtained was chromatograp-
hed over Bi02 column. Elution of the column with CHCI3: 
MeOH (96:4, v/v) gave 22 d • Ig , 557. yield) as an oil. 
1—[2—Hydroxy—l—(hydroxymethyl)ethoxy]methyl—4(5H)—oxo— 
lH-pyrazoloC3.4-d]pyri(nidine ( 23 ) 
A mixture of 2 2 (0.4g, 95 mmol) , PdCl2 (50 mg) 
and MeOH (20 ml) was shaken in hydrogen atmosphere (45 
lbs pressure) for 14 hr and filtered. The filterate was 
passed through ion exchange resin (IR-45, UH form) and 
eluted with MeOH. The solvent from the eiuate was 
removed. The product was c hromatographed over Sio-;? 
column. Elution of the column with CHCl3:MeQH (80:20, 
v/v) afforded 23 (0. 2q , 557. yield); m.p.: 162° (EtOH); 
MS (m/2): 240 (M"*"); I R (KBr): 1680 (C=0) ; UV (MeOH): 
251, 206 (pH-11); 270, 231 (pH-1); 250, 208 (pH-7); PMR 
(CDCl3-DMS0-d6) : 7.95 (s,lH, H - 6 ) , 7.9 (s, IH, H - 3 ) , 
5.75 (s, 2H, H - 1 - ) , 3.55-3.7(m, IH, H - 4 ' ) , 3.3-3.5 (m, 
4H, H-3-, 5 ' ) ; Found: c, 40.0; H, 5.0; N, 23.3; 
C9H12N4O4 requires: C, 40.1; H, 5.2; N, 23.4*/.. 
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1 —(; 2—Benzyl oxy-l- ( benzy 1 ox y methyl )ethoxy ] n]^ t ii Y Ij::^  -
aminQ-lH-pyrazQlQ[5.4-d]pyrimidine (25) 
Compound 21^ (2. og , 4 mmol ) and methanolic ammonia 
(Methanol saturated with ammonia at 0 ) (25 mi) was 
heated in steel bomb at 120 for 14 hr. Solvent and 
excess of ammonia were removed and the residue was 
chromatographed on Sio2 column. Elution with CHCI3: 
MeOH (96:4, v/v) gave 25. as an oil (Ig , 507. yield); MS: 
419 (M"*"); P MR (CDCI3): 8.3 (s, IH, H-6) , 7.8 (s,lH, H-
3 ) , 7.3 and 7.2 (each s, 5H, Ph-H), 5.8 (s, 2H, H-1), 
4.5 and 4.4 (each s, 2H, 2OCH2), 4.0 (m, IH, H-4 ), 3.7-
3.3 (m, 4H, H-3' and H-5'); Found: C, 65.9; H, 6,0; N, 
16.7;C23H25N5a3 requires:C, 65.8; H, 6.1;N, 16.8/1. 
1—C2—Hydroxy—l—(hydroxymethyl)ethoxy]methy1—4—amino-lH-
pyrazoleC3.4-d]pyrimidine (26) 
Compound 25. ( 0. 8g , 1.9 mmol), PdCl2(i00 mg ) and 
MeOH (30 ml) was shaken in H2 atomosphere (45 lbs pres-
sure) for 14 hr and filtered at celite. The filterate 
was passed through ion exchange resin (IR-45, OH form) 
and eluted with MeOH. The solvent from the eluate was 
removed on rotary evaporator and the product was chroma-
tographed over Si02 column. Elution of the column with 
CHCl3:MeOH (80:20, v/v) gave 26. (0. 3g, 407. yield ); 
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m.p.: 182°; MS (m/z); 239 (M ); IR (KBr): 3100 (NH); PMR 
(CDC]3-DMSa-d^ ) : 8.1 (s,lH, H-h) , 7.5 (s,lH,H-3), 
5.7(s,2H,H-l•), 4.3(m,lH,H-4•), 3.1-3.5(m, 4H, H-3', 
5'); Found: C, 45.2; H, 5.5; N, 29.3; C9Hi3N^03 re-
quires : C , 45 . 2 ; H, 5,6; N, 28.77., 
l-[2-Benzvloxv-l-< phthloylimidomethy1)ethoxy jmethy1-4-
( 5H)-oxo-lH-pyrazolo[3,4-d]pyri(nidine ( 28 ) 
A mixture of 24_ (3. Og, 20 mmol ) and 2-chloromet-
hy1-oxy-1-benzyloxy-3-phthaloy1imidopropane (27, 9.Og, 
25 mmol) and dry benzene (150 ml) was stirred at ambient 
temperature for 2 hr and then refluxed for 14 hr. The 
residue was taken in CHCI3, washed with NaHC03 (2 x 150 
ml), NaCl (2 x 100 ml), H20 dried (Na2S04) and the 
solvent removed. The product thus obtained was chroma-
tographed over Si02 column. Elution of the column with 
CHCI3: MeOH (98:2, v/v) gave 2B. as an oil (2.5 g, 527. 
yield); MS (m/z): 459 ( M"*" ) ; PMR (CDCI3): 8.5 (s,lH,H-6), 
8.2(s,lH, r,H-3), 7.6-7.8 (m, 5H, Ph-H), 7.3 (s, AH, Ph-
H ) , 5.7 (s, 2H, H-1'), 4,4 (s,2H, 0CH2Ph), 4-4.2 (m, IH, 
H-4'),3.4-3.8 (m, 4H, H-3', 5'), 
l-C2-BenzylDxy—l-(aminomethvl)ethoxy3methyl-4(5H)-oxo—IH 
-pyrazoloC3»4—djpyrimidine (29) 
A mixture of 28. (2-0 g, 4 mmol), MeOH (60 ml) and 
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hydrazine hydrate (6 ml, 987.) was kept at Q for 12 hr . 
The solvent from the resulting mixture was removed at 
reduced pressure. The residue extracted with CHCI3 and 
the solvent removed at reduced pressure. The crude 
product was chromatographed over Si02 column. Elution 
of the column with CHCI3: MeOH (95:5, v/v) gave 29^  as an 
oil (0.8 g, 407. yield); MS (m/z): 329 (M"^); P M R (CDCI3): 
8.2 (5,1H, H-6), 7.9(s,lH,H-3), 7.2(s,5H, Ph-H), 5.75 
(s,2H, H - l ) , 4.2(s,2H, CH2Ph), 3.9-3.6(m,IH,H-4'), 3.4-
3.2(m,4H,H-3', 5'). 
l-[2—Hydroxy—l-(aminomethy1)ethoxy]methyl-4(5H)-oxo-lH-
pyrazolo[3.4—d]pyrimidine (30) 
A mixture of 29 (0.6 g, 1.8 mmol), MeOH (30 ml), 
PdCl2 (0.09 g) was shaken under H2 atmosphere (45 lbs 
pressure) for 12 hr and filtered through celite. The 
filterate was passed through ion exchange resin (IR-45, 
OH form). The solvent from the eluate was removed and 
prduct was chromatographed over Si02 column. Elution of 
the column with CHCI3: MeOH (80:20, v/v) gave 30 (0.2 g, 
307. yield); m.p.:202° (EtOH); MS (m/z): 239 (M"^); UV 
(MeOH): 250, 206 (pH-7); 271.6, 211.8 (pH-11); 250.2, 
207.2 (pH-1); PMR (CDC 13-DMSO-d^) : 8.0 (s,lH, H-6) , 
7.8(s,lH,H-3), 5.8 (s, 2H, H-l'), 3.0-2.5 (m,4H, H-3', 
5'),2.6-2.4(m, IH, H-4'); Found: C, 45.1; H, 5.5; N, 
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a 
w 
29.3; C9Hj^3N503 requiresrC, 45.2; H, 5.4; N, 29 . 37. . 
l-[2-Benzvloxv-l-(phthaIovIlniidomethyl )ethoxy jmethy l-4-
a(T>inQ-AH~pyrazolo[3^ 4—djpyriinidlne ( 32 ) 
A mixture of 4-amino-iH-pyrazolo[ 3 , 4-d^ ] pyr imidine 
(31,2.0 g, 0.015 mmol), dry DMF (25 ml) and NaH (0.5 g, 
0.02 mmol) was stirred at ambient temperature far 1 hr. 
To it was added 2-chloromethy1oxy-1-benzy1Qxy-3-phthalo-
ylimidoglycerol (27, 8.Og, 0,02 mmol) in dry DMF (15 ml) 
nd stirred for 2 hr and then refluxed for 12 hr. Resu-
lting mixture was cooled, H2O was added and extracted 
ith CHCI3, washed with H2O (2x150 ml),dried (Na2S04) 
and concentrated iri vacuo. The crude product thus ob-
tained was chromatographed over Si02 column. Elution of 
the column with CHCl3:MeOH (98:2, v/v) gave 32. as an oil 
(1.9g, 557. yield); MS (m/z): 458 (M"^); P MR (CDCI3): 8.0 
(s, IH, H-6), 7,7 (s, IH, H-3), 7.25 (s, 5H, Ph-H), 7,4-
7.6 (m, 4H, Ph-H), 5.6 (s, 2H, H-1'), 4.9(s, 2H, 
0CH2Ph), 4,1-4,3 (m,iH, H-4'), 3.4-3,6 (m,4H,H-3', 5 ) , 
l-{!2-Benzvloxy-l—(aminomethyl )ethoxy Jmethy l-4-a^^ino-lH-
pyrazolo^3.4—dDPvrimidine (33) 
A mixture of 32. ( 1, 2g , 0,03 mmol), MeOH (50 ml) 
and hydrazine hydrate (5 ml) was kept at 0 for 12 hr. 
The solvent and excess of reagent were removed under 
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reduced pressuer. The residue was taken in CHC13 (50 
ml) and concentrated. The residue was taken in CHCI3 
(50 ml) and concentrated. The crude prduct thus ob-
tained was chromatographed over Si02 column. Elution of 
the column with CHCl3:MeaH (95:5, v/v) gave 33^ as an oil 
(0.5 g, 407. yield); MS(m/z): 328 (M"^); PMR (CDCI3-DMSO-
d^):8.25 (s, lH,H-6), 8.15 (s, IH, H-3), 7.2 (s, 5H, Ph-
H ) , 5.8(s, 2H, H-1'), 4.35(s,2H, CH2Ph), 4.1-4.3(m,IH,H-
4'), 3.5-3.6(m,4H,H-3', 5"); Found: C,58.5; H, 6.1; N, 
25.6; Ci6^^20'^602 ''equires : C, 58.6; H,6.3; N, 25.7"/.. 
1—C2-Hydroxy-l—(amlnomethyI)ethoxy3methyl-4-amino-lH-
pyrazoIo[3.4-d]pyrimicline (34 ) 
A mixture of 33. (0.4g, 1.2 mmol) and PdCl2 (&0 
mg), MeOH (25 ml) was shaken at 45 lbs pressure under H2 
atmosphere. The catalyst was filtered, and the filte-
rate was neutralized with resin (IR-45, OH form) and the 
solvent removed. The crude product thus obtained was 
chromatographed over Si02 column. Elution of the column 
with CHCI3: MeOH (80:20, v/v) afforded 34L (0. 2g, 587. 
yield); MS (m/z): 238 (M'*"+i);PMR (CDCl 3-DMSO-d^) : 8.4 
(s,lH,H-6), 8.1 (s,lH, H-3), 5.9 (s,2H,H-l'), 4.0-4.5 
(m, IH, H-4"), 3.6-3.8 (m, 4H, H-3'5'), 5.O(bs, 2H, N-
H ) ; Found: C,45.4; H,5.4;N,35.3; C9Hi4N^a2 requires: 
C,45.6; H,5.8; N, 35.47.. 
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l-CBenzoyloxyethoxyJmethyl-4-methy1thio~lH-pyrazolo 
[5,4-d]pyrimidine (36) 
To a stirred mixture of 4-methy1thio-lH-pyrazo-
loC3,4-d]pyrimidine (19, 3.Og, 18 mmol), Et3N (20 ml) 
and dry DMF (50 ml) was added drapwise a solution of 
benzoyloxyethoxymethy1ene chloride (6.0 g, 28 mmol) 
(prepared by passing dry HCl gas into paraformaldehyde 
and l-benzoyloxy-2-hydroxyethane mixture in dry CH2CI2 
at 0 for 2 hr) and stirring continued for 15 hr. The 
solvent and excess of reagent were removed at reduced 
pressure. The residue was extracted with CHCI3 washed 
with H2O, dried (Na2SG4) and concentrated iri vacuo. The 
product thus obtained was chromatographed over Si02 
column. Elution of the column with CHCI3 gave 36^  as an 
oil (2.2 g, 607. yield); MS (m/z): 344 (M"*"); PMR 
(CDCI3): 8.65(s,lH,H-6), 7.7-8.1 (m,2H, Ph-H), 7.1-7.5 
(m,3H,Ph-H), 5.85(s, 2H,H-1'), 4.1-4.4(m,2H,H-3'), 3.6-
3.9(m,2H,H-4'), 2.6(s, 3H,SCH3); Found: C, 55.8; H,4.7; 
N, 16.3; Ci^Hi^N^03S requires: C,55.7; H, 4.7; N, 16.47.. 
l-CHydroxyethoxvlmethvl-A-methyl thio-l^^-pyrazoloC3.4-
d]pyri^Ilidine (37 ) 
A mixture of 36_ (2. Og, 6 mmol) and methanolic 
ammonia (methanol saturated with ammonia at 0 ) was kept 
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at ambient temperature for 24 hr. The solvent and 
excess of reagent from the resulting mixture was removed 
and the residue was chromatographed over S1O2 column. 
Elution of the column with CHCI3: MeOH (96:4, v/v) 
afforded 37 (1. Ig, 55X yield); m.p. : 94° MS (m/z): 240 
(M"*"); IR(KBr): 3336 (OH); PMR (CDCl 3-DMSO-d^ ) : 8.8 (s,lH 
H-6), 8.5 (s,lH, H-3), 5.8(s, 2H,H-1'), 3.6 (m, 4H, H-
3'), 2.6(s,3H,SCH3); Found: C, 45.0; H, 5.0; N, 23.3; 
C9Hj^2'^402S requires:C, 45.1; H,5.2; N, 23.3V.. 
l-[Hydroxyethoxy]methYl-4(5H)-oxo-lH-pyrazolo[3.4-d] 
pyrimidine (38) 
Method—1 
Compound 37^ (0.5g, 2 mmol ) in dioxane (60 ml) was 
refluxed with aq KOH (207., 15 ml) for 12 hr. The resul-
ting mixture was cooled, neutralized with acetic acid 
and the solvent removed at reduced pressure. The resi-
due was extracted with CHCI3, washed with H2O, dried 
(Na2S04) and concentrated. The crude product thus ob-
tained was chromatographed over Si02 column. Elution of 
the column with CHCl3:MeOH (90:10, v/v) gave 38^ (0. 2g, 
307. yield); m . p . : 138-40°( EtOH ) ; UV(MeOH): 250.6, 207.8 
(pH-7); 221.2, 215.2 (pH-11); 250.8, 212.6 (pH-1); MS 
(m/2): 210 (M"^); PMR (CDCl3-DMS0-d^) : 7,95 (s, IH, H-6), 
7.9 (s, IH, H-3), 5,7 (s, 2H, H-l),3,5 (m, 4H, H-
141 
3',4'); Found: C, 45.7; H, 4.8; N, 26.6; CeH|oN403 
requires: C,45.8; H, 4.9; N, 26.67.. 
Method - 2^  
A mixture of 39^  (0.8 g, 2.5 mmol ) and methanolic 
ammonia (methanol saturated with ammonia at 0 ) was kept 
for 24 hr at ambient temperature. The solvent and 
excess NH3 were removed at reduced pressure. The crude 
product thus obtained was chromatographed over SiQ2 
column. Elution of the column with CHCI3 : MeOH (92:8, 
v/v) gave 38 (0.5 g, 60"/, yield); m.p.:138-40° (EtOH). 
1—CBenzoyloxyethoxy3methy1-4(5H)—0x0—IH—pyrazolo[3.4—d] 
pyrimidine (39) 
The compound 24^ (3.0g, 20 mmol ) in benzene (40 
ml) was refluxed with 1-benzoyloxy-2-chloromethoxyethane 
(35, 6.og, 28 mmol) for 16 hr. The resulting mixture 
was cooled, filtered and evaporated. The residue extra-
cted with CHCI3,washed with NaHC03, dried (Na2S04) and 
concentrated. The product thus obtained was chromatog-
raphed over Si02 column. Elution of the column with 
CHCl3:MeOH (98:2, v/v) gave 38. (1.7 g, 587. yield); m.p. 
: 118-19°(EtOH) ; MS (m/z): 314 (M"^); IR (KBr): 1710 
(C=0); PMR (CDCI3): 8.25 and 8.1 (each s, 2H, H-6, H-3), 
8.0-7.8 (m, 2H, Ph-H), 7.4-7.2 (m, 3H, Ph-H), 5,5 (s,2H, 
142 
H ~ l ) , 4.5-4.3(m, 2H, H-3'), 4,l-3.8(m, 2H, H-4'); Found 
: C, 57.3; H, 4.8; N, 17.9; Cx^^i/^N^O^ requires: C, 57.4; 
H,4.5; N, 17.77.. 
l-LHydroxyethoxy]methyl-4-aminQ-lH-pyrazolo[3,4-
djpyrimidine (40) 
A mixture of 37_ (0.5 g, 21 mmol ) and methanolic 
ammonia (methanol saturated with ammonia at 0 ) was 
heated in a steel bomb at 120 for 14 hr. The solvent 
and excess of ammonia from the resulting mixture was 
removed at reduced pressure. The product thus obtained 
was chromatographed ower SiQ2 column. Elution of the 
column with CHCI3: MeOH (90:10, v/v) gave 40. (0.3 g, 507. 
yield); m.p,:153-54° (EtOH); MS (m/z): 209 (M'^);PMR 
(CDCl3-DMS0-d^) : 8.2 (s, IH, H-6), 8.1 (5,1H, H-3), 
5.7(s,2H,H-l'), 3.6(s,4H,H-3' and 4'); Found : C, 45.9; 
H, 5.3; N, 33.5; CgHj^j^N502 requires: C, 45.8; H, 5.3; N, 
33.77.. 
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CHAPTER - 4 
SYNTHESIS OF 3,4,6-TRISUBSTITUTED-1H-
PYRAZ0L0l3,4-d]PYRIMIDlNE NUCLEOSIDES 
AND THEIR BIOLOGICAL ACTIVITY 
14B 
4. J INTRODUCTION 
Pyrazo 1 o[ 3 , 4-d 1 pyr imj cJ J ne nucleosides have re-
ceived renewed attention in recent years because of 
their significant biological activities . Allopuri-
nol, ( pyrazol o[ 3 , 4-d^] py r imid ine-4 ( 5H )-one , 1 ) is found 
active ij2 v i tro against several Leishman la and Tr y ^  
panosoma species. In both Leishmania and i rypa-
14 
nosoma species, allopurinol (1) is converted into 
allopurinol ribonuc1eoside-5'-phosphate (HPPR-MP)(2) by 
a unigue enzyme of the parasite, nucleoside phosphoribo-
sy1 transferase. Seguential conversion of HPPR-MP by the 
parasite enzymes adenylosuccinate synthetase and succi-
no-AMP-lyase gives 4-aminapy r azo I o[ 3 , 4-d^] py r imid ine ( 4-
APP)ribonucleoside-5•-phosphate (3) which is eventually 
incorporated into the cellular RNA of the parasite, 
resulting in lethality to the parasite ' . This con-
version is analogous to the conversion of IMP to AMP in 
mammalian cells ' . The incorporation of 4-APP-TP into 
J-
the RNA of the parasite is unigue, since mammalian cells 
a.rG incapable of converting it into its 5'-phos-
phate ' . This biochemical differences between the 
host and the parasite, offers considerable potential for 
developing antileishmanial drugs. 
4-APP has been found to be effective in the 
14V 
] 9 , 20 
treatment of experimental ch.^gas disease in mice 
Moreover, the ribonuc1eoside derivatives of allopurinol 
and 4-APP were shown to be several fold more active than 
allopurinol against promast igotes L_^  braz 11 lensis and L^ ^ 
21 22 
max icana and L_^ tropica in vitro. As a part of this 
on going program, several 3-substituted 6-amino 
allopurinol ribonuc1eosides, including 6-azacadeguomycin 
23 (4) have been synthesized. 
Several varieties of cyclic, acyclic nucleosides 
have been synthesized in recent years. Some of these 
nucleosides have shown significant anticancer, antipara-
sitic, antiviral and anti1eishmania 1 activities. Ftora-
24 
phur (5-F1uoro-1-tetrahydrofury1-urac11) (5), 9-(hyd-
25 
roxyethoxy methyl) guanine (6) , 1-(benzoy1oxyethoxy 
26 
methyl) allopurinol (7) , exhibit high order of activi-
ties. Although in these nucleoside the glycone moiety 
is not the usual D-ribose or D-deoxyribose. The tetra-
hydrofuryl, hydroxyethoxy methy^ moieties present in 
these compounds, due to their hydrophobic nature may be 
facilitating the transport of these molecules across the 
cell membrane. Inside the cell all these compounds 
might be converted into riboside by the action of ribo-
furanosyl transferases into the corresponding ribosides. 
4-Amino-lH-pyra2oloC3,4-d^]pyrimidine (8) and its 
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ribosides , 3-substituted-4APP ribosides and 3,4,6-
tr isubsti tuted pyrazol o[ 3 , 4-d^ ] pyrimidine nucleo-
29 30 
sides ' exhibit high order of cytotoxicity. 
4.2 OBJECTIVE OF THE PRESENT STUDY 
The reports presented above prompted us to under-
take the synthesis of cyclic and acyclic nucleosides of 
3 , 4 , 6-trisubsti tuted pyrazolo[ 3 , 4-d.] pyrimidines and to 
evaluate their biological activities. 
4.3 PRESENT STUDY 
The present chapter deals with the synthesis of 
3-cyano-4 , 6-di methyl thio-lH-pyrazo loC3,4-d^]pyrimidine 
(15) , 6-amino-l-(tetrahydrofuran-2-y1 )-4(5H)-oxo-lH-
pyrazolo[3,4-d^]pyrimidine-3-carboxy 1 ic acid (20), 4-
amino-1-(tetrahydrofuran-2-yl)-^-methy1thio-lH-pyrazo-
lo[3 ,4-d_]pyrimidine-3-carboxamide (21), 4-amino-l-( tet-
ra hyd ropy ran-2-yl ) -6-methy 1 thio-lH-pyrazolo[3,4-d^]pyri-
midine-3-carboxamide (26), 6-amino-l-C(2-hydroxyethoxy)-^ 
methyl 3-4 (5H)-ox o-iH-pyrazolo[3, 4-d^]py rimidine-3-carbo-
xylic acid (31), 4-amino-l-C(2-hydroxyethoxy)methy1]-6-
methyl thio-lH-pyrazoloC3 , 4-d.] pyrimidine-3-carboxamide 
(33) , 4-methoxy-6-methy 1 thio-l-(3-D-ribofuranosy 1-lH-
pyrazolo[3,4-d^]pyrimidine-3-imido carboxylate (37) and 
their biological activity. 
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4.4 SYNTHESIS 
4.4.1 Synthesis of 3-cvano-4.6-dimethy1thio-lH-pyrazolo[3,4 d] 
pyrimidine (15) 
3-Cyana-4 , 6-dimethy lthio-lH-pyrazolo[ 3, 4-d^ ] pyri-
midine (15) (Scheme 1) the key intermediate, was synthe-
29 
sized following the procedure of Korbukh . Condensa-
tion of tetracyanoethylene (9) with semicarbazide (10) 
gave 3,4-dicyano-5-amino-l-carbamoy1 pyrazole (11), 
which on heating with water at 100 gave 3,4-dicyana-5-
amino-lH-pyrazole (12) in fairly good yield. Reaction 
of 1^ with CS2 in pyridine yielded the 3-cyano-4-imino-
6-mercapto-lH-pyrazolo[3,4-d[]-l ,3 ,6-thiazine (13). The 
compound 13 on treatment with hydrochloric acid followed 
by sodium hydroxide gave 3-cyano-4,6-dimercapto-lH-
pyrazoloC3,4-d^] pyrimidine (14) in good yield. Methyla-
tion of l£t_ with methyl iodide in sodium hydroxide gave 
3-cyano-4 ,6-di methyl thio-lH-pyra2olo[3 , 4-o[] pyrimidine 
29 (15) in 73'/. yield. In the pmr spectrum of i^, two 
sharp singlets at 2.6 and 2.7 were due to the methyl-
thio functions. In the IR spectrum, sharp peak at 2245 
cm was for -CN group. In the mass spectrum of Ib^, the 
molecular ion peak was at m/z 237 (M ). The other 
significant ion in the spectrum was at m/z 190 
(C7H4N5S). 
15i 
NC' 
V /CN 0 
/ = < ^ + H2NCNHNH2 
NC 
(1) 
10 
(iii) 
H2N 
r CN I 
N 
I 
CONH2 
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(11) 
NC> 
H 
12 
SMG 
f .CN 
N 
lii 15 
Reagents 
(i) NaOAc.3H20, H^O 
(ii) U^O,A 
(iii) CS-,-pyridine,^ , 60 hr 
(iv) Conc.HCl, NaOHClN), AcOH 
(v) CH I, NaOH 
Scheme - 1 
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4.4.2 Synthesis of 6-amino-l-(tetrahydrofuran-2-y1) 4(SHD-oxo-
lH-pyrazoloLS.A—d Jpyrimidine-3—carboxy 1 ic acid (20) 
Condensation of 3-cyano-4,6-dimethy1thio-lH-pyra-
201oC3,4-d_]pyrimidine (15) (Scheme 2) with 2, 3-d i hydro-
furan (16) in anhydrous ethyl acetate, in the presence 
of p-toluene sulphonic acid afforded 3-cyano-4,6-dimet-
hylthio-l-( tetrahydrofuran-2-y 1 )-lH-pyrazolo[3,4-d^]pyri-
midine (17) in 717. yield. In the pmr spectrum of 17, 
the two singlets integrating for 6 protons at 2.7 and 
2.6 were due to the two methylthio groups. The multip-
let at 6-7 was assigned to the anomeric proton, which 
appeared at lower field as compared to the C-4' protons, 
due to deshielding effect. In the mass spectrum of 1_7. 
the molecular ion peak was at m/z 307 (M ). The other 
significant ion peaks were at m/z 71 (C4H7O), m/z 253 
(C9H9N4OS2), m/z 190 (C7H4N5S) and m/z 237 (CgH7N5S2) 
(Fig. 1). 
Treatment of jLT^  with IN sodium hydroxide in dio-
xane at 80 gave 4,6-dimethy1thio-1-(tetrahydrofuran-2-
yl )-lH-pyrazoloC3,4-d.]pyrimidine-3- carboxamide (18). 
The absorption band for CN group in the IR spectrum 
of compound 18. was absent, instead a band at 1690 cm 
appeared for a carboxamide group. In the pmr spectrum of 
18 there were two singlets at 7.88 and 7.6 for carbo-
154 
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Fig-l Mass spectral fragmentation pattern of 3-cyano-
4,6-dimethylthlo-l-(tetrahydrofuran-2-y])-lH-pyrazolo 
[3.4—dPpyrimidlne 
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xamide protons and two singlets integrating 3 protons 
each at l.bT. and 2.55 were due to two thiomethyl 
function. In the mass spectrum of 1^, the molecular ion 
peak was at m/z 325 (M ). The other significant ion 
peaks were at m/z 71 (C4H7O), m/z 281 (C^ ^ Hj^ 3^4082) , m/z 
253 (C9H9N4OS2) and m/z 255 (CgH9N50S2) (Fig. 2 ) . The 
above data confirmed the structure of the compound 18. 
Treatment of 18^  with 6N sodium hydroxide in dio-
xane and methanol at refluxing temperature afforded 6-
methy1thio-1-(tetrahydrofuran-2-y1)-4(5H)-oxo-lH-pyra2 0-
loC3,4-d^]pyrimidine-3-carboxyl ic acid (19) in 62'/. yield. 
In the pmr spectrum of the compound 1,9^, one singlet 
integrating for 3 protons at 2.5 suggested that one of 
the methyl thio group has been removed. Compound J^S. had 
two methylthio groups at position 4 and b> respectively. 
The methylthio group at position 4 is more susceptible 
to nucleophilic substitution hence it was selectively 
removed by hydroxyl function . Compound 19^  did not 
show the two singlets for carboxamide function which 
suggested that carboxamide group has been converted 
into carboxylic acid. In the IR absorption of 1^ two 
bands were present at 1660 and 1670 cm for carboxylic 
acid. In the mass spectrum of the compound 1^ the 
molecular ion peak was at m/z 296 (M ). The other 
significant ion peaks were at m/z 71 (C4H7O), m/z 251 
'0' 
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m/z 281 
(CjjHj3N^OS2) 
15/ 
SMe 
XONH^ 
H 
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Fig-2 Mass spectral fragmentation pattern of 4.6-
dimethy1thio—1—(tetrahydrofuran-2-y1)-lH—pvrazoIoC3.4-d3 
pyrimidine—3—carboxamide 
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15B 
(C;J^QHJ^IN4Q2S) , m/2 223 (CQH7N4a2S) (Fig. 3 ) . 
Treatment of 1^ with ethanolic ammonia in a steel 
bomb at 150 gave 6-amino-1-(tetrahydrofuran- 2-v1 )-
4(5H)-oxo-lH-pyrazoloC3,4-d^]pyrimidine-3-carboxylic acid 
(20). In the pmr spectrum of 20^, there is a replacement 
of methylthio group by amino function, and a broad 
singlet for 2 protons at 7.6 for amino function. In 
the mass spectrum of ZO^ , the molecular ion peak was at 
m/2 265 (n ), The other significant, ion peaks were at 
m/2 71 (C4H7O), m/z 221 < C9H j^  j^N502) and m/z 237 
(CgH^N504) (Fig. 4 ) . The mass, pmr, IR and UV spectra of 
compound 20^ were in complete agreement with the assigned 
structure. 
4-4.3 Synthesis of 4—amino-1—(tetrahydrofuran—2-Y1)-6-methyl-
thio-lH-pyrazoloC3,4-d]pyrimidine-3—carboxamide (21) 
Treatment of 4,6-dimethy1thio-1-(tetra hydrofura-
n-2-yl )-IH-pyrazo loC 3 , 4-d.] pyrimidine-3-carboxamide (18) 
(Scheme-3) with methanolic ammonia in a steel bomb at 
120 gave 4-amino-l-(tetrahydrofuran-2-yl)-6~methyl-
thio-lH-pyra2olo[3 , 4-d^ ] pyrimidine-3-carbaxamide (21) in 
excellent yield. In the pmr spectrum of 21^, there was 
only one singlet integreting for 3 protons at 2.5 
suggesting that one of the methylthio group has been 
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re.noved . Compound 1^ had two methylthio groups at posi-
tion 4 and 6 respectively. The methylthio group at 
position 4 is more susceptible to nucleophilic substitu-
tion reaction, and is expected to be replaced selectivi-
ty. In the mass spectrum of 2J^ , the molecular ion peak 
+ 
was at m/2 294 (M ). The other significant ion peaks 
were at m/z 71 (C4H7O), m/z 250 {C^QHi2^^0S),m/z 222 
(CQHBN5QS) and m/z 208 (CyHgN^S) (Fig. 6 ) . 
Treatment of 3-cyano-4,6-dimethy1thio-1-(tetrahy-
drof uran-2-y 1 )-lH-pyrazolo[3 , 4-d^]pyrimidine (17) with 
methanolic ammonia in a steel bomb at 120 gave 4-amino-
l-(tetrahydrofuran-2-yl)-6-methylthiQ-lH-pyra2olo[3,4-
d^ ] pyrimidine-3-carboxamidine (22) in good yield. In the 
pmr spectrum of 22^ there was only one singlet at 2.5 
for 3 protons suggesting that one of the methylthio 
group has been replaced. Compound IZ had two methylthio 
groups at position 4 and 6 respectively. The IR spec-
trum at. compound 22^  does not contain the absorption band 
of a cyano group that was present in the spectrum of 
starting compound 1^ (2245 cm ). 
The mass spectrum of 22^ had the molecular ion 
peak at m/z 293 (M ). The other significant ion peaks 
were at m/z 222 (CgHgNsOS), m/z 250 (Cio'^12N5aS) , m/z 
223 (C7H9N7S) and m/z 236 (Cio^^l2N40S) (Fig. 5 ) . The 
163 
NH2 
I 
m/z 222 
(CgH^NjOS) \ 
NH 2 
/ 
NH2 f 
U-y^ r f^NH2 
MeS^^N 
m/z 293 
(Cj^Hj^N^OS) 
1 
m/z 250 
NH2 NH 
H 
m/z 223 
(C^HgN^S) 
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1B5 
mass, pmr, IR and UV spectra of compound 2^ were in 
complete agreement with the assigned •i^tructure. 
4,4.4 Synthesis of 4-aininQ-I-( tetrahydropyran-2-yl )-6-methy 1-
thiQ-lH-pyrazoloC3.4~d3pyrimidine-5-carboxamide (26) 
Condensation of 3-cyano-4,6-dimethy1thio-lH-pyra-
zolo[3,4-d^] pyrimidine (15) (Scheme 4) with 3,4-dihydro-
2H-pyran (23) in anhydrous ethyl acetate, in the presen-
ce of p-toluene sulphonic acid (PTSA) afforded the known 
compound 3-cyano-4,6-dimethylthio-1-(tetrahydropyran-2-
32 yl )-lH-pyrazoloC3,4-d_]pyrimidine (24) in 66"/. yield. 
In IR spectrum, sharp peak was at the 2245 cm for -CN 
group and in the mass spectrum of 24^  the molecular ion 
+ 
peak was at m/z 321 (M ). The other significant ion 
peaks were at m/z 85 (C5H9O) m/z 237 (CQH7N5S2), m/z 
190 (C7H4N5S) and m/z 252 (C9HQN4OS2) (Fig. 7 ) . 
Treatment of 24^ with IN sodium hydroxide in dio-
xane at 80 gave 4,6-dimethylthio-1-(tetra hydropyran-2-
y 1 )-lH-pyrazolo[3 , 4-d^]pyrimidine-3- carboxamide (25). 
The IR spectrum of 25^ does not contain the absorption 
band of a cyano group and a new band appeared at 1690 
cm for CONH2 group. Compound 24_ had a band for cyano 
group. In the pmr spectrum, there was a broad singlet 
at 7.45 for two carboxamide protons, and two singlets 
integrating for 6 protons each at 2.65 and 2.55 were 
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due to the two methylthio group. In the mass spectrum 
+ 
of 25. the molecular ion peak was at m/z 339 (M ). The 
other significant ion peaks were at m/z 212 (C7HgN4S2), 
m/z 252 (C9HBN4OS2), m/2 295 (Ci2Hi5N4aS2) (Fig. 8 ) . 
Amination of 4,6-dimethy1thio-1-(tetrahydropyran-
2-yl )-lH-pyrazolo[3, 4-d^]pyrimidine-3-carboxamide (25) 
with methanolic ammonia in a steel bomb at 120 afforded 
4-amino-l-(tetrahydropyran-2-yl)-6-methylthio-lH-pyrazo-
lo[3,4-d^3pyrimidine-3-carboxamide (26) in good yield. 
In pmr spectrum of 26., a singlet at 2.5 for 3 protons 
suggesting that one of the methylthio groups has been 
replaced. Compound 2_5 had two methyl thio groups at 
position 4 and 6 respectively. The methylthio group at 
position 4 is more susceptible to nucleophilic substitu-
tion reactions and is expected to be substituted selec-
tivity . In the mass spectrum of 26. the molecular 
ion peak was at m/z 308 (M ). The other significant ion 
peaks were at m/z 85 (C5H9O), m/z 224 (CyHgN^QS), m/z 
222 (CgHgN^QS) (Fig. 9 ) . The pmr, IR and mass spectral 
data were in agreement with the assigned structure. 
4.4.5 6-AminQ-l[(2-hydroxyethoxy)methyl]-4(5H)-oxa-lH-
pyra2oloC3.4—d]pyriniidine-3-carboxylic acid ( 31 ) 
Condensation of 3-cyano-4,6-dimethy1thio-lH-pyra-
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zoloC3,4-d^] pyrimidine (15) (Scheme 5) with benzoyloxy 
ethoxy methylene chloride (27) in DMF in the presence of 
triethylamine afforded 3-cyano-l-[(2-benzoy1oxyethoxy)-
methyl-4 ,6-di methyl thio-lH-pyrazolo[3 , 4-d,] pyr imidine 
(28) in good yield. In the pmr spectrum of 28^  two 
singlets at 2.6 and 2.7 integrating for 3 protons 
each, were due to two methylthio groups and one singlet 
at 5.9 for two protons was due to the -OCH2N- protons. 
The IR spectrum showed a band at 2245 Cm for -CN 
group. 
o 
Debenzoy 1 ation of 28^ with saturated (at 0 ) 
solution of ammonia in methanol leads to a complex 
mixture of products. It was carefully resolved and the 
pure compound which did not have a cyano function was 
used in subsequent reactions. 
Benzoyl group of 28. could not be removed by the 
action of a solution of sodium methoxide in absolute 
.r, ,. 
methanol without conversion of the cyano group to an 
imino ester group. The compound 28^ was then treated 
with sodium methoxide in methanol at 20 which finally 
afforded 4-methoxy-l-[(2-hydroxyethoxy)methyl]-6-methyl-
thio-lH-pyrazoloC3,4-d.]pyrimidine-3-imidocarboxy late 
(32) in excellent yield. In the pmr spectrum of 32^, two 
singlets at 4.1 and 3.82, integrating for 3 protons 
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each, were due to two methoxy groups, and one singlet 
appeared at 2.6 for 3 protons suggesting that one of the 
methylthio groups has been substituted. There was one 
singlet at 5.7 integrating for two -aCH2N- protons. In 
the mass spectrum of 32^, the molecular ion peak was at 
m/z 327 (M ). The other significant ion peaks were at 
m/z 58 (C2H4Na), m/z 269 (C J^ QI^  14^^4032 ^  ' ^^'^ 253 
(C9Hj^;l^N502S) and m/z 266 (C10H12N5O2S) (Fig. 1 3 ) . The 
IR spectrum of 32 does not contain the absorption band 
of a cyano group that was present in the spectrum of 
starting compound 28 (2245 cm ). The mass, pmr, and IR 
spectral data were in complete agreement with the assig-
ned structure. 
Treatment of 3-cyano-l-[(2-benzoyloxyethoxy)met-
hyl ] -4 ,6-di methyl thio-lH-pyrazolo[3 , 4-d^]pyrimidine ( 28) 
with IN sodium hydroxide in dioxane at 80 gave 4,6-
dimethy1thio-l-C(2-hydroxyethoxy)methy1]-lH-pyrazo-
lo[3,4-d^] pyrimidine-3-carboxamide (29) in 78"/. yield. 
The IR spectrum of 29^ does not contain the absorption 
band of a cyano group that was present in the spectrum 
of starting compound 28^ (2245 cm ). A new band appeared 
at 1685 cm for carboxamide group. In the pmr spectrum 
of 29^, two broad singlets for two protons at 6.9 and 
7.25 for carboxamide group, two singlets integrating 3 
proton each at 2.55 and 2.6 were due to the methylthio 
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Fig—13 Mass spectral fragmentation pattern of 4—methoxy-
6—methylthio-l-hydroxyethoxymethyl-lH-pyrazoloC3.4-d] 
pyrimidine—3—imidocarboxylate 
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group and a singlet at 5.7 for -aCH2N two protons.. In 
the mass spectrum of 29^  the molecular ion peak was at 
m/z 329 (M ) and other significant ion peaks were at 
m/2 75 (C3H7Q2), m/z 268 (C9H J^QN50S2 ) , m/z 254 
(CeH9N5QS2), m/z 312 (C^iH^/^N^02S2) , m/z 285 
(CJ[^QHJ|^3N402S2) (fig. 10). The IR, mass and pmr spectral 
data were in complete agreement with the assigned struc-
ture , 
Treatment of 29^  with 6N sodium hydroxide in met-
hanol at refluxing temperature afforded 6-methy1thio-1-
[(2-hydroxyethoxy)methyl]-4(5H)-oxo-lH-pyrazolo[3,4-d] 
pyrimidine-3-carboxy1ic acid (30) in good yield. In the 
pmr spectrum of 30^, one singlet integrating for 3 pro-
tons at 2.5 was due to the methylthio group. In the 
mass spectrum of the compound 30, the molecular ion peak 
+ 
was at m/z 300 (M ). The other singificant peak were at 
m/z 75 (C3H7O2), m/z 255 (C9H-^ j. N4a2S2) , m/z 182 
(C£,H^N40S) and m/z 238 (C<jH^^N/^6^S) (Fig. 11), 
Treatment of 30^ with ethanolic ammonia in a steel 
bomb at 150 gave 6-amino-l-[(2-hydroxyethoxy)methyl]-
4(5H)-oxo-lH-pyrazolo[3, 4-d.] pyrimidine-3-carboxy 1 ic acid 
(31). Removal of methylthio group by amino group and 
appearance of a broad singlet was confirmed by disappea-
rance of signlet for SMe group at 7.3 integrating for 2 
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protons suggested the presence of amino group. In the 
aglycone moiety, H-3' and H-4' are attached to one 
hetero atom each, thus there is likely to be very small 
or negligible diffence in their chemical shifts. The 4 
proton singlet at 4.5 was assinged to H-4' and H-3' 
protons. In the mass spectrum 3J^  the molecular ion peak 
was at m/z 269 (M ). The mass and pmr spectral data of 
compound 31 were in complete agreement with the assigned 
structure. 
4.4,6 Synthesis of 4—amino—1—[ (2—hydroxyethoxy)inethy 1 ]-6-met-
hy1thio—IH—pyrazolo[3,4-d]pyrimidine-3—carboxamide (33) 
Amination of 4,6-dimethy1thio-1—[(2-hydroxyetho-
xy)methyl]-lH-pyrazoiaC3,4-d^]pyrimidine-3-carboxamide 
(29) (Scheme 6) with methanolic ammonia in a steel bomb 
at 120 afforded 4-aminQ-l-[(2-hydroxyethoxy)methy1]-6-
methy 1 thio-lH-pyrazoloC3, 4-d^ ] pyrimidine-3-carboxamide 
(33) in excellent yield. In the pmr spectrum of 33., a 
singlet integrating for 3 protons at 2.5 suggesting 
that one of the methylthio group has been replaced. 
Compound 29^  had two singlets for methylthio groups at 
position 4 and 6 respectively. There were four singlets 
integrating one proton each for CONH2 and NH2 groups at 
8,9, 8.27, 8.12 and 8.0 suggesting that four protons 
oi two amino groups have been shifted down field due to 
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the deshielding effect. In the mass spectrum of 33^ , the 
molecular ion peak • was at m/z 298 (M ). The other 
significant ion peaks were at m/z 254 (C9HJL2N5O2S) , m/z 
237 (CgHgN^OS), m/z 224 (CyHgN^OS) (Fig. 12). The 
pmr and mass spectral data were in complete agreement 
with the assigned structure. 
It is known that in the case of 4,6-dichloro 
pyrazoloC3,4-d_]pyrimidine that the substituent in the 4-
position have considerably higher reactivity in nucleop-
hilic substitution reactions as compared with the sub-
33 34 
stituent in the 6-position ' . The stability of the 
6-methylthio group is very high in the trisubstituted 
29 pyrazolo[3,4-d_]pyrimidines and their nucleosides 
A comparison of the reactivity of the cyano 
group in the 3-positian and the methylthio group in 
position 4 with respect to the nucleophilic reagents 
such as h)<jdrogen sulfide, sodium methoxide in methanol, 
and hydroxy 1 amine showes that the cyano group, which 
reacts under milder conditions, is more reactive both in 
heterocyclic bases and in the corresponding nucleosides. 
Nucleophilic replacement of the methylthio groups by the 
action of the reagents indicated above with out involve-
ment of the cyano group can not be realized ' 
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4.4.7 Synthesis of 4-methoxv-6-methy1thio-l-g-D-ribofurartosyl-
iH~pyrazoloC3.4-d]pyrimidine-3-imidQcarbQxy late ( 37 ) 
Condensation of 3-cyano-4,6-dimethy1thio-lH-pyra-
zoloC3,4-d_]pyrimidine (15) (Scheme 7) with 1-0-acetyl-
2,3,5-tri-O-benzoy1ribofuranose (34) in the presence of 
BF3.aEt2 gave the known compounds 3-cyana-4,6-dimethy1-
thio-l-a-D-2',3',5'-tri-O-benzoy1ribofuranosy1-IH-pyra-
zola[3 ,4-d_]pyrimidine (36) and 3-cyano-4 , 6-dimethy 1 thio-
l-(3-D-2' ,3' 5 5 '-tri-O-benzoy 1 ribof uranosyl-IH-pyrazo-
29 lo[3,4-d,]pyrimidine (35) 
Debenzoylation of 3^ with saturated (at 0 ) solu-
tion of smmonia in methanol leads to a complex mixture 
of products. It was carefully resolved and the pure 
compound which did not have a cyano function was used in 
subsequent reactions. An attempt was made to remove the 
benzoyl group by the action of sodium methoxide in 
absolute methanol without conversion of the cyano group 
to an imino ester group. So, the treatment of 35^  with 
sodium methoxide in methanol at 10 temperature afforded 
the known compound 4-methoxy-6-methy1thio-1-B-D-ribofu-
ranosyl-lH-pyrazolo[3,4-d.]pyrimidine-3-imidocarboxy late 
30 (37) in good yield. The IR, UV and PMR spectral data 
of 35^, 36^ and 3Z were identical with reported values. 
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.5 BIOLOGICAL 
Antiviral 
ACTIVITY 
activity 
The compounds synthesized were screened for their 
antiviral activity by Dr. M.N. Joshi in the Virology 
Division of Central Drug Research Institute, Lucknow. 
The compounds were screened against Ranikhet 
Disease Virus (RDV) culture in chick embryo ir^ vi tro 
according to Babbar Procedure ' . The results 
obtained sre summarized in the Table 1-5. 
Table—1 Antiviral activity of 3.4.6-tris^bstit^ted-lH-
pyrazoIo[3^4-d3pyrimidine 
S.No. 7. inhibition 
15 73 
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Table-2 Antiviral activity of 1-tetrahydrofurany1-3,4,6-
trisubsti tuted pyrazolo[3,4-d3pyrimidine 
N^^S rr^ 3 J 
S.No. R^  R/ R3 y. inhibition 
17 SMe SMe CN 0 
IB SMe SMe CONH2 0 
19 OH SMe CCOH 25 
20 OH NH- COOH 0 
22 NH' SMe C(NH)NH' 10 
21 NH- SMe CONH' 15 
18B 
Table-3 Antiviral activity of 6—methylthio-1-tetrahyd-
ropyrany1-3 ^4-disubstituted-lH-pyrazQloL3,4-d] 
pyrimidine 
% 
N 
MeS^^N'^'^N 
,^3 
^ 
<C3 
S.No- Ri R- 7. inhibition 
24 SMe CM 10 
25 SMe CONH- 10 
26 NH-- CONH2 25 
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Table-4 Antiviral activity ai I-hydroxyethoxymethy1-
3,4,6-1 r isubs t i tu ted-lH-py ra zoloC 3,4--cl 3 pyrimi dine 
R, A 
N' ^-^ 
S.No, R/ R/ R- inhi bi tion 
28 SMe SMe CN COPh 20 
29 SMe SMe CONH2 H 10 
30 OH SMe COOH H .r, 10 
31 OH NH' COOH H 30 
32 OMe SMe C(NH)OMe H 63 
33 NH- SMe CONH-^ H 10 
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Table-5 flntiviral activity of 6-methy1thio-3,4-disubst-
ituted —1-p—D-ribof uranosy 1-lH-pyrazoIoL'^. 4-d ] 
pyritnidine 
^ 
^ 3 
MeS^N-^^Kj N 
ROn ,0-
OR 
S.No, R. R- R 7. inhibition 
35 SMe CN PhCO O 
37 OMe C(NH)OMe H <S4 
18B 
EXPERIMENTAL PROCEDURE 
3^4-DicYano-5-aminQ-lH-pYra2ole^ (12) 
To a solution of NaOAc.3H20 (13.6 g) and 
H2NCONHNH2 (10, 11.6 g) (Scheme 1) m H2Q (200 mi) was 
added tetracyanoethylene (9, 12.8 g ) . The mixture was 
stirred at ambient temperature for 24 hr and filtered. 
The solid product thus obtained yielded 3,4-dicyanQ-5-
amino-1-carbamoy 1 pyrazole (11) (17.ig, 80V. yield). 
The compound JJ^  (1 g) was suspended in H2O (25 
ml) and refluxed for 3 hr, cooled and filtered to give 
5-amino-3,4-dicyano-lH-pyrazole (12) (0.4g, 60'/. yield); 
m.p. : 250° (HoO) ; MS (m/z) : 133 (M"^); IR (KBr) : 2245 
(CN) . 
29 3-Cyano~4.6-dimercapto-lH-pyrazolQC3.4-d]pyrimidine 
(14) 
A mixture of 3,4-dicyano-5-amino-lH-pyrazole(12, 
10 g, 75 mmol), pyridine (100 ml), and carbon disulfide 
(150 ml) was refluxed for 60 hr, cooled and filtered. 
The solid was washed with water and transferred to a 
beaker containing cone HCl (200 ml). The acidic mixture 
was allowed to stand at 20 for 2 hr and filtered and 
washed with cold water, dried over CaCl2 to give 3-
cyano-4-imino-6-mercapto pyrazolaC3 , 4-d.3-l , 3 , 6-thiazine 
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(13)^'^ (14.3g, 90V. yield). 
A mixture of compound K5 (14.3 g, 68 mmo1) and 6N 
NaOH (250 ml) was maintained at 20 for 10 hr and neut-
ralized with dil acetic acid to pH-6 and filtered, 
washed with cold water and dried over ^2^5 ^° ^^"^^ 
required compound 1_4_ (13 g, 967. yield); m.p.:>300 
(H2O); IR (KBr) : 2245 (CN). 
3-Cyano-4.6-dimethvlthio-lH-pyrazolo[3.4-d3pyrimidine 
(15) 
A mixture of 3-cyano-4,6-dimercapto-lH-pyra20-
loC3,4-d_3pyrimidine (14,9g, 38 mmal) , 2N NaOH (100 ml) 
and methyl iodide {9 gm) was stirred at ambient tempera-
ture for 3 hr. The resulting mixture was neutralized 
with acetic acid and filtered. The solid thus obtained, 
was washed with water, acetone and dried over P2O5 to 
give r5 (7 g, 737. yield); m.p.: 252 (EtOH); IR (KBr): 
2245 (CN); MS (m/z) : 237 (t^ "^ ,); NMR (CDCI3) : 2. <S, 2.7 
(each 5, 6H, SCH3); Analy. Calcd. for CgH7N5S2: C, 
40.5; H, 2.97; Found : C, 40.3; H, 2.9. 
3-Cyano-4,6—dimethylthio—l-(tetrahydrofuran-2-yl)-lH-
pyrazolQ[3.4—djpyrimidine (17) 
A mixture of 3-cyano-4,6-dimethy1thio-lH-pyrazo-
laC3,4-d^3pyrimidine (15, 1 g, 4.2 mmol ) , 2,3-dihydrof u-
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ran (16, 1.5 g, 21 mmol), p-toluene sulphonic acid 
(pTSA) (0.2g) and ethyl acetate (50 ml) was stirred at 
70 for 6 hr. The resulting mixture was cooled, washed 
with aq K2CO3 solution, H2O, dried (Na2SQ4) and the 
solvent was removed in. vacuo. The crude product thus 
obtained was chromatographed over Si02 column. Elution 
of the column with CHCl3:hexane (75:25, v/v) gave I^ 
(0.9 g, yield 71'/.); m.p. : 125° (CHCI3 + Hexane) ; MS 
(m/z) : 307 ( M"^  ) ; UV ( MeOH ) : 290.4,252 (pH-7); 
315.2,291.5 (pH-1); 290.8 (pH-11); IR (KBr): 2245 (CN) ; 
PMR (CDCI3): 6.7 (m, IH, H-1' ), 3.9-4.2 (m, 2H, H-4' ) , 
2.7 (s, 3H, SCH3), 2.6 (s, 3H, SCH3), 2-2.5 (m, 4H, H-2' 
and H-3'); Analy. Calcd. for Cj^2'^i3'^5°^2 = '^ ' ^<^-B; H, 
4.26; Found: C, 46.7; H, 4.2'/.. 
4.6-Dimethylthio-l-(tetrahvdrofuran-2-vl)-lH-
pyrazolo[3,4-d]pyrimidine-3—carboxamide (18) 
A mixture of compounder/ .iZ (^  9> 3.3 mmol), dio-
xane (30 ml) and IN NaOH (8 ml) was heated with stirring 
at 80 for 2 hr. The resulting mixture was cooled, 
neutralised with resin IRC-50 (H form) and evaporated 
in vacuo. The crude product, thus, obtained was chroma-
tographed on SiQ2 column. Elution of the column with 
CHCI3 : MeOH (96:4, v/v) gave the compound 18. (0.6g, 60V. 
yield); m.p. : 138° (MeOH); MS (m/z): 325 (M"^); IR 
19:^  
(KBr): 1690 (CONH2 ) ; UV (MeOH) : 290 (pH-J); PMR 
(CDCI3): 7.88 and 7.6 (each 5, 2H, CaNH2), 6.5b (m, IH, 
H-1'), 3.9-4.1 (m, 2H, H-4'), 2.62 (s, 3H, SCH3), 2.55 
(5, 3H, SCH3), 2-2.5(m, 4H, H-3' and H-4'); Analy. 
Calcd. -for Ci2^^^02S2 : C, 44.3; H, 4.6, Found: C, 44.1; 
H, 4.57.. 
6-Methy1thio-1-(tetrahydrofuran-2-yI)-4(5H)-oxo-lH-
pyrazoloC3,4—d3pyrimidine-3—carboxylic acid (19) 
A mixture of 18^  (0.5 g, 1.5 mmol ) , dioxane (15 
ml), MeOH (15 ml) and 6N NaOH (15 ml) was refluxed for 2 
hr. The resulting mixture was cooled to ambient tempe-
+ 
rature, neutralized with resin IRC-50 (H form), fil-
tered, and lyophilized. The crude product, thus ob-
tained was crystallized with methanol to give 1^ (Q.2ag, 
627. yield); m.p. : >300 (MeOH); IR (KBr): 1660, 1670 
(COOH), 3200-3400 (NH2,0H); MS (m/z): 296 ( M"^  ) ; PMR 
(CDCl3-DMS0-d^) : 6.45 (m, IH, H-1'), 3.7-4.2 (m, 2H, H-
4'), 2.5 (s, 3H, SCH3), 1.8-2.3 (m, 4H, H - 2 ' , 3 ) ; Analy. 
Calcd. for Cj^  j^ Hj^ 2'^ 404S: C, 44.6; H, 4.08; Found: C,44.5; 
H, 47.. 
6-Amino-l-(tetrahydrofuran-2-y1)-4(5H)-oxo-lH-
pyrazolo[3,4-d]pyrimidine-3-carboxylic acid (20) 
A mixture of 1^ (0.2g, 0.67 mmol) and ethanolic 
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ammonia (30 ml absolute EtQH at 0 was 5aturatt:>d with 
Q 
NH3) was heated in a steel bomb at 150 for 30 hr. 
cooled and excess of reagent and the solvent were re-
moved iji vacuo. The crude product, thus obtained, was 
charcoaled in MeOH and evaporated to give the compound 
20 (O.lg, 587. yield); m.p.: 224 (decomp.); MS (m/z): 
265 (M"^); IR (KBr): 1<S70 (C = 0 ) , 3200-3400 
(NH2,0H); UV(MeOH): 272.4, 268.0; PMR (DMSO-d^): 7.6 
(bs, 2H, NH2), 6.5 (m, IH, H-1'), 3.75-4.15 (m, 2H, H-
4'), 1.9-2.5 (m, 4H, H-2',3'); Analy. Calcd, for 
C10H11N5O4: C, 45.3; H, 4.18; Found: C, 45.2; H,4y.. 
4-Amino-6-methy1thio-1-(tetrahydrofuran-2-Yl)-IH-
pyra2olo[3,4—djpyrimidine—3—carboxamide (21) 
A mixture of JLB. (^  g» 3.1 mmol) and methanolic 
ammonia (30 ml, MeOH saturated with ammonia at 0 ) was 
heated at 120 in a steel bomb for 15 hr. The solvent 
and excess of reagent from the resulting mixture were 
removed ijri^  vacuo. The crude product thus obtained was 
chromatographed over SiQ2 column. Elution of the column 
with CHCI3 : MeOH (92:8, v/v) afforded 2i_ (0.65 g, 727. 
yield); MS (m/z); 294 (M"^); m.p. : 165° (MeOH); IR 
(KBr): 1680 (CONH2); PMR (DMSO-d^); 8.7, 8.2, 8.1 and 
7,8 (each s, 4H, 2 x NH2), 6.45 (m, IH, H-1),3.8-4 (m, 
2H, H-4'), 2.5 (s, 3H, SCH3), 2-2.4 (m, 4H, H-3' and 
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A ] ; Analy. Calcd. for C j^  j_ Hj_4N^D2S: C, 44.8; H, 4.77. 
Found : C, 44.7; H, 4.67.. 
4-Amino-6-methy1thio-j-(tetrahydrofuran-2-Y1)-IH-
pyra2olQC3.4—d]pyrimidine-3-carbQxamidine (22) 
A mixture of 3-cyano-4,6-dimethy1thio-1-(tetrahy-
drof uran-2-y 1 ) -IH-pyrazo 1 o[ 3 , 4-d^ ] pyr imid ine (17, 0.5 g, 
1.6 mmol) and methanolic ammonia (30 ml, MeOH saturated 
with ammonia at 0 ) was heated at 120 in a steel bomb 
for 12 hr. The solvent and excess of reagent from the 
resulting mixture were removed irt^ vacuo. The crude pro-
duct thus obtained was chromatographed over Si02 column. 
Elution of the column with CHCl3:MeQH (96:4, v/v) gave 
the 22. (G.3 g, 717, yield): m.p.: 142° (MeOH) ; MS (m/z): 
293 (M"^); IR (KBr) : 3200-3400 (NH21VH) ; UV 
(MeOH): 273.4, 246.8; PMR (CDCl 3-DMS0-d<^) : 6.5 (m, IH, 
H-1'), 3.S-4.2 (m, 2H, H-4'), 2.5 (s, 3H, SCH3), 1.9-2.3 
(m, 4H, H-3' ,4- ) . , 
3-Cyano~4 .6-difnethy 1 thiQ-l-( tetrahydropyran-2-y 1 ) -IH-
pyrazoloFS.A-dDpyrimidine ( 24 ) 
A mixture of 3-cyana-4,6-dimethy1thio-lH-pyrazo-
lo[3,4-d]pyrimidine (15, Ig, 4.2 mmol), 3,4-dihydro-2H-
pyran (23, 1.5 ml, 17.8 mmol), p-toluene sulfonic acid 
(pTSA) (0.2 g) and ethyl acetate (50 ml) was stirred at 
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70 for 5 hr. The resulting mixture was cooled, washed 
with aq K2CO3 solution, H2O, dried (Na2S04) and the 
solvent removed xr\. vacuo. The crude product thus ob-
tained was chromatographed aver Si02 column. Elution of 
the column with CHC13 : Hexane (75:25, v/v) gave the 
compound 2± (0.39g , 667. yield); mp : 179 (Hexane + 
CHCI3) ; MS (m/z): 321 (M'^); IR (KBr) : 2240 (CN) ; UV 
(MeOH): 313.2, 290, 250 (pH-7), 290.8, 251 (pH-11), 
316.4, 291.2 (pH-l); PMR (CDCI3): 6.2 (dd, IH, J=12 and 
3 Hz, H-1'), 3.5-4.2 (m, 2H), 2.8 (s, 3H, SCH3), 2.7 (s, 
3H, SCH3), 1.5-2.3 (m, 6H); Analy. Calcd. for 
C13H15N5OS2: C, 48.5: H, 4.5; N, 21.2; Found : C, 48.8; 
H, 4.7; N, 21.5"/.. 
4,6-Dimethvlthio-l-(tetrahydropyran-2-y1)-lH— 
pyrazolo[3.4-d]pyrimidine-3-carboxamide (25) 
A mixture of compound 24^ (iQi 3.1 mmol ) , dioxane 
(30 ml) and IN N^aOH aq (8 ml) was heated with stirring 
at 70 for 2 hr. The resulting mixture was cooled, 
neutralized with resin IRC-50 (H form) and evaported in 
vacuo. The crude product, thus obtained, was chromatog-' 
raphed on Si02 column. Elution of the column with 
CHCl3:MeOH (97:3, v.v) gave the compound 25 (0.7 g, 707. 
yield); m.p. : 205° (MeOH); MS (m/z) : 339 (M"^); IR 
(KBr) : 1690 (CONH2); UV (MeOH) : 284 (pH-7), 246.4 (pH-
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7 ) , 270, 236.8, (pH-1); PMR (CDC 13-DMSO-d^) : 7.45 (bs, 
2H, CONH2), 5.9 (dd, IH, J=12 and 3 Hz, H-1'), 3.9-4.1 
(m, 2H), 2.65 (s, 3H, SCH3), 2.55 (s, 3H, SCH3), 1.5-2.2 
(m, 6H). 
4-ftmino-A-inethy 1 thio-l-( tetrahydropvran-2-vl )-lH-
pyrazolQ[3,4—d]pyrimidine—3—carboxamide (26) 
A mixture of 25^  (0.2 g, 0.58 mmol ) and methanolic 
ammonia (30 ml, MeOH saturated with NH3 at 0 ) was 
heated at 120 in a steel bomb for 15 hr. The solvent 
and excess of reagent from the resulting mixture were 
removed iji vacuo. The crude product, thus obtained was 
chromatographed ever Si02 column. Elution of the column 
With CHCl3:MeQH (94:6, v/v) afforded 26. (0.12 g, 657. 
yield); m.p,: 182° (MeOH); MS (m/z): 308 (M"^); IR (KBr) : 
1690 (CONH2); PMR (DMSO-d^): 8.85, 8.15, 8.05 and 7.95 
(each s, 4H, 2 x NH2), 5.5 and 5.78 (dd, IH, J=12 and 
2.8 Hz, H - 1 ) , 3.8-4 (m, 2H), 2.5 (s, 3H, SCH3), 1.4-2.1 
(m, 6H); Analy. Calcd. for 012*^16^6022: C, 46.7; H, 5.2; 
Found : C, 46.5; H, 5.3*/.. 
3-Cyano-l-C(2-benzoyloxyethoxv)methyl]-4.6-dimethylthio-
lH—pyrazolo[3.4-d!|pyrimidine (28) 
A mixture of 3-cyano-4,6-dimethy1thio-lH-pyrazolo 
[3,4-d.]pyrimidine (15, 2g, 8.4 mmol), Et3N(25 ml) and 
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dry DMF (45 ml) was stirred at 10 . To it was added 
dropwise a solution of (2-ben2Qyloxyethoxy)methy1ene 
chloride (27, 5g, 23 ml) (prepared by passing dry HC1 
gas into a mixture of paraformaldehyde and l-benzoy1oxy-
2-hydraxy ethane in CH2CI2 at O for 2 hr) and the 
mixture was stirred at ambient temperature for 15 hr . 
The solvent and excess of reagent from the resulting 
mixture were removed under reduced pressure. The resi-
due was extracted with CHCI3, washed with H2O, dried 
(Na2S04) and concentrated in_ vacuo. The crude product, 
thus obtained was chromatographed over S1O2 column. 
Elution of the column with CHCI3 gave 23 (2.1 g, 627. 
yield); m.p. : 102° (Hexane + CHCI3): rS (m/2) : 415 
CM"^); IR (KBr) : 2245 (CN) ; UK/ (MeOH) : 292, 251 ( pH-7 ) , 
252, 228.4 (pH-1), 292, 251.2 (pH-11); PMR (CDCI3): 7.9-
B.2 (m, 2H, Ph-H), 7.4-7.7 (m, 3H, Ph-H), 5.9 (s, 2H, H-
1'), 4.4-4.7 (m, 2H, H-3'), 3.9-4,2 (m,2H, H-4•), 2.7 
(5, 3H, SCH3), 2.6 (s, 3H, SCH3). ,_ 
4.6-Dimethvlthio-l-C(2-hydroxyethoxy)methyl3-IH-
pyrazoIoC3.4-d]prylmidine-3-carboxamide (29) 
A mixture of compound 28. (Ig, 2.4 mmol ) , dioxane 
(25 ml) and IN NaOH aq (8 ml) was heated with stirring 
at 80 for 2 hr. The resulting mixture was cooled, 
neutralized with resin IRC-50 (H form) and the solvent 
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evaporated iri vacuo. The crude product, thus obtained, 
was chromatographed on Si02 column Elution of the column 
with CHCl3:MeOH (96:4, v/v) gave compound 29 (0.6 g, 78"/. 
yield); m.p.: 142° (MeOH) ; MS (m/z): 329 (M"^); IR ( KBr) : 
1685 (CONH2); UV (MeOH): 289.6, 249.2; PMR (CDCI3-DMSO-
d^) : 6.9 and 7.25 (bs, 2H, CONH2), 5,7 (s, 2H, H-1'), 
3.63 (s, 4H, H-3',4'), 2.6 (s, 3H, SCH3), 2.55 (s, 3H, 
SCH3); Analy. Calcd. for CJL j^H •15N5O3S2: C, 40.1; H, 4.5; 
Found : C, 40; H, 4.5*/.. 
6-Methylthio-i-C(2-hydrQxvethoxv)methvl3-4(5H)-oxo-lH-
pyrazolo[3.4-d]pyriinidine-3—carboxylic acid ( 30 ) 
A mixture of 29^  (0.5 o, 1.5 mmol), MeOH (25 ml) 
and 6N NaGH (15 ml) was refluxed tor 2 hr. The resul-
ting mixture was cooled at ambient temperature, neutra-
lized with resin IRC-50 (H form), filtered and concen-
trated iji vacuo. The crude product thus obtained was 
crystallized from MeOH to give 30. (0.3 g, 677. yield); 
m.p.: 250° (decomp) (MeOH); MS (m/z) : 300 ( M"^ ) ; IR 
(KBr): 1670 (COOH), 3200, 3400 (NH2, OH); UV (MeOH) : 
270.8, 242 (pH-7), 270, 238 (pH-1); PMR (CDCI3-DMSO-
d ^ ) : 5.6 (s, 2H, H-l'), 3.5 (s, 4H, H-3',H-4'), 2.5 (s, 
3H, SCH3), 
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6-Amino-l-C(2-hydroxyethaxv)methy1]-4(SHj-oxo-lH-
pyrazoloCS. 4-d]pyrimidine-5-carboxylIc acid (31) 
A mixture of 30^  (0.2 g, 0.67 mmol) and ethanolic 
ammonia (25 ml, EtOH saturated with NH3 at 0 ) was 
heated in a steel bomb at 150 for 25 hr. The solvent 
and excess of NH3 from the resulting mixture were re-
moved in^  vacuo. The crude product thus obtained was 
charcoaled in MeOH and solvent evaporated- The product 
was crystallized from (H2O) to give 3X (O.lg, 55'/. 
yield); m.p.: >300° (decomp.) (H2O); MS (m/z) : 269 
(M"^); U V (MeOH): 270 (pH-7) , 268 (pH-11), 268 (pH-1); IR 
(KBr) : 1670 (C=0) ; PMR (DMSO-d^,) : 7.35 (bs, 2H, NH2), 
5.55 (s, 2H, H-l'j, 4.5(s,4H, H-3', 4'); Analy. Calcd. 
for C9Hj[^ j^ N505J C, 40.1; H, 4.1; Found : C, 40.2; H, 
4 .3-/.. 
4-Amino-i—[ (2—hydroxyethoxy)methyl 3~6~w>ethy 1 thio-lH-
pyrazoloC3.4-d]pyrifnidine-3—carboxamide ( 33 ) 
v" 
A mixture of 4,6-dimethy1thio-l-C(2-hydroxyethoxy) 
methyl ]-lH-pyrazoloC 3 , 4-d_]pyrimidine-3-carboxamide (29, 
0.5g, 1.5 mmol) and methanolic ammonia (30 ml, MeOH 
saturated with ammonia at 0 ) was heated at 120 in a 
steel bomb for 15 hr. The excess of'ammonia and the 
solvent were removed iji vacuo. The crude product thus 
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was obtained was chromatographed over S1O2 column. 
Eiution of the column with CHCI3 : MeOH (93 : 7, v/v) 
gave 3^ (0,3 g, 717. yield); m.p. : 158° (MeOH) ; MS (m/z): 
298 (M"^); IR (KBr) : 1670 (CONH2) ; UV (MeOH): 295, 248 
(ph-7) 248.4, 295 (pH-li), 246.4, 295 (pH-1); PMR (DMSQ-
d ^ ) : 8.9, 8.27, 8.12, 8.0 (each s, 4H, 2 x NH2), 5.63 
(s, 2H, H - 1 ) , 3.55-3.47 (m, 4H, H - 3 ' , 4 ) , 2.5 (s, 3H, 
SCH3) ; Analy. Calcd. for Cio'^14'^6°3S = C, 40.2; H, 4,7; 
Found: C, 40.1; H, 4.6'/.. 
4—Methoxy—1—[ (2—hydroxyethoxymethyl ]-6-<nethyl thio-lH-
pyrazoloC3.4—d]pyrimidine-3—imidocarboxylate (32) 
To a suspension of 3-cyano—1-C(2-benzoyloxyethoxy) 
methyl ]-4 ,6-di methyl thio-lH-pyrazaloC3 , 4-d_]pyrimidine 
(28, 0.5 g, 1.2 mmol) in MeOH/acetonitrile (25 ml, 3:1, 
v/v) was added to freshly prepared sodium methoxide in 
methanol (IN) until pH-10 was reached and the mixture 
left at ambient temperature for 18 hr. It was then 
treated with IRC-50 (H form) resin and worked up. The 
crude product, thus obtained was chromatographed over 
Si02 column. Eiution of the column with CHCl3:MeOH 
(96:4, v/v) gave the compound 32^ (0.26 g, 687. yield); mp 
: 122° (MeOH); MS (m/z) : 327 (M"*"); IR (KBr): 3200, 2900 
(NH2); UV (MeOH) : 287, 245.6, 250.4; PMR (DMSO-d^): 
5.7 (s, 2H, H-1'), 4.1 (s, 3H, OCH3), 3.82 (s,3H, 
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0CH3),3.4- 3.55 (m, 4H, H-3',4'), 2.6 (s,3H, SCH3); 
Analy. Calcd. far Ci2*^17'^5°42 = '^ ' ^^' ^' ^'^S Found: C, 
43.8; H, 5.17.. 
3-Cyano-4.6-dimethylthio-l-a-D-2'.3'.5'-tri-0-benzoy1 
ribof uranosyl-lH-pyrazoloC3.4-d]pyriinidine ( 36 ) 
A mixture of 3-cyano-4,6-dimethy1thio-lH-pyrazolo 
[3,4-d.]pyrimidine (15, 2 g, 8.4 mmol ) and 1-0-acetyl-
2,3,S-tri-O-benzoylribofuranose (34, 6 g, 11.9 mmol) in 
dichloroethane (150 ml) wat. refluxed for 30 min. To it 
was added BF3.0Et2 (5.0 ml) and the mixture was refluxed 
for 2 hr. The solvent from the resulting mixture was 
removed in vacuo• The product was extracted with ethyl 
acetate, washed with aq NaHC03 solution, dried (Na2SD4) 
and the solvent removed. The crude product, thus ob-
tained, was chromatographed over Si02 column. Elution 
of the column with CHC13 : MeOH (99.5 : 0.5 v/v) gave 36 
as an oil (o.2 g, 57. yield); IR (KBr) : 2245 (CN) ; UV 
(MeOH): 292.6, 252f ' PMR (CDCI3): 8-8.3 (m, 2H, Ph-H), 
7.3-7.6 (m, 3H, Ph-H), 6.95 (d, IH, J ^  • ^  2 ' =^ • "^  ^ ^ , H-
1'), 5.6-5.3 (m, 2H, H-2',3'), 4.8 (m, IH, H-4'), 4.3 
(m, 2H, H-5'), 2.7 (s, 3H, SCH3), 2.6 (s, 3H, SCH3). 
3-Cyano-4.6-dimethylthio-l-f3-D-2' .3' .5'-tri-O-benzoyl 
ribofuranosyl—lH-pyrazoloC3,4-d]pyrimidine (35) 
Continued elution of the column with CHCl3:rieOH 
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(99:1, v/v) after the removal of compound 36^  gave 35^ as 
an solid foams (3.2 g, 577, yield); m.p.: 74 (Hexane + 
CHCI3); IR (KBr) : 2245 (CN); UV(MeOH): 291, 251 (pH-7), 
292.4, 251.2 (pH-1), 292, 227 (pH-11); PMR (CDCI3): 8-
8.3 (m, 2H, Ph-H), 7.4-7.7 (m, 3H, Ph-H), 6.7 (d, IH, 
J^' 2' "^  2 ^ 2 , H-1'), 6.3-6.5 (m, 2H, H-2',3'), 4,6-5.1 
(m, 3H, H-4',5'), 2.75 (s, 3H, SCH3), 2.7 (5, 3H, SCH3). 
4-Methoxv-6—methyIthio-1—B-D—ribofuranosyl-lH-
pyrazoloCS.A-dlpyrimidine-S-imidocarboxylate (37 ) 
To a suspension of 3-cyano-4,6-dimethy1thio-l-Q-
D-ribof uranosy l-lH-pyrazola[3,4—d_]pyrLmidine (35, 2g , 2.9 
mmol) in MeGH/acetonitirle (45 mi, 3:1, v/v) was added 
freshly prepared sodium methoxide in methanol (IN) until 
pH-10 was reached. The mixture was left at ambient 
temperature and after 15 hr, resin IRC-SQ (H form) was 
added to pH less than 5. The resin was filtered off and 
the solvent of the filtrate was removed in. vacuo. The 
crude product, thus obtained, was chromatographed over 
Si02 column. Elution of the column with CHCI3: MeOH 
(92:8, v/v) gave the compound 371 (0-7 g, 627. yield); 
m.p. : 165° (MeOH); MS (m/z) : 385 (M"*"); IR (KBr) : 3200 
(NH,OH); UV (MeOH): 290.1, 250.4 (pH-7), 290.0, 250.8 
(pH-1); PMR (CDCl3-DMS0-d^): 6.3 (d, IH, Ji',2'=^-5 Hz, 
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H - i ) , 4 . 7 ( m , I H , H - 2 ' ) , 4 . 4 (m, I H , H - 3 ' ) , 4 . 1 3 ( s , 
3 H , O M e ) , 3 . 9 5 ( s , 3 H , - O M e ) , 3 . 6 - 3 . 8 ( m , 3 H , H - 4 - , 5 ) , 
2 . 6 ( s , 3 H , S C H 3 ) ; A n a l y . C a l c d , f o r C i / jN j ^9N50^S: C, 
4 3 . 6 ; H , 5 . 0 ; Found : C, 4 3 . 5 ; H, 4 .9* / . . 
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